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Summary
The aim of this project is to study the molecular hiology of Japanese encephalitis 
(JE) virus. Comparison of the nucleotide and amino acid sequence of live attenuated JE 
vaccine virus SA14-2-8 with its virulent wild-type parent SA14 virus, and two other 
attenuated vaccine viruses derived from SA14 virus (SA14-14-2/PHK and SA14-14- 
2/PDK) revealed that only five amino acids in the parental SA14 virus have been substi­
tuted in all three attenuated vaccines. The two amino acids substituted in the E protein 
(E-138 and E-176) may attenuate the JE vaccine viruses by altering the virus-cell 
receptor interaction while the mutations in nonstructural protein 2B (NS2B-63) and NS3- 
105 are in functional domains of the virus-specified trypsin-like serine proteinase. Thus, 
attenuation of the vaccine viruses may, in part, he due to an altered viral proteinase 
activity which could affect the replication cycle of the virus. The genome of the highly 
mouse neuroinvasive wild-type strain P3 was also sequenced and compared to that of 
two other wild-type JE viruses that are poorly neuroinvasive in mice. The results 
suggested that the structural, NS2B and NS5 proteins and 3’ non-coding region may 
he involved in the increased neuroinvasiveness of P3 strain.
Strain variation of wild-type JE virus was examined by comparing the 5’ terminal 
2434 nucleotides. The amino acid homology of the envelope (E) protein gene of the 
viruses was 95.8% or greater. Full genomic homologies of JE virus strains SA14,
11
JaOArS982 and P3 were higher than 98% at both nucleotide and amino acid levels.
Four variable E protein amino acids (E-51, E-209, E-244 and E-366) were 
identified. E-51, E-244 and E-366 are found in peptides with functional T-helper cell 
epitopes in two other flaviviruses. Therefore, these amino acids may be important in 
defining the imunotypes of JE virus.
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Chapter 1
General Introduction
1.1 Taxonomy and classification of arboviruses
At the start of this century (1902), yellow fever (YF) virus was recognised as 
being arthropod-borne by Major Walter Reed and co-workers. They demonstrated that 
this disease was transmitted to man by mosquitoes carrying a filterable agent/virus. 
This represented a major breakthrough both for medicine and in the potential control 
of this type disease. It also provided the first example of an arthropod-borne virus.
The term arbovirus, introduced in 1942, derives from arthropod-borne and was 
used as an umbrella classification for those viruses that are maintained in a 
transmission cycle between susceptible vertebrate hosts and blood-sucking arthropod 
vectors. An essential point of the definition of an arbovirus is that the arthropod does 
not merely provide a mechanical transportation of virus from one infected host to 
another, but is a true host, in which virus multiplies before its transmission. 
Arthropods involved in the transmission of diseases in this way include mosquitoes, 
ticks, midges (Culicodes species) and sandflies {Phlebotomus species) (World Health 
Organisation Technical Report, 1967).
Following the early YF research, field studies resulted in the isolation of 
several of other arboviruses, including Japanese encephalitis (JE), dengue fever 
(DEN), St. Louis Encephalitis (SEE), Murray Valley encephalitis (MVE) and Rift 
Valley fever, all of which wave associated with large epidemics in man and/or in 
animals (World Health Organisation Technical Report, 1967). In 1953 thirty-five 
viruses were classified as arboviruses. The 1985 edition of the International Catalogue
of Arboviruses lists 504 registered members, 32 of which are designated as "probably 
or not arboviruses" (Karabatsos, 1985).
Original classification of arboviruses was based on their morphology and 
serological relationships according to tests employing complement fixation (CF), 
haemagglutination inhibition (HAT) and neutralization (N). The groups, originally 
recognised as antigenically distinct from one another, were named A, B and C (Casals 
and Brown, 1954; Casals, 1957). By 1980 most arthropod transmitted viruses studied 
were reclassified as four major taxonomic groups (Schlesinger, 1980): (1) the 
Togaviridae family, containing genera Alphavirus and Flavivirus (Casals A and B 
groups respectively); (2) the family Bunyaviridae (Casals group C); (3) the family 
Rhabdoviridae; and (4) the family Reoviridae. Currently registered arboviruses are 
now separated into 63 serogroups (Karabatsos, 1985).
The grouping of both alphaviruses and flaviviruses within the same family 
became increasingly unsatisfactory as the viruses were subjected to further study. 
Clear differences between the genera have been demonstrated by molecular analyses 
of their respective members. The alphavirus genome transcribes a subgenomic 26 S 
messenger RNA (mRNA) corresponding to the 3’ end of the genome containing genes 
coding for the structural proteins (Kaarianen and Soderlund, 1978). However, no 
subgenomic RNA could be demonstrated in flavivirus infected cells (Westaway, 1973; 
Westaway and Shew, 1977). In 1984, based on these differences, the International 
Committee on Taxonomy of Viruses (ICTV) approved a recommendation by the 
ICTV Study Group to transfer the flaviviruses from the Togaviridae into a distinct
family, which was named the Flaviviridae (Westaway et al., 1985 •).
1.2 Flaviviridae
1.2.1 Classification and life cycle
The family name of Flaviviridae is derived from yellow fever virus (flavus 
is the Latin for yellow). Currently 72 viruses have been classified in the Flaviviridae, 
which contains hepatitis C virus and two genera, the flaviviruses and pestiviruses. 
The former is divided into eight major antigenic complexes (Westaway et al., 1985 ; 
Calisher et al., 1989) (see table 1.1). All flavivirus genus viruses share a group- 
specific antigen (Brinton, 1986). Antigens presented on the virion surface are reactive 
in binding assays, complement-fixation assays, haemagglutination-inhibition and 
neutralization assays.
Flaviviruses are classified within the family and genus, which incudes 
approximately 68 distinct members, most of which are known transmitted by the bite 
of infected mosquitoes or ticks. The biological assays used are haemagglutination 
(HA), HA inhibition (HAI), plaque reduction neutralization tests (PRNTs), 
immunofluorescence (IF), and assays involving enzymes and radio-isotopes. These 
assays are based on the envelope protein antigens possessed by flaviviruses. 
Originally, flaviviruses were grouped by their cross-reactivities in HAI tests using
Table 1.1 Antigenic complex of some flaviviruses.
Principal
Vector
Antigenic
Complex
Viruses
Tick: Tick-borne
encephalitis:
Russian spring-summer encephalitis, Central 
European encephalitis, Omsk haemorrhagic 
fever, Kyasanur forest disease, Langat, 
Negishi, Powassan, IvOuping-ill, Phnom- 
Penh bat, Carey island, Karshi, Royal 
Farm.
Tyuleniy: Tyuleniy, Saumaurez Reef, Meaban
Mosquito: Japanese
encephalitis:
Japanese encephalitis, St. Louis encephalitis. 
Murrey Valley encephalitis. West Nile, 
Kunjin, Usutu, Stratford, Kokobera, Alfuy, 
Koutango
Nataya: Nataya, Tembusu, Bagaza, Yokose, Israel 
Turkey meningoencephalitis
Uganda S: Uganda S, Banzi, Edge Hill, Bouboui
Dengue: Dengue -1, -2, -3, -4
No known 
vector:
RioBravo: Rio Bravo, Entebbe bat, Daker bat, Apoi, 
Saboya, Bukalasa bat
Modoc: Modoc, Cowbone Ridge, San Perlita. Sal 
Vieja
Unclassified: Gadgets Gully, Kadam, Cacipacore,
Montana myotis leukoencephalitis, Zika, 
Sokuluk, Tamana bat, Bussuquara, llheus, 
Jugra, Naranjal, Rocio, Sepik, Wesselsbron, 
Spondweni, Yellow fever
1989.
polyclonal antisera (Casals and Brown, 1954). Based on cross-neutralization using 
polyclonal hyperimmune sera, DeMadrid and Porterfield classified 36 flaviviruses into 
seven antigenic complexes. However, six viruses were antigenically distinct and did 
not fall within any of these groups. More recently, 68 members of the Flaviviridae 
were classified into eight antigenic complexes based on cross-neutralization tests 
utilizing polyclonal antisera (Calisher et a l, 1989). This subdivision corresponds very 
well to sequence homology data on the major envelope protein (Heinz et al. , 1990). 
Of the 68 currently registered members of the flavivirus genus most are 
mosquito-borne (48%) (responsible for epidemics of diseases such as YF, DEN and 
JE), and tick-home (27%). However, isolates from bats and rodents without known 
insect vectors have also been identified (Calisher et a l ,  1989). The life cycle of the 
arthropod-bome flavivimses involves a complex relationship among insect vectors, 
vertebrates, humans and the environment (Chambers et a l ,  1990).
1.2.2 Flaviviruses of Medical Significance
Approximately half the 68 currently registered flaviviruses have been 
associated with human disease (Karabatsos, 1985). Many members have been isolated 
from humans during either sporadic or epidemic outbreaks of disease, and the 
flavivimses represent one of the most important groups of vimses from a medical 
point of view. Three flavivimses cause epidemics that cause panregional and global 
concern (Monath, 1986). They are YF, DEN and JE vimses. All three of these 
vimses are mosquito borne. YF has been recorded as a scourge of mankind for at
least two centuries, and major epidemics still occur, despite the introduction of live 
attenuated vaccines in the 1930’s. There are four serotypes of DEN virus (DEN 1-4), 
and all give rise to ’classical’ dengue fever, a self-limiting febrile illness associated 
with a rash. DEN virus is transmitted by the bite of an infected mosquito, and DEN 
viruses cause the highest morbidity rates of any flavivirus (Halstead, 1988). There 
continue to be severe epidemics of DEN, also worrying signs that the disease is re­
appearing in regions from which it had been eradicated. For example, an outbreak 
was recorded in Rio de Janiero in 1986 and reported in every subsequent year. Before 
this DEN had been absent from Brazil for over 50 years (Shatzmayer et ah, 1986).
JE virus is the cause of Japanese encephalitis, which is the most common form
IS
epidemic encephalitis in the world today. The virus associated with endemics and 
epidemics in south-east of Asia. Mortality rates are usually 10-20% in most 
epidemics. In a significant proportion of patients who survive the disease, permanent 
neurological impairment occurs,^as a sequel, . j Massive vaccination programmes 
have been undertaken inAsî^v countries, yet large populations in the region remain 
at risk from JE virus. It is thought that vaccination strategies are undermined by the 
high degree of antigenic variation exhibited by different subtypes of JE virus
(Susilowati er «/., 1981).
Besides the three major diseases described above, there are several other 
mosquito-bome flaviviruses of medical significance. St. Louis encephalitis (SLE) was 
first reported as a serious public health problem in the United States in the 1960’s, 
and continued sporadic outbreaks give cause for concern (Kokemot et ah, 1969).
MVE virus causes intermittent epidemics in Australia in regions that have experienced 
high rainfall levels (Forbes, 1975). Epidemics usually coincide with high population 
levels of the mosquito vector, and occur mainly between January and March (Shope, 
1980). West Nile virus (WN), unlike the serologically related JE, SLE and MVE 
viruses, is not usually associated with encephalitis (except in elderly persons), and 
causes a generalised fever, rash and lymphadenopathy (Sprigland et a l ,  1958). The 
virus is found in Africa, the Middle East, Europe and Asia. In hyperendemic areas, 
infection usually occurs during childhood as evinced by high numbers of sero-positive 
adolescents and adults (McIntosh et a l,  1976).
Several flaviviruses which are transmitted by ticks cause encephalitic disease 
in humans. Tick-borne encephalitis (TBE) has long been recognised as a public health 
problem in Eastern Europe, and the virus caused high mortality in Russia in the 
1930’s, prompting great efforts to isolate the causative agent and produce a vaccine 
(Silber and Soloviev, 1946). The term TBE encompasses a number of different viral 
subtypes found in different geographical areas. The far Eastern subtype is also known 
as the causative agent of Russian Spring-Summer encephalitis (RSSE) (Silber and 
Soloviev, 1946), while the Western subtype is also known as central European 
encephalitis (Ackerman et a l ,  1986).
Two further tick-home flaviviruses cause diseases that are largely 
haemorrhagic (rather than encephalitic) in nature. Kyasanur Forest disease (KFD) 
occurs annually in India, causing hundreds of infections in man, characterised by 
fever, mild meningoencephalitis and haemorrhagic fever. The mortality rate varies
8
between 1 and 10% (Work 1958; Sreenivasen et al. , 1979). Omsk haemorrhagic fever 
(OHF) caused large outbreaks in 1944 and 1946 in the Omsk region of the Common 
Wealth of independent States. As it’s name suggests, the disease causes fever with 
associated haemorrhage, but the case fatality rate is low (1-2%) (Shope, 1980).
1.2.3 Flaviviruses of Veterinary Importance
Eight flaviviruses have so far been reported to cause disease in domesticated 
and/or wild animals, and to be of major economic importance in the former group. 
The mosquito-borne JE virus is the most important in terms of economic impact, 
causing epizootic encephalitis in horses, and still-birth/abortion in pigs in many parts 
of Asia (Umenai et al. , 1985). The virus has also been shown to infect both wild and 
domesticated boars (Habu et al., 1977). Pigs and birds have been established as the 
principal viraemic amplifying hosts of JE virus, with Culex species of mosquito 
responsible for the transmission of the virus to man (Beuscher and Scherer, 1959).
Louping ill (LI) virus is a member of the TBE complex that causes 
neurological disease in sheep, mainly in Scotland (Monath, 1989). It has also been 
responsible for economic losses due to infection of pigs, red grouse and deer (Reid 
et a l ,  1982; Bannatyne et al., 1980). The same viruses or serologically related 
viruses have been isolated in Spain, Norway, Bulgaria, Portugal and Turkey.
Wesselsbron (WSL) virus, which is not classified within any antigenic
complex (see Table 1.1) is found in South Africa, where it causes abortion and death 
of new-born lambs and pregnant ewes (Henderson et al. , 1970). It was also isolated 
from a cow which died during an epizootic Rift Valley fever attack in Zimbabwe in 
1978 (Blackburn and Swanpoel, 1980). It has since been proposed that WSL infection 
occurs on a much greater scale than the number of recorded cases implied, and 
serological evidence suggests that detailed epidemiological studies are required of 
livestock where virus infection (Swanpoel, 1988).
Between 1958 and 1959, turkey populations in Israel were dramatically 
affected by flavivirus causing morbidity approaching 50% and case-fatality rates of 
between 10 and 12% (Komarov and Kalmar, 1960). The causative agent was Israel 
Turkey Meningo-encephalitis (ITME) virus, and the only other recorded outbreak of 
the disease occurred in South Africa (Barnard et al. , 1980). A reservoir for the virus 
has never been found.
Several other flaviviruses cause diseases of veterinary importance to varying 
degrees. Horses have been infected by WN virus (Guillon et a l ,  1968), and by 
Kunjin virus, which was isolated from the spinal cord of a horse with severe 
encephalomyelitis in Australia (Badman et al., 1984).
1.3 Molecular biology of flaviviruses
In recent years, our understanding of flavivirus specified proteins has been
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greatly increased. This is mainly based on the determination of the nucleotide 
sequences of flavivirus genomes, the first complete genomic sequence was that of YF 
vaccine virus by Rice et al. (1985).
1.3.1 Genome organization
The RNA genome of flaviviruses is a single-stranded positive sense RNA 
molecule approximately 11 kb in length, containing a short untranslated 5’ terminal 
and a longer 3’ non-coding region (Rice, 1990). No subgenomic messenger RNAs 
(mRNAs) have been identified in flavivirus infected cells. The genomic RNA is 
infectious and the only virus-specific RNA molecule that has been detected in 
flavivirus infected cells; thus the viral RNAs act directly as message RNA (Chambers 
et al., i19i>l)). Flaviviral genomic RNA has a type 1 cap at its 5’ end 
(m^GpppAmpNi), which probably aids in the binding of RNA to ribosomes, and lacks 
cap-associated and internal base methylated adenine residues (Mathukrishnan et al., 
1975, 1976; Wengler etal., 1978; Cleaves and Dubin, 1979). The 5’ cap is followed 
by the conserved dinucleotide sequence AG. All mosquito-bome flavivimses appear 
to lack a 3’-terminal poly (A) tract (Brinton, 1986; Rice et al., 1986), and terminate 
with the conserved dinucleotide uridylic acid (CUqh) (Wengler et al., 1978; Wengler 
and Wengler, 1981; Deubel et al., 1983). However the presence of a 3’ poly(A) 
tract has been detected in several TBE vims strains (Mandl et al., 1991).
YF was the first flavivims for which the nucleotide sequence was determined
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in entirety (Rice et a l ,  1985). Since then, several other flaviviruses have also been
completely sequenced. These are JE (Sumiyoshi et a l , 1987; Hashimoto et a l , 1988;
Aihara et a l ,  1991), Central European (CE) TBE (Mandl et a l , 1989a), Far Eastern
(FE) TBE (Pletnev et a l ,  1990), Langat (LGT) (lacono-Connors and Schmaljohn
1992), Powassan (POW) (Mandl et a l ,  1993), WN (Castle et a l ,  1985 and 1986;
Wengler et a l ,  1985), MVE, (Dalgarno et a l ,  1986), Kunjin (KUN) (Coia et a l ,
1988), and DEN serotypes 1, 2 , 3 and 4 (Fu et a l ,  1992; Hahn et a l ,  1988;
Osatomi and Sumiyoshi, 1990; Mackow et a l , 1987). From these data, it was found
that flavivirus RNA encodes a single uninterrupted m;iocistronic message (open
reading frame), which is 10,296 nucleotides in length for JE virus. The polycistronic
message is translated into a polyprotein precursor of 3432 amino acids. The figures
are similar for other flaviviruses (Chambers et a l ,  1990). The 5’ non-coding region
is shorter than the 3’ non-coding region in mosquito-bome flavivimses; whereas in
TBE complex vimses, the length of the 3’ non-coding region is variable.
^  T&B (CB t~S)
5’ and 3’ non-coding regions^are very similar in size
-fAjL
(Mandl et a l ,  1989a; Pletnev et a l ,  1990). In JE vims,^5’ non-coding region is 95 
nucleotides in length, whilst the 3’ non-coding region consists of 578 nucleotides 
(Sumiyoshi a /., 1987)
Co- and post-translational processing of polyprotein of flavivimses by host 
cellular and viral proteinases give rise to at least 10 vims-specific polypeptides (see 
Section 1.5.4). The order of proteins encoded is:
5’-C-prM(M)-E-NSl-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3’ (see Fig. 1.1)
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Three structural proteins, capsid (C), membrane (M and its’ precursor prM) 
and envelope (E) are encoded by the 5’ one quarter of the genome, the remaining 
three quarters code for seven non-structural proteins (NSl, NS2A, NS2B, NS3, 
NS4A, NS4B and NS5) (Sumiyoshi et al. , 1987). Functiomof these proteins will be 
discussed later^
Some degree of sequence conservation can also be confirmed in the 5’ non­
coding region of the flavivirus genome; hairpin loop structures are also predicted in 
this region (Brinton and Dispoto, 1988).
There are several regions in the genome that are conserved among flavivirus 
sequences thus far determined. There are 90 nucleotides at the 3’ terminus of most 
mosquito-bome vimses that may be organised into a stable hairpin loop stmcture 
(Brinton et al., 1986; Grange et a l ,  1985). Two short conserved repeat features 
(named CSl and CS2) are also found 5’ to the 3’ putative secondary stmcture 
sequence. It has been postulated that base-pairing of these terminal sequences could 
lead to cyclization of the viral genome that may be important for regulating genome 
translation, replication or packaging (Brinton and Dispoto, 1988; Sumiyoshi et al., 
1987).
1.3.2 RNA replication
Flavivim^can replicate in a wide variety of cultured cells of vertebrate and
14
arthropod origin. Flavivirus replication is closely associated with membranes of the 
perinuclear endoplasmic reticulum (ER) (Chu and Westaway, 1985, 1987; Grun and 
Brinton, 1986). The specific steps of flavivirus replication have not been 
characterized in detail. It appears that following translation of infecting genomic 
mRNA, complementary minus-strand RNAs are synthesised that in turn act as 
templates for the production of further genome-length positive sense RNA molecules. 
These may then either be translated to produce the viral proteins, encapsidated into 
virions, or used to produce more negative-sense RNA molecules (Brinton, 1986). 
Evidence suggests that plus-stranded RNA molecules are synthesized from the 
genome-length minus-stranded templates by a semiconservative mechanism involving 
replicative intermediates and replicative forms. Replicative forms are defined as 
duplex RNA molecules; replicative intermediates as nascent single-stranded RNA 
molecules (Chu and westaway, 1985).
Synthesis of flaviviral RNA is detectable six hours after infection in vertebrate 
cells (Chu and Westaway, 1985). From studies on replicative intermediates, it appears 
that between 10 and 15 minutes are required for the synthesis of flavivirus genome- 
length products (Chu and Westaway, 1985; Cleaves et a l ,  1981).
1.3.3 Processing of the flavivirus polypeptide
As mentioned before, the flavivirus genome encodes a single long polyprotein 
that then undergoes co- and post-translational modification (Rice and Strauss, 1990).
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The mechanisms thought to be implicated with each cleavage are shown in Figure 
1.1. There are at least five distinct processes involved.
Based on cells free studies, it is thought that the structural proteins prM and 
E and NSl are translocated into the lumen of the ER, there host cell signal peptidase 
mediates their N-terminal cleavages (von Heijne, 1984) contributed by the C-terminal 
hydrophobic regions of anchored-C, prM and E respectively (Chambers et al. , 1990). 
In addition a similar signal peptidase sequence is also found to precede the N- 
terminus of NS4B. However, Lobigs (1993) reported that NS3 (viral proteinase, see 
below) is required for correct processing of a polyprotein segment encompassing the 
MVE virus structural proteins, in which NS3-mediated cleavage may release the C 
protein from its membrane anchor and triggers the appearance of prM protein. This 
suggests that cleavage of prM by signal peptidase in the lumen of endoplasmic 
reticulum is controlled by a cytoplasmic cleavage catalyzed by a viral proteinase. 
Although the N-terminus of NS2A follows a cleavage sites that fulfils the basic 
prerequisites for a signalase site, it lacks the required upstream hydrophobic region 
(Chambers et al., 1990). However, Falgout et al. (1989) have shown that NSl and 
NS2A junction is cleaved by a unknown host-specified enzyme or a viral proteinase 
in the lumen of the ER.
However, Amberg et al. (1994) reported that NS2B and NS3 proteinase 
domain were the only YF specific proteins required tiL  C termin<^ of the
virion capsid protein a cells-free trans cleavage assay for yellow fever virus. 
Their results of in vivo tr^sient-expression studies do not support ^ above temporal
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cleavage order. Rather, C-prM processing was dependent on an active NS2B-NS3
proteinase, which indicates that signalase-mediated cleavage in the lumen of the
iÂjL
endoplasmic reticulum may be dependent on prior cleavage at anchC dibasic site 
(Amberg et al., 1994).
Cleavage sites generating the N-termini of NS2B, NS3, NS4A and NS5 are 
highly conserved among flaviviruses, and occur after two basic amino acid residues 
(a combination of lysine and arginine), which are usually flanked by amino acids with 
short side-chains, such as glycine, serine or alanine (Chambers et al., 1990). A viral 
specified proteinase was postulated for the cleavage at such sites, and recent studies 
suggest that the cytoplasmic cleavages at junctions of NS2A-2B, NS2B-3, NS3-4A, 
NS4A-NS4B and NS4B-NS5 are catalyzed by the viral encoded serine proteinase 
NS3, probably the function of a domain within NS3. However, the proteolytic 
function of NS3 requires NS2B to form a complex for trypsin-like serine proteinase 
functional activity (Chambers et al., 1990, 1991) (see below). It has also been 
demonstrated that NS2B in trans is also necessary for the cleavage at the N-termini 
of NS2B and NS3 (Falgout et a l ,  1991).
Recently, Lin et al. (1993) reported that the NS4A/4B site cleavage occurred
only during co-expression of NS2B and the proteinase domain of NS3. It has been
confirmed that signalase cleavage generating the N-terminus of NS4B requires a prior
NS2B-NS3 proteinase-mediated cleavage at a novel site (termed the NS4A/2k site)
which is conserved among flaviviruses and located 23 residues upstream of the
iJuL
signalase site. The mutation at^NS4A/NS4B signalase site did not eliminate
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processing in the NS4 region. In contrast, substitutions at the NS4A/2k site, which 
were engineered to block NS2B/NS3 proteinase-mediated cleavage , eliminated 
signalase cleavage at NS4A/NS4B site (Lin et a l ,  1993).
The C terminal hydrophobic sequence is removed from C protein. This 
membrane-spanning domain functions as a translocation signal for prM and anchors 
the C protein to the ER membrane (anchored C protein). The cleavage occurs at a site 
consistent with that recognized by the viral proteinase NS3, and the presence of this 
cleavage site is conserved in all flaviviruses (Chambers et a l ,  1990). In addition, 
cellular methionine amino acid peptidase has been shown to remove the initiation 
methionine from the N terminus of C protein; prM is processed late during virus 
maturation by a trans-Golgi enzyme to generate the M protein present only in 
extracelluar virus particles (Rice et a l,  1986).
Many questions concerning flavivirus replication remain unanswered. The 
processing of the flavivirus polyprotein and a discussion on the role of NS3 can be 
found in a detailed review by et a l (1990).
1.3.4 Flavivirus structural proteins
All flaviviruses contain three structural proteins: Capsid (C) protein, 
membrane (M) protein and envelope (E) protein (Rice et a l ,  1985). The several 
regions of the E protein contain T-helper(Tj,)-cell epitopes as defined by MVE virus
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peptides which are highly conserved among JE serocomplex viruses and contain 
dominant lA^ restricted T-helper cell epitopes (Mathews et a l , 1992). It has also been 
confirmed that MVE virus and the more distantly related DEN-2 virus share some T -^ 
cell epitopes in the E protein (Mathews et a l , 1992; Roehrig et a l , 1994).
1.3.4.1 The C protein.
The C protein forms a structural part of the virus nucleocapsid, and that is 
present in virions as a small (MW 12-14 kd) highly positively charged protein (19.6% 
Lys + Arg for JE virus (Sumiyoshi et a l ,  1987)). The basic nature of C is believed 
to offset the charged RNA molecule with which it is associated (Rice et a l ,  1986). 
Although the amino acid sequence of the C protein exhibit little homology among the 
flaviviruses so far sequenced, regions of hydrophobicity and hydrophilicity are 
conserved, including a C-terminal hydrophobic domain that is immediately preceded 
by a hydrophilîc region, and also a central hydrophobic region (Mandl et a l , 1988). 
The N-terminal portion contains a hydrophilic section that, in mosquito-bome 
flavivimses, is intermpted by a hydrophobic insert that is not found in tick-home 
flavivimses.
The precursor to the virion C protein is known as anchored C, and contains 
a 22 amino acid C-terminal hydrophobic section (for JE vims) which is not found in 
mature virions (Sumiyoshi et a l ,  1987; Nowak et a l ,  1989). Purified C does not 
elicit neutralizing antibody when injected into mice but has group reactive antigenic 
determinants (Brinton et a l ,  1986).
19
1.3.4.2 The pre-membrane (prM) protein
The prM protein is a glycosylated precursor ( MW 18-19 Kd) of M protein 
modified by addition of carbohydrate and undergoes a delayed cleavage to form M 
and the N-terminal segment, "pr" (the fate of which is unknown) (Chambers et al. , 
1990). Immature virions exhibit a significantlower specific infectivity, HA activity 
and fiision activity (Heinz et a l ,  1993). The proteolytic cleavage of prM by a 
cellular protease is believed to represent the last step yielding fully infectious virus. 
Since cleavage of prM can be prevented by agents that increase the pH in acidic 
intracellular compartments (Heinz et al., 1993), acidic compartments of the secretory 
pathway are believed to be involved in this final maturation step. The N-terminal pr 
segment is predominately hydrophib'<  ^ and contains six conserved cysteine residues, 
all of which are involved in di-sulphide bridging (Nowak and Wengler, 1987). The 
mature form of the M protein is not glycosylated and purified M protein does elicit 
a neutralizing antibody response following inoculation into mice. It is postulated that 
a part of the M protein may be exposed on the surface of flavivirus virions and is 
associated with the E protein, and may play a role in virus/cell interactions (Brinton, 
1986). It is a component of the viral spike, and has functions involved with the 
binding to and entry into cells. It is has been confirmed, by crosslinking, 
solubilization and sedimentation analysis, that there are prM-E heterooligomeric 
complexes. This suggests that the function of prM protein is to protect the E protein 
from undergoing the irreversible conformation changes in the acidic compartment of 
the secretory pathway that are necessary for triggering fusion activity in the endosome 
during virus entry. The presence of prM also affects the binding of monoclonal
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antibodies to the E protein, especially at sites which have been shown to undergo acid 
pH-induced conformational changes in mature virion (Heinz et a l ,  1994).
1.3.4.3 The envelope (E) protein
The envelope (E) protein (MW 53-59 kd) is the largest structural protein of 
flavivirus and the major component of the virion surface (Chambers et a l , 1990). It 
is glycosylated in most flaviviruses. There is circumstantial evidence that E protein 
mediates several important viral functions, especially during the early stages of viral 
life cycle, such as receptor binding and fusion activity. It induces the formation of 
neutralizing and protective antibodies, and active immunization with isolated forms 
of the protein can provide solid protection against the disease (Heinz and Mandl, 
1993). There is evidence from many viral systems (Tyler and Fields, 1990) that E 
protein, due to their importance for virus entry, represent important determinants of 
virulence. Heinz and Mandl (1993) have suggested that different parts of E protein
4
may contribute to the control^virulence and attenuation based on the studies of the 
escape mutants of several flaviviruses.
Roehrig et a l (1994) identified DEN-2 virus E protein T^-cell epitopes and 
Mathews et a l (1991) also reported that many DEN-2 and MVE virus epitopes 
contain both empirically defined T- and B-cell epitopes. The E protein is a typical 
membrane protein consisting of a large N-terminal ectodomain, anchored in the bi­
layer by means of a hydrophobic C-terminal domain (Chambers et a l ,  1990).
The E protein contains 12 cysteine residues, those are absolutely conserved
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among all flavivirus E proteins sequenced so far, and are all involved in the formation 
of six di-sulphide bridges (Nowak and Wengler, 1987). The E protein is the most 
studied flaviviral protein, and several two-dimensional models of its structure have 
been proposed. They are mainly based on: a. determination of the intra-molecular 
disulphide bridges for WN virus (Nowak and Wengler, 1987); b. studying the 
biological and topological properties of E protein epitopes defined by MAbs (for a 
review see Heinz, 1986); c. physical and immunological characterization of E protein 
fragments derived by protease or chemically induced cleavage (Guirakhoo et al., 
1989b; Mandl et al. , 1989b); d) localization of antibody binding sites to the deleted 
forms of the JE virus E protein expressed in bacteria (Mason et a l ,  1987; Mason,
1989); e. sequence analysis of neutralization-resistant mutants of YF and TBE viruses 
(Lobigs et al., 1987; Mandl et al., 1989b); f. reactivity of antipeptide sera with 
native E protein from MVE and DEN-2 viruses (Roehrig et al., 1989).
However, the most detailed studies have utilized the CE-TBE virus E protein 
as a model (Fig. 1.2). Heinz and colleagues (1990) characterized the TBE E protein 
using a panel of MAbs in competitive binding assays. The model of E protein that 
they proposed exhibits a specific folding of the polypeptide chain into a "head" 
structure (amino acids 1-400) composed of three protein domains: A, B and C. These 
correspond to distinct MAb-defined antigenic domains which are probably involved 
in different functional activities. The remainder of molecule consists of membrane
4co
anchor (amino acids 448 to 496) and a "stem structure" famino acid^ to which no 
MAb-defined epitopes have been assigned so far (Heinz and Mandl, 1994).
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Figure 1.2 Structure of the TBE virus E protein 
(taken from Heinz et al. 1990)
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1) A. B. C; correspond to different antigenic protein domain recognized by MAbs.
2) Disulphide bridges are marked by connecting solid lines.
3) Thin lines indicate variable sequences.
4) Thick lines indicate hypervariable sequences.
5) Diamonds indicate potential N-glycoprotein sites for TBE and other flaviviruses.
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Domain A is composed of two discontinuous parts of the polypeptide chain 
in the disulphide rich region from amino acids 50-125, and 200-250. One part is 
stabilized by three disulphide bridges. Whilst all three domains contain epitopes that 
are involved in haemagglutination inhibition and neutralization, only domain A 
contains flavivirus cross-reactive epitopes. It is therefore not surprising that the amino 
acids which form this domain contains the most highly conserved sequence element 
(amino acids 98-111) among all flavivirus E proteins, and is postulated to be involved 
in acid-catalyzed fusion (Heinz et a l ,  1990; Roehrig et ah, 1989). Domain A is 
sensitive to dénaturation and carries several epitopes involved in 
neutralization,haemagglutination and fusion inhibition. However, some amino acids 
in this domain also exhibit regions of variability. (Guirakhoo et al., 1989a).
Domain B consists of a trypsin-resistant region from residues 300-395 (see 
Figure 1.2) and can be isolated in antigenically reactive form by trypsin digestion 
(Winkler et al., 1987). The structural integrity and antigenic reactivity of this domain 
are dependent on a disulphide bridge between amino acids 307 and 338, and this 
domain also binds neutralizing, haemagglutination- and fusion- inhibiting antibodies. 
Using an E protein subregion from JE virus expressed in E. coli, this domain has 
been shown to contain both JE specific and serogroup cross-reactive neutralizing 
epitopes (Mason et al., 1987). The epitopes in this domain of CE-TBE virus E 
protein are resistant to sodium dodecyl sulphate (SDS), acidic pH and trypsin, but 
sensitive to reducing agents (Guirakhoo et al., 1989). Two studies suggest that this 
region may be involved in tissue tropism, and perhaps in virus-host cell interactions 
(Heniz et a l ,  1990; Lobigs et a l ,  1990).
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Domain C is composed of a disulphide free loop, made up of amino acids 
131-177 (Chambers et a l ,  1990), which connect two discontinuous parts of domain 
A. Using MAbs, no functional activities have been associated with this domain. 
Epitopes in this domain are not denatured by SDS, but are sensitive to protease 
treatment (Guirakhoo et a l ,  1989). So far, no specific serological and biological 
functions has been assigned to this domain.
Recently, Heinz and his colleagues (1991) have isolated a soluble form of the 
E protein from TBE virus, and obtained a crystallized E protein. It is possible that 
X-ray crystallographic analysis will yield a three-dimensional structure of the E 
protein which matches closely that of the native E protein. This, in turn, will be 
greatly helpful in elucidating the functional activities and antigenic properties of this 
protein.
1.3.5 Non-Structural proteins
Compared to the structural proteins, the non-structural proteins of flaviviruses 
have been relatively poorly studied. However, recently they have been subjected to 
more intense scrutiny. There are seven non-structural (NS) proteins encoded by the 
flavivirus genome (Rice, 1990) (see Figure 1.1).
1.3.5.1 NSl protein
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The NSI protein is a glycoprotein (MW 39-41 Kd) and may exist as different 
forms that can be found on the cell surface, in the culture fluid of infected cells and 
in the serum of infected animals (Russell et a l ,  1980). The nucleotide and deduced 
amino acid sequence of this protein has a high degree homology among different 
flaviviruses and contain 12 strictly conserved cysteine residues (except DEN-4 virus) 
(Gibson et a l ,  1988). The N-linked glycosylation in flavivirus NSl proteins so far 
examined also exhibits a high degree of conservation dependent on the vector 
involved in transmitting the virus (Chambers et a l ,  1990). All mosquito-bome 
flaviviruses contain two potential sites with an additional site between them seen in 
members of the JE serocomplex, except for JE virus itself. TBE serocomplex viruses 
share one of these sites but have two additional unique sites (Chambers et a l , 1990). 
This protein has been identified as the soluble complement fixing antigen of 
flaviviruses.
The protein is largely hydrophilic except for the C-terminal region, which 
contains a hydrophobic region for anchoring NSl in the plasma membrane. The 
function of NSl is not known but it is suspected to be involved in viral 
morphogenesis (Rice et a l,  1986). Since NSl is expressed on the surface of 
flavivirus infected cells it is capable of eliciting an immune response from the host. 
NSl has been confirmed to play a role in protection by stimulating host defence other 
than viral neutralization (Gibson et a l,  1988). Kulkarni et a l  (1992) reported that 
membrane associated NSl could stimulate T^-cell response in mice. Immunization 
with YE virus NSl or DEN-2 virus NSl elicited protective inununity in mice against 
lethal virus infection (Schlesinger et a l ,  1985, 1987).
26
For several flaviviruses, including DEN-2, St. Louis encephalitis and 
Powassan viruses, NSl, has a dimeric form with a size of 75 - 86 Kd MW in non­
denatured samples of infected cells, but is converted to a monomer by dénaturation 
(Winkler et al. , 1988; 1989). However, two different NSl proteins (NSl 42 kd MW 
and N S r 58 kd MW) were found in JE virus infected Vero cells. NSl (58 kd MW), 
which has only been identified in JE virus infected cells, contained C-terminal 
sequences encoded by the NS2A region of the genome (Mason et al., 1987). 
Furthermore, homo and heterodimers of NSl and NSl’ appeared to be present in the 
JE virus-infected cells (Fan and Mason, 1990).
1.3.5.2 Four small non-structural proteins
NS2A, NS2B, NS4A and NS4B are four small non-structural proteins. All 
exhibit regions of hydrophobicity that are conserved between different flaviviruses. 
This suggests that these proteins are membrane associated (Chambers et al., 1990).
NS2A (MW 18 Kd) has been implicated in the processing of NSl (Falgout et 
al., 1989). Two forms of NS2A in YF virus infected cells have been observed with 
molecular weights of 20 and 22 kd respectively; the structural basis and significance 
of these forms is not clear (Chambers et al., 1989).
NS2B protein (MW 13 kd) is involved in the processing of regions of the 
flaviviral polyprotein that are cleaved by the proteinase domain encoded by NS3 (see 
following section). It has been demonstrated that NS2B, in addition to the NS3
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proteinase domain, is required for cleavage of all the dibasic sites in the flavivirus 
polyprotein in both DEN-4 virus (Falgout et a l , 1991) and YF virus (Chambers et 
a l ,  1991) infected cells. NS2B also appears necessary for a series of internal 
cleavages of NS3 (Falgout et a l ,  1993). However the precise nature of the role 
played by NS2B remains unclear.
The functions of NS4A (23 Kd) and NS4B (28 Kd) proteins are poorly 
understood. Preugschat and Strauss (1991) reported that a 30-Kd precursor of NS4B 
was found in DEN-2 virus infected mammalian and mosquito cells at 6 to 9 hours 
post infection. This precursor may be 2k-NS4B protein. NS4A and NS4B may be 
involved in membrane localisation of NS3 and NS5 via protein-protein interactions 
(Chambers et a l ,  1990). However, it was suggested that NS4B is not a simple 
membrane associated protein but rather consists of multiple membrane-associated 
regions and cytoplasmic loops (Lin et a l , 1993). Cauchi et a l  (1991) also found that 
membrane-associated NS4B isolated from DEN-2 virus infected cells was susceptible 
to proteinase digestion. No post-translational modification of these proteins has been 
detected, although NS4B contains a potential N-linked glycosylation site (Lee et a l , 
1990).
1.3.5.3 NS3 protein
NS3 is the second largest viral protein (MW 67 Kd), is highly conserved 
among different flaviviruses and has a net positive charge (Mandl et a l , 1989). It has 
been observed that NS3 is tightly attached to endoplasmic reticular membrane in
28
infected cells although NS3 sequence data suggest that NS3 is hydrophilic and not 
a transmembrane protein. Immunofluorescence assays indicate that NS3 and NS5 
form a complex in the perinuclear fraction (Edward and Takegrami, 1993). NS3 may 
be bifunctional having a nucleotide triphosphatase/helicase and viral proteinase 
activities (Rice et a l ,  1989).
As stated in the previous section, the N terminal one-third of NS3 has been 
identified as important in the processing of the flavivirus polyprotein at dibasic 
cleavage sites surrounded by short-side-chain amino acids. Within the N-terminal one 
third of NS3 (residues 1-180), a region was identified by sequence comparison and 
molecular modelling which exhibited homology to the trypsin family of chymotrypsin- 
related serine proteinases (Bazan and Fletterick, 1989; Gorbalenya et a l ,  1989a). 
This region, with the help of NS2B, has been demonstrated to catalyze the 
cytoplasmic cleavages of NS2A-NS2B, NS2B-NS3, NS3-NS4A and NS4B-NS5 
(Lobigs, 1993). Recently, Lin et a l (1993) reported that the NS4A/4B site cleavage 
occurred only during co-expression of NS2B and the proteinase domain of NS3. They 
found that the signalase cleavage generating the N-terminus of NS4B requires a prior 
NS2B-NS3 proteinase-mediated cleavage at a novel site (termed the NS4A/2k site).
NS3 also contains regions that exhibit homology with the D-E-A-D family of 
RNA helicases (Gorbalenya et a l ,  1989b), specifically between residues 191-508 of 
YF NS3 protein. Although two functions are proposed for NS3, there is no evidence 
that supports cleavage of the protein into two separate proteinase and helicase 
domains although Arias et a l (1993) reported that NS3 protein of DEN-2 virus could
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be cleaved into NS3’ (50 KD) fragment at the conserved RNA helicase sequence 
motif. The importance of the NS3’ protein and its role in the replication cycle of 
flavivirus remain to be determined.
Kurane et al. (1991) observed that 7 of 12 CD4^ T-cell clones examined, with 
four different DEN virus specificities, recognize NS3 strongly. Purified NS3 induced 
a high level of proliferation of peripheral blood monocytes from a donor in bulk 
cultures (Kurane et al. , 1991). This suggests that NS3 contains specific CD4^ T cells 
epitopes.
1.3.5.4 NS5 protein
NS5 protein (MW 104-106 Kd) is the largest protein and highly conserved 
among flaviviruses (Mandl et al., 1989a). It is thought that most of NS5 is present 
in the perinuclear membrane fractions of IE virus infected cells (Chambers et al.,
1990). Analysis of the deduced amino acid sequence, suggests that NS5 may be 
bifuctional like NS3. A sequence motif that is conserved in a number of S- 
adenosylmethionine (SAM)-utilizing methyltransferases W implicated in SAM binding 
has been identified in the N-terminal portion of NS5 proteins of flaviviruses (Koonin,
1993). It is hypothesized that the N-terminal of NS5 protein is a methyltransferase 
involved in viral RNA capping. Another function is the viral RNA dependent RNA 
polymerase. A highly conserved domain of flaviviruses (in JE virus, residues 531- 
675) contains the sequence motif Gly-Asp-Asp (Rice et al., 1985, 1986). This motif 
is present in the polymerase region from several positive stranded RNA viruses and
30
is believed to play a role in RNA-dependent RNA synthesis (Kamer and Argos, 
1984). Although NS5 lacks of any long hydrophobic stretches, it has been found 
associated with membranes (Chambers et a l ,  1990). Anti-NS5 antibodies are able to 
inhibit in vitro RNA synthesis (Edward and Takegrami, 1993).
1.3.6 Virion morphology and physicochemical properties
1.3.6.1 Morphology
Electron micrographs of negative stained purified virus preparations reveal
spherical particles with a diameter of about 50 nm that carry a fringe of small surface
tfuL.
projections of about 5 nm. The outer surface of^ v^irus is covered in projections that 
are 5-10 nm in length that terminate in a 2 nm diameter knob that mainly consists of 
the viral E and M protein (Murphy, 1980). The nucleocapsid core contains a single 
copy of single-stranded RNA that is of positive polarity and complexed with a single 
species of capsid protein (Westaway, 1980).
1.3.6.2 physichemical properties
The buoyant densities of flaviviru^ are 1.22-1.24 g/cm^ in caesium chloride 
gradientsand 1.18-1.20 g/cm^ in sucrose respectively (Smith et a l , 1970). Infectious 
particles have a sedimentation co-efficient in sucrose of between 175 and 218 S 
(Boulton and Westaway, 1972). The infectivity of most flavivirus virions exhibit 
maximal stability in the range pH 7-9 (Brinton, 1986); However tick-borne
31
flaviviruses can tolerate lower values (pH 3 for 24 hours) (Pogodina, 1958). Virions 
are rapidly inactivated at 50®C, with a decrease in infectivity of about 50% in 10 mins 
at this temperature (Portfield et a l ,  1978).
Using St. Louis encephalitis virus as a model, the chemical composition of a 
flavivirus is 6% RNA, 66% protein, 17% lipid and 11% carbohydrate (Trent and 
Neave, 1980). However both the lipid type and overall content varies depending upon 
the cell line in which the virus is propagated. This indicates that the virion 
phospholipid is derived from the pre-existing host lipids (Trent and Neave, 1980). 
Virions have also been shown to be sensitive to ultraviolet light, both ionic and non­
ionic detergents, and trypsin digestion.
1.3.7 Flavivirus replication in cell culture
Flaviviruses can replicate in primary and continuous cells derived from many 
mammalian, avian, and arthropod sources. Evidence suggests that the flavivirus enters 
cells by receptor-mediated endocytosis (Gollins and Porterfield, 1986), presumably 
mediated by the virion E protein and plasma membrane receptors. However, the 
cellular receptors for flaviviruses have not been identified (Chambers et a l ,  1990). 
Virions are later found in uncoated vesicles, where an acid-catalyzed
membrane fusion is thought to release the nucleocapsid into the cytoplasm (Gollins 
and Porterfield, 1986). The uncoating of virions, translation of the infecting virion 
RNA, and the initiation of RNA replication have not been studied in detail. Viral
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RNA synthesis can be detected at three to six hours post-infection, with the release 
of infectious virus beginning at approximately 12 hours post infection (Murphy, 1980, 
Chambers et ah. 1990).
A major change of flavivirus infected cells is proliferation and hypertrophy 
within rough endoplasmic reticular membranes that virus particles accumulate. Host 
cells macromolecular synthesis is not markedly decreased until the late stage in 
flavivirus infection, when cytopathic effects (CPE) appear (Murphy, 1980). Cellular 
pathological change include mitochondrial damage, fragmentation of reticular 
membranes, formation of distended vacuoles and inclusion bodies, increase in 
lysosomal bodies, and rarefaction of cytoplasm. Activities of lysosomal enzymes 
increases in the infected cells.
1.4 Japanese encephalitis
1.4.1 History of Japanese encephalitis
JE is a mosquito-borne infectious disease caused by JE virus, a member of the 
family Flaviviridae. As early as 1871 JE like disease has been recognized in horses 
and humans (for a review see Rosen, 1986). Epidemics of JE were recorded every 
year between 1873 to 1968. In the 1920s, a few encephalitis cases were reported in 
north and north east China (Wang, 1986), and several national wide epidemics of JE 
occurred in Japan. JE is now throughout much of Asia and is considered
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the most important^mosquito-bome viral encephalitis (Huang et al, 1982). JE virus 
was first isolated in 1933 (Drobyshevskaya and Korsunova, 1954). Hayashi 
reproduced the disease in intracerebrally inoculated monkeys in 1934. The prototype 
strain of JE virus was obtained from the brain of a patient who died of encephalitis 
in Tokyo and is termed strain Nakayama (for review see Monath, 1990; Rosen, 
1986). Mosquito transmission was suspected as early as the 1930s, and Mitamura et 
al. (1938) reported isolation of JE virus from the mosquito Culex tritaenorhynchus. 
During that time JE had been given several different names such as summer 
encephalitis, epidemic meningo-encephalitis and Japanese B encephalitis. The name 
was unified under Japanese B encephalitis in 1946 as the virus was a member of the 
group b arboviruses.
1.4.2 Epidemiology of Japanese encephalitis
JE is generally transmitted to man via the bite of mosquitoes, and, even if 
virus is present in the blood and other bodily secretions during acute infection, direct 
spread from one human to another seems unlikely due to the low level of infectious 
virus. Therefore, it follows that prerequisites for the initiation of epidemics are that 
there is an available reservoir of infectious virus, and high levels of mosquito 
populations to maintain the transmission cycle (Rosen, 1986). Nevertheless, the 
viraemia in humans is insufficient to enable a mosquito to become infected, thus 
humans are a dead-end host. Though only a small fraction of persons infected with 
JE virus develops clinical manifestation of encephalitis, those manifestations are so
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severe that the disease is greatly feared.
Currently, fewer than 20 cases of JE occur annually in Japan. In China, large 
numbers of cases (>10,000) occur annually, but the annual incidence is declining 
since JE vaccine has been administrated. However, epidemic activity in India, Nepal, 
and the northern part of southeast Asia has increased since the 1970s. Outbreaks in 
India between 1973 and 1983 have involved over 10,000 cases. In northern Thailand, 
annual outbreaks occur with an attack rate of 10-20 per 100,000.
1.4.2.1 Geographic distrihution
JE virus has been found throughout most of Asia from southeastern Russia in 
the north to Indonesia in the south. JE is present in almost each province of China, 
except Xingjang and Tibet. The western limit of JE is Goa on the west coast of India. 
In the east limits of JE distribution are the islands of Japan, Taiwan and Philippines. 
In the south, its limit is the eastern part of the Indonesian archipelago. Countries with 
proven epidemics of JE are India, Nepal, Sri Lanka, Burma, Laos, Thailand, 
Kampuchea, Vietnam, Malaysia, Singapore, Philippines, Indonesia, Saipan, China, 
Maritime Siberia, Korea and Japan. JE was reported in Guam island but the virus did 
not persist there (for a review sees Rosen, 1986). Little is known about the 
epidemiology of JE in Bangladesh. The disease was reported for the first time in 1977 
based on a clinical diagnosis without serological confirmation (WHO report, 1977).
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1.4.2.2 Seasonal variation
Epidemiologically, there are two different seasonal patterns of JE according 
to the climate. In tropical areas, such as south India, Indonesia, Malaysia and 
Singapore, transmission of JE virus may occur year around, so that sporadic JE cases 
occur throughout the whole year and there is no obvious seasonal variation in the 
incidence of the disease (Umenai et al., 1985). However, in temperate zones and in 
the northern part of the tropical zone, such as most parts of China, Japan, Korea, 
Nepal, Thailand and Vietnam, there are clear seasonal differences in the incidence of 
JE. JE patients are generally seen from July when the rainy seasons begins, reaching 
a peak in late August or early September when the mosquito population is at the 
maximum. Normally the epidemics cease in late October (Huang et al., 1982). An. 
epidemiological survey in India demonstrated the sequence of increasing rainfall 
followed by an increase in vectors, seroconversion in sentinel farm animals, and 
finally, seroconversion and illness in the human population (Mani et al., 1991). This 
sequence of events has been observed elsewhere.
1.4.2.3 Age distribution of JE patients
Age distribution of JE patients varies between regions. In temperate zones, 
such as Korea, Thailand, China and Japan, most cases were in children under 14 
years old . and the highest age-specific attack rate usually occurs in children
aged 3-6 years old. The observation that higher morbidity occurs in children 3-6 years 
is consistent with a higher risk in this group due to behaviourial factors; perhaps 
increased play outside, especially after dusk, allows increased exposure (Hoke et al.,
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1992). However, after JE vaccine has been wildly used, the number of children with 
JE has decreased while elderly patients over 60 years old has tended to increase 
(Ishii, 1986; Huang et al., 1982; Umenai et al., 1985). In addition, adult travellers 
to areas where JE virus is transmitted are susceptible to devastating infections.
1.4.2.4 Strain variation
Strain variation among JE virus isolates has been demonstrated by many 
workers. It was first reported in 1954 by Hale and Lee using polyclonal antisera. In 
1984, Kobayashi et al. characterized variation of JE virus antigenicity with MAbs. 
They reported there are several distinct immunotypes in wild-type JE virus. However, 
several studies could not correlate strain variation to geographic location (Okuno et 
al., 1968; Kobayashi et al., 1984; Hammam and Price, 1966). Okuno et al. (1968) 
analyzed 26 strains of JE virus isolated from Japan and South-east Asia with a panel 
of anti JE virus MAbs and distinguished the virus into three antigenic distinct 
groups. Oligonucleotide fingerprint analysis of JE virus strains from different 
geographical origins showed that Nakayama strain of JE virus had a great similarity 
with the Asansol strain from West Bengal, another strain, Bankura from West Bengal 
was clearly different to Nakayama; whereas Bhopal and Beijing-1 strains were 
relatively close to each other. As with antigenic variation, no geographic relationship 
could be related to the strain variation (Banerjee and Ranadive, 1990). Although 
strain variation has been reported, Hoke et al. (1988) found the monovalent 
Nakayama-NIH vaccine was as good as a bivalent vaccine consisting of the 
Nakayama-NIH and Beijing-1 (a different immunotype of JE virus), and the
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antibodies induced in recipients vaccinated with Nakayama-NIH were capable of 
neutralizing IE strains from India and other Nakayama sub-strains (Poland et al. , 
1990).
1.4.2.5 Vertebrate host of JE virus
Humans, swine and equines are the main vertebrate hosts in which IE virus 
could cause disease under natural conditions. However, many other vertebrates are 
infected inapparently with JE virus. Interest on these vertebrates is centred either on 
their role as sources of infection for mosquitoes that transmit JE virus or their role 
as a host in which JE virus may overwinter.
It is well established in several countries that swine are a very important 
source of infection for mosquito species that transmit JE virus to humans (Buescher 
et al., 1959; Simpson et al., 1976). Every year in Asia there is a big population of 
new-born swine which are susceptible to JE virus infection. However, despite their 
importance in the epidemiology of JE, swine are not an essential part of the basic 
cycle of JE virus as there are none in certain islands where JE virus is found. JE 
virus causes only stillbirth in swine and not encephalitis.
JE virus has only occasionally been isolated from human blood (Chan and 
Loh, 1966) the viraemia is almost absent by the time symptoms of JE virus infection 
are apparent. It is thought that the human viraemia is not of a high enough titre to 
allow transmission of virus from human to human via mosquitoes.
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Equines sometimes develop encephalitis following JE virus infections (Bums 
et al. , 1949; Wang et al. , 1982), however, they are not a significant source of viral 
infection for mosquitoes since their population is low and turn-over slow rendering 
few equines susceptible in JE endemic areas (Gould et a l ,  1964). Cattle and water 
buffalo are hosts to the same mosquito species that feed on swine and often have 
neutralizing antibody to JE vims. However, they only develop low viraemia that are 
insufficient to infect mosquitoes (Carey et a l ,  1969).
Birds are generally considered as the basic vertebrate host of JE vims. JE 
vims has been isolated from a variety of wild species in nature, both domestic and 
wild birds have been shown to develop viraemia high enough to infect mosquitoes. 
Young birds exhibit higher viraemia than old ones of the same species (Boyle et a l ,  
1983; Dhanda et a l,  1977). The importance of birds as a source of infection for 
species of mosquitoes than transmit JE vims to humans is still not clear. It is difficult 
to interpret the serological data of the birds due to false positive or negative results 
due to cross-reactivity of antibodies to other flavivimses known to infect birds.
1.4.2.6 Invertebrate host of JE virus
It is now clear that mosquitoes are certainly the principal vectors and perhaps 
the only vectors of JE vims to infect humans and domestic animals. The existence of 
JE vims is not dependent on humans but mosquitoes are essential to infect humans 
with the vims. There is no question that Culex tritaeniorhynchus is the most important 
mosquito involved in transmitting the vims as the incidence of JE disease parallels the
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geographic range of the mosquitoes. Other species of mosquitoes have also been 
demonstrated to transmit JE virus. There, in order of importance, are C. vishnui, C. 
gelidus and C. Juscocephala (for review see Rosen, 1986 and references therein). C. 
pipiens and C. quinquefasciatus probably transmit JE virus to humans to some extent 
since they have been found infected naturally, though they are less important than the 
Culex species listed above.
Although JE virus can replicate in a wide variety of arthropod hosts when 
incubated parentally, isolation of the virus from arthropods other than mosquitoes in 
nature has been reported only twice, once from midges, Lasiohelea taiwana, collected 
while biting humans in China, and the other is from ixodid ticks, Haemaphysalis 
japonica, in Russia (Rosen, 1986 and references therein).
1.4.2.7 Overwintering
In the natural history of JE virus, the major unsolved problem is how the virus 
survives the winter in the temperate zones. It is not clear if JE virus does over winter 
in these areas. The overwintering question also is an unsolved problem for related 
mosquito-bome flavivimses that cause encephalitis in humans. There are three 
possibilities: first the vims is reintroduced to temperate zone each year; second, JE 
vims passes winter locally in a vertebrate host; and third JE vims passes winter 
locally in an invertebrate host. However, to date, convincing evidence does not exist 
to validate any of the proposed overwintering hypotheses. All positive findings so far 
either have not been confirmed by other investigators or are suspect because they
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conflict with other data (Huang et a l ,  1982; Rosen, 1986).
1.4.3 Clinical manifestations and pathology of JE
The clinical incubation period of JE is about one to two weeks. The illness 
may be manifested by a febrile headache syndrome, aseptic meningitis, or encephalitis 
(Gatus and Rose, 1983). In the full-blown encephalitis form, the onset is rapid, 
patients generally give a history 1 - 3  days headache often accompanied with fever, 
chills, anorexia, nausea, vomiting, dizziness and drowsiness. These symptoms are 
followed by the appearance of nuchal rigidity, photophobia, altered status of 
consciousness, hyper excitability, and varying objective neurological signs, including 
dull musk-like facies, muscular rigidity, cranial nerve palsies, tremulous eye 
movement, coarse tremors of the extremities, involuntary movements, generalized and 
localized paresis, incoordination, and pathologic reflexes. Convulsion are frequent in 
children but rare in adult patients. Mortality is approximately 25% (Hoke et a l ,  
1992). Death occurs on the fifth to ninth day or during a more protracted course with 
cardiopulmonary complications. A poor prognosis is associated with respiratory 
dysfunction.
Examination of cerebrospinal fluid reveals normal or moderately increase 
pressure, slightly increased total protein, and lymphocyte pleocytosis of 10 to 1000 
mononuclear cells/ml.
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Neuropsychiatrie sequelae occur in 70% of survivors and are particularly 
severe in children. Sequelae include Parkinsonism, convulsive disorders, motor 
abnormalities, impaired intellect and emotional disorders. The social prognosis of 
survivors is generally poor (Simpson et al., 1947).
1.4.4 Pathogenesis and pathology of JE
Considerable variation exists among JE strains in neurovirulence and 
peripheral pathogenicity for human beings. Mechanisms of penetration of the blood 
brain barrier are not known. Virus may replicate in blood vessels, facilitating early 
replication in the brain (Huang et al., 1982). During the acute stage of JE, the brain 
appears to have vascular congestion, mild edema, small haemorrhages, and minimal 
overlying cellular exudate. Virus can be isolated from all areas of the brain. 
Microscopic lesions include neuronal degeneration and necrosis, neuronophagia, glial 
nodules, and perivascular inflammation. These changes occur in grey matter and 
predominantly affect diencephalic, mesencephalic and brain stem structures. A variety 
of pathological changes in extraneural tissues have also been noted including 
hyperplasia of the germinal centre of lymph nodes, enlargement of malpighian bodies 
in spleen, intestinal myocarditis, and focal haemorrhages in the kidneys (Monath, 
1990 and references therein).
Experimental encephalitis showed that JE virus-specific memory B-cells persist 
in the central nervous system of mice for months (Gerhard and Koprowski, 1977).
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Burke et al. (1985) reported the presence of JE virus-specific IgM in serum and 
cerebrospinal fluid (CSF) long after recovery from acute encephalitis illness in^small 
proportion of Thai children. Recently, Ravi et al. (1993) reported that JE virus 
antigens could be detected in CSF of confirmed JE patients from 30 to 251 days after 
onset of symptoms, and virus was isolated from CSF of the patients after three weeks 
of illness. In one case JE virus was isolated at 117 days after illness. The persistence 
of JE virus in the human nervous system may account for clinical phenomenon of late 
sequelae in some JE patients.
In one study of fatal cases, JE viral antigens were localized to neurons, with 
no evidence of glial cell infection. Dual Auman infections with JE and herpes simplex 
viruses have been reported (Hayashi and Arita, 1977). In analogous experiments in 
mice, JE viral antigens were localized in herpesvirus infected areas of brain, 
suggesting that JE virus gained access to the central nervous system at sites of blood- 
brain barrier disruption caused by the herpesvirus.
Transplace^al infection in swine results in abortion and stillbirth; abortuses 
show encephalitic lesions. The virus also produces hyospermia in boars (Habu et al. , 
1977). Histopathological changes include epididymides, spermatogenic arrest and 
inflammation of the tunicatestis. Transplacental infection in humans has been 
documented, resulting in abortion and isolation of the virus from the fetuses 
(Chaturvedi et a l ,  1980). Pregnant mice inoculated intraperitonea6  ^ also transmit 
JE virus to the fetus, with subsequent abortion (Mathur et ah, 1982).
43
1.5 Prevention of the JE
1.5.1 Control of vector and vertebrate host
The use of pesticides to control JE virus vector has generally been effective 
only in limited areas for a short time and at great cost. Ultra-low-volume fenitrothion 
delivered from fixed-wing aircraft was effective in reducing Culex tritaeniorhynchus 
adult mosquito population by nearly 80% over a 4 day period in Korea (Self et al. , 
1973). The use of herbicides/ larvacides CNF (p-nitro-phenyl 2,4,6 trichloro-phenyl- 
p, nitrophenyl ether) and nitrofen (2,4-dichloro-phenyl^, nitrophneyl ether) are 
credited with decreasing the numbers of Culex tritaeniorhynchus mosquitoes in the 
Kyoto city area, Japan in the early 1970s (Maeda et a l ,  1978). Huang (1982) 
partially credits the decrease in morbidity in Beijing from 15-25/100,000 to 
2.5/100,000 between 1949 and recent years to the mosquito control programme that 
started in 1950. However, spraying pesticides to control the vector is of limited 
effectiveness and mosquitoes have developed resistance to insecticides.
The use of light or wing-beat sound traps near pigsties has been recommended 
to aid in the control of Culex tritaeniorhynchus mosquitoes (Kerdpibule et al., 1989). 
Keeping people from mosquitoes by distancing housing from rice fields and pigsties 
can help. Personal precautions should be taken by residents of endemic regions and 
travellers to those areas, to avoid mosquito bites.
Control of vertebrate hosts has not proven to be efficacious in the prevention
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and control of JE. Pigs are the major source of family income in many parts of Asia, 
and no serious programme has ever been mounted to induce farmers to reduce 
numbers of pigs raised. Although it is possible to select strains of mice that are 
relatively resistant or susceptible to flavivirus infection, no attempts has been reported 
to produce swine strains that are genetically resistant to JE virus. Extermination of 
the potential bird amplifying host population is considered impractical. Konishi et al. , 
(1992a) reported using a vaccinia virus encoding the prM, E and NSl genes of JE 
virus can prevent JE virus viraemia in swine, which may benefit controlling JE 
vertebrate hosts.
1.5.2 Inactivated Vaccines
It has been known that animals surviving peripheral inoculation of a 
sufficiently large dose of wild-type JE virus are immune to challenge with lethal doses 
of virus. During 1935 -1940, the first formalin-killed vaccine, mouse brain-type, was 
prepared by Japanese investigators using the Kalinina strain. Its protective effect was 
tested in man and animals (Mitamura et al., 1936, 1940). In 1945, the American 
Army made a crude mouse-brain vaccine in Okinawa. Subsequently in 1948 - 1949, 
another crude formalin-inactivated supernatant from infected mouse-brain 
homogenate was used to prepare a vaccine from JE virus strain Nakayama (see 
review by Stephenson, 1989). This vaccine was confirmed to provide some protection 
but was soon replaced by a better purified mouse-brain type vaccine because it did 
not provide a significant level of protection and had several side effects (Takaku et
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al., 1972). The purification process has received subsequent modifications, for 
example, ultracentrifugation, ethanol precipitation and filtration etc. Those 
modifications were successful in removing many of undesirable side effects from the 
vaccine (reviewed in Takaku et al., 1972).
Use of the Nakayama-NIH (ie, the Japanese National Institute of Health 
subculture of Nakayama) inactivated vaccine has been evaluated for safety and 
efficacy in several field trials, which confirmed its safety and the vaccine provides 
about 80% protection in a short period after one dose vaccination. A booster 
vaccination has been used seven to 14 days after,^first dose to generate protection 
levels of about 95% (Monath 1990). It was recommended that further booster 
vaccinations should be repeated once every three to four years to maintain a 
protective level of antibody (Oya, 1986). In a special survey in Japan for assessing 
the side effect of this vaccine, some mild symptoms were noted in 1.2% of vaccinees 
although no severe post-vaccination side affects were found. However, in Japan this 
vaccine is not administered to children with certain diseases for fear of side affects. 
Currently, the Nakayama-NIH mouse brain formalin inactivated vaccine is
manufactured in Japan, Korea, Thailand, Taiwan, and India. The JE vaccine is also
iAsi. iÂJu 
administrated inU.K. and U.S.A. to travellers.A / \
Okuno et al. (1968) reported that Nakayama-NIH vaccine induced cross 
neutralizing antibody which reacted to almost the same extent with nine different JE 
virus strains as the homologous strains, even though strain variation between isolates 
of wild-type JE virus has been reported (Poland et a l ,  1990). In consideration of
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antigenic divergence of JE virus strains, two bivalent vaccines have also been 
produced and tested. Inactivated JE strains Nakayama-NIH and Beijing-1 were 
compared as a bivalent vaccine to monovalent Nakayama-NIH vaccine. The study 
concluded that two doses of either monovalent or bivalent vaccine provided the same 
level of protection against JE virus (Hoke et a l , 1988). Another bivalent preparation 
of Nakayama and PI strains showed a higher seroconversion rate than the monovalent 
vaccine alone (Gu et a l ,  1987). Because of possible allergic reactions to the mouse- 
brain derived vaccine, the Chinese government instituted a programme to develop an 
inactivated vaccine grown in primary baby hamster kidney (PHK) and chick embryo 
fibroblast (CEE) cells. A wild-type strain of JE virus called P3 was selected due to 
its good antigenicity and immunogenicity. The formalin-inactivated vaccine purified 
from P3 virus infected PHK cells has been widely used in China from 1967 for the 
vaccination of young children aged between 1 - 1 0  years old. This vaccine is highly 
effective and protection rates in excess of > 90% have been reported (Yao, 1986 and 
Gu et a l , 1987). Approximately 75 million dose of this P3 virus based vaccine were 
administrated in China annually.
1.5.3 Live attenuated JE vaccine
Many workers have been continuously attempting to develop live attenuated 
JE vaccines. As early as 1957, Bhatt and Work reported that JE prototype strain 
Nakayama has been attenuated to a degree for mice after it was repeatedly passaged 
in primary monkey kidney (PMK) cell cultures. However, they found that this variant
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recovered it virulence for mice following passage in CEF cells.
In 1963, Hammon and his co-workers (Rohitayodhin & Hammon, 1962) 
reported that JE virus variant OCT-541 was highly attenuated by continuous passages 
in PHK cells, and this variant grew well at temperature from 24°C up to almost 37°C, 
but was temperature resistant at higher temperatures. Studies in human volunteers 
revealed that live attenuated strain OCT-541 vaccine was over-attenuated and could 
not replicate in man to induce protective inununity (Sigh et a l , 1973).
In several far-eastern countries, the development of a live attenuated JE 
vaccine has been proceeding for decades. Japanese virologists in several laboratories 
derived attenuated variants for use as a live JE vaccine. These variants have been 
given extensive trials in domestic animals. The most widely used is the M strain, a 
mutant derived from the Mukai isolate by repeated serial passage in embryonic mouse 
skin cultures (Inoue, 1964). Although no viraemia was detected, pigs inununized with 
this mutant mounted a long-lasting inunune response. Open field trials have also 
demonstrated that this vaccine virus is capable of protecting pigs against JE infection 
and reducing viraemia sufficiently to prevent the transmission of virus by feeding 
mosquitoes (Kodama et a l , 1986). Other developed attenuated viruses have also been 
used in experimental trials. However, the results were not satisfactory (Takehara et 
a l ,  1969; Hanunon g/ aZ., 1963; Hammon a/., 1966).
To date, the most promising attenuated JE virus vaccine is the Chinese 
SA14-14-2 virus derived from wild-type strain SA14 (Yu et a l , 1973) after initially
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failing to attenuate the P3 strain of JE virus by repeated passage in primary avian 
fibroblast culture. The safety and efficacy of this attenuated vaccine have been 
confirmed in human vaccinees (Yu et a l ,  1981, 1988; Ao et a l ,  1983).
JE virus SA14 strain was, a low peripheral pathogenic but highly neurovirulent 
strain for mice, isolated from mosquitoes collected in Sian, China in 1954. A 
significant drop in neurovirulence was observed after 11 passages by intracerebral 
inoculation of newborn mice, and after 100 passages in PHK cells (see Fig. 1.3). The 
first attenuated low neurovirulence variant, 12-1-7, was obtained by picking a small 
size plaque when the virus was purified (for review see Li, 1986, Yu et a l , 1962, 
1973; Li, 1986). The SA14-2-8 vaccine virus was further attenuated by treatment of 
the 12-1-7 with ultraviolet irradiation and plaque purification; SA14-5-3, a highly 
attenuated and stable virus, was prepared from 12-1-7 virus by additional plaque 
purification passages in PHK cells. SA14-5-3 virus was further passaged in suckling 
mice six times subcutaneously by infecting skin and subcutaneous tissue as virus 
material for subpassages; subsequently SA14-14-2/PHK virus was obtained following 
plaque purification in PHK cells (Yu et a l ,  1981; Li, 1986). Both laboratory and 
field tests showed that the three vaccine viruses were highly attenuated and non­
mosquito competent (Yu et a l ,  1962, 1973), the attenuated phenotype is stable 
following several passages in suckling mouse brain and various tissue culture. 
However, SA14-14-2 vaccine virus is more immunogenic than SA14-5-3 vaccine virus 
so that 100 fold less infectious SA14-14-2 virus was required to infect and stimulate 
immunity in humans. Moreover, the seroconversion rate and geometric mean antibody 
titres were higher following the SA14-14-2 vaccine immunization than the SA14-5-3
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vaccination (Liu, 1985). Like SA14-5-3 virus, the SA14-2-8 virus was attenuated but 
not sufficiently immunogenic for use as a vaccine.
SA14-5-3, then SA14-14-2 vaccine viruses were tested for safety and 
immunogenicity in susceptible animals. Subsequently^ human field trials from small 
groups to large scale, SA14-5-3 virus was used for vaccination of 1 - 10 year old 
children. No abnormal reaction was noticed after 14 days vaccination, and protective 
efficacy of one dose of SA14-5-3 vaccine was 85% (Yu et a l, 1873). By 1986 5 
million children were vaccinated with SA14-5-3 vaccine and by 1990, 20 million 
children had been vaccinated with SA14-14-2 vaccine. Seroconversion rates of > 
90% were reported from children receiving a single dose of SA14-14-2 vaccine and 
no untoward side effects were recorded (Li, 1986; Yu, personal communication).
Unfortunately, the SA14-14-2 vaccine is produced in PHK cells which are not 
approved by the World Health Organization (WHO) for viral vaccine production or 
licensed for human use. Although no apparent adverse reaction has been observed in 
humans receiving SA14-14-2 vaccine produced in PHK cells, alternative cell substrate 
might offer advantage in standardization of vaccine, including testing for adventitious 
agents and production. Therefore, Eckels et al. (1988) passed SA14-14-2/PHK virus 
nine times in primary dog kidney (PDK) cells to prepare the SA14-14-2/PDK vaccine. 
The antigenic differences between SA14-14-2/PHK and SA14-14-2/PDK are slight 
(Wills et al., 1993), and seven amino acid substitutions differentiate the genomes of 
these two vaccine viruses (Nitayaphan et al., 1990; Aihara et al., 1991). However, 
the clinical trial using SA14-14-2/PDK vaccine were not as successful as SA14-14-
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2/PHK vaccine (Barrett, personal communication). All of the candidate vaccine 
strains; SA14-2-8, SA14-5-3, SA14-14-2/PHK and SA14-14-2/PDK viruses are 
attenuated for humans and are not encephalitogenic in adult mice inoculated 
intracerebrally with 10^  pfu of virus (Yu et al. 1981; Chen and Wang, 1974). The 
passage history of the attenuated vaccine viruses derived from SA14 are summarized 
in Figure 1.3.
In this laboratory two attenuated vaccine candidates have been developed by 
passage of wild-type strains Nakayama-original and 826309 six times in HeLa cells. 
Nakayama HeLa p6 and 826309 HeLa p6 were significantly attenuated for adult mice. 
However, further studies, such as the in vivo protection and the genetic basis of their 
attenuation, are required to characterize these two attenuated virus strains (Gao, 
1990).
1.5.4 Future vaccine
In order to overcome the problem of possible allergic reaction to inactivated 
mouse brain derived vaccine and regain of virulence of live attenuated vaccine, 
interest has arisen in using the flavivirus soluble complement-fixing antigen NSl 
protein as a vaccine (Gibson et a l,  1988) as this protein stimulates protective 
immunity (see section 1.3.5.1). Also, the vaccines manufactured using recombinant 
DNA technology A«^ e,been studied. Viral proteins have been expressed in yeast (Fujita 
et at., 1987), E. coli (Mason et a i ,  1989), baculovirus (Brandt, 1990) and vaccinia
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Fig. 1.3. The derivation of live attenuated vaccine clones of JE 
virus by passage of the wild-type strains SA14 in cells and mice.
S A 1 4 l  virulent parent isolated from m osquitos in China.
11 X p a s sa g e s  in newborn mice,
100 X p a s sa g e s  in PHK cell culture,
3 X plaque purification.
First attenuated variant ultraviolet irradiation and 
C l o n e  1 2 - 1 - 7  plaque purification in PHK cells
6 X animal p assag es ,
6 X plaque purification.
S A 1 4 - 5 - 3  S A 1 4 - 2 - 8
5 X suckling m ouse p assag es , 
2 X plaque purification.
S A 1 4 - 1 4 - 2 / P H K
9 X p a s sa g e s  and plaque purification in 
Primary dog kidney (PDK) cell culture.
S A 1 4 - 1 4  2 / P D K
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(Mason et a l ,  1991; Haishi et a l ,  1989; Yasuda et a l ,  1990). Expressed proteins 
are generally antigenic and provide protective immunity to small animals. However, 
E. coli expressed products were only antigenic, and did not induce protection to JE 
virus challenge (Manso et a l ,  1989). Konishi et a l ,  (1992) reported that mice 
immunized with a subviral particle containing the JE virus prM/M and E proteins are 
protected from lethal JE virus infection. Immunization with recombinant vaccinia 
viruses synthesE/^ JE virus E protein or prM and E proteins protected mice from a 
lethal intraperitoneal challenge with JE virus; while the recombinant expressing only 
the non-structural protein (NSl) provided low levels of protection from a similar 
challenge dose of JE virus (Konishi et a l ,  1992b). Also, Konishi et a l ,  (1992a) 
reported using a vaccinia virus encoding the prM, E and NSl genes of JE virus can 
prevent JE virus viraemia in swine.
Genetic manipulation has resulted in the recovery of biologically active and 
infectious genome RNAs of YE, DEN-4 and JE viruses from full length cDNA (Rice 
et a l ,  1989; Lai et a l ,  1991; Sumiyoshi et a l ,  1992) known as infectious clone 
technology. Capped RNA transcripts of JE JaOArS982 strain were infectious when 
used to transfect appropriate host cells, and the virus produced was indistinguishable, 
by several criteria, from the parent virus used for cDNA cloning (Sumiyoshi et a l , 
1992).
Besides their application to molecular genetic studies of flavivirus replication, 
functional flavivirus cDNA clones and recombinant DNA technology are useful for 
exploring diverse approaches that may lead to new vaccines that are efficacious, safe
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and economical. Those approaches includes (1) the expression of flavivirus-specific 
proteins for subunit vaccines, (2) the engineering of infectious recombinant viruses, 
using vectors such as vaccinia, (3) the construction and/or propagation of live- 
attenuated flavivirus vaccine strains. For all of these strategies, the single most 
important concern for evaluation of candidate vaccines is establishment of biological 
test systems and a set of criteria relevant to the prevention of human disease. 
Complete genomic sequences have been determined for parental and attenuated 
strains of JE virus (Nitayaphan et a l,  1990; Aihara et a l ,  1991). Identification of 
attenuating mutations of JE virus should facilitate monitoring of different lots of live 
attenuated strains.
1.6 Nucleotide sequence analysis of JE virus
1.6.1 Comparison of the nucleotide and deduced amino acid sequences of 
JE wild-type viruses with other Haviviruses
In 1985, the sequence of the entire genome of the 17D-204 strain of YF 
vaccine virus was published (Rice et a l ,  1985). This was the first full-length 
sequence of a flavivirus to be determined, and provided the opportunity to understand 
in greater detail the structure, organisation and processing of the genome. Two years 
later the entire sequence of the wild-type JE virus, JaOArS982, was determined 
(Sumiyoshi et a l ,  1987). Subsequently, the genomic sequences of several other JE 
wild-type virus strains have also been determined (Sumiyoshi et a l , 1987; Hashimoto
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et a l ,  1988; Nitayaphan et a l ,  1990 Aihara et a l ,  1991). Currently, many other 
flaviviruses have also been fully sequenced. These are Central European (CE) TBE 
(Mandl et a l ,  1989a), Far Eastern (FE) TBE (Pletnev et a l ,  1990), LOT (lacono- 
Connors and Schmaljohn 1992), POW (Mandl g/ a l , 1993), WN (Castle et a l , 1985 
and 1986; Wengler et a l ,  1985), MVE, (Dalgamo et a l ,  1986), KUN (Coia et a l ,
1988), and DEN serotypes 1 , 2 ,  3 and 4 (Fu et a l, 1992; Hahn et a l ,  1988; 
Osatomi and Sumiyoshi, 1990; Mackow et a l ,  1987).
Non-coding regions and amino acid sequences of several important flaviviruses 
have been compared in Tables 1.2 to 1.4. Table 1.2 shows that all flaviviruses 
possess similar number of nucleotides and amino acid residues in each genome 
segments with some variations. The number of nucleotides and amino acids for M and 
NSl protein gene of all flaviviruses sequenced so far are the same except POW virus 
which has one more amino acid in NSl protein gene. For NS2B and NS4A protein 
genes, the differences of numbers are only within 2 amino acids. Tables 1.3 and 1.4 
both show the amino acid homologies among JE antigenic complex viruses are much 
higher than other flaviviruses, which is consistent with the serological results 
determined by cross-neutralization assays using polyclonal antisera (Calisher et a l ,
1989). YF virus is no more closely related to the JE and DEN viruses than to TBE 
complex viruses although it is also mosquito transmitted.
It can been seen from Tables 1.3 and 1.4, that the amino acid homologies in 
the non-structural proteins are higher than those of structural proteins in all viruses 
compared. These may due to the structural proteins being subjected to immune
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Table 1.2. Number of nucleotides in several flaviviruses non-coding regions and 
protein genes.
Virus SLE WN MVE JE KUN TBE LOT POW DENI DEN2 DEN3 DEN4 YF
5’ 101 54 100 98 78 114 114 111 72 100 94 101 118
C 354 366 372 378 366 336 336 342 342 339 342 339 363
preM 282 276 276 276 276 279 279 267 273 273 273 273 267
M 225 225 225 225 225 225 225 225 225 225 225 225 225
E 1503 1491 1503 1500 1503 1488 1488 1491 1482 1482 1482 1482 1476
NSl 1056 1056 1056 1056 1056 1056 1056 1059 1056 1056 1056 1056 1056
NS2A681 693 681 681 693 690 690 690 654 654 654 654 654
NS2B 393 393 393 393 390 393 393 393 3930 390 390 390 390
NS3 - 1857 1857 1857 1857 1863 1863 1866 1857 1857 1857 1854 1869
NS4A - 447 447 447 447 447 447 447 450' 450 450 447 447
NS4B - 768 765 765 765 753 753 756 744 744 744 735 750
NS5 - 2715 2715 2715 2715 2706 2706 2709 2700 2700 2700 2679 2715
3’ - 669 341 585 290 113 - 483 461 464 432 387 510
DEN3, DEN4 and TBE virus are taken from Nitayaphan e t a l. (1990); Dalgarno e t al. 
(1986), Castle e t al. (1986), Coia e t al. (1988), Mandl et a l. (1989a), lacono-Connors and 
Schmaljohn (1992), Mandl et a l. (1993), Trent et al. (1987), Hahn e t a l. (1987), Fu e t al. 
(1992), Blok e t al. (1992), Osatomi and Sumiyoshi (1990) and Falgout e t a l. (1993), and 
Pletnev e t al. (1990) respectively. -: No sequences data available.
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pressure so that there are more variations. Similarly, NSl shows more variation than 
other non-structural proteins. It is known that the NSl protein participates in 
stimulating host protective immunity (Rusell et a l ,  1980; Rice et a l  1988), which 
may also contribute to more variations in NSl proteins.
Table 1.4 shows that the amino acid homologies of E protein only are higher 
than that of all structural proteins calculated in total, which indicates that the amino 
acid divergences are smaller than C, prM and M proteins. It is likely that the broad 
cross-reactions among flaviviruses, commonly observed in HAI assays and 
occasionally in N tests, are due to immune recognition of conserved E protein 
domains that mediate important biological functions in the flavivirus life cycle, e.g. 
specific binding to host cells or virus fusion with membranes during penetration.
1.6.2 Comparison of nucleotide and deduced amino acid sequences of wild- 
type parent and its derived attenuated vaccines
The full genome of SA14 (wild-type parent) and its attenuated vaccine viruses 
(SA14-14-2/PHK and SA14-14-2/PDK) have been sequenced in two institutes 
(Nitayaphangr a /., 1990; Aihara gW/., 1991). This has allowed comparisons to be made 
at a molecular level between a IE wild-type parent and its vaccine virus derivatives.
Table 1.5 shows the changes seen in the non-coding region and amino acid sequence of 
the polyprotein between the parent SA14/JAP (i.e, SA14 sequence determined by a
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Table 1.5. comparison of amino acid differences in protein genes and nucleotide 
differences in 5’ and 3’ non-coding regions between JE wild-type and vaccine viruses.
Position SA14/ SA14/ SA14/ SA14 -14-2
NT AA USA CDC JAP PHK PDK
39 5'NC U U U A A
292 C-65 Leu Leu Leu Ser Ser
1296 E-107 Leu Leu Leu Phe Phe
1389 E-138 Glu Glu Glu Lys Lys
1503 E-176 H e H e H e Val Val
1506 E-177 Thr Thr Thr Ala Thr
1704 E-243 Glu Glu Glu Glu Lys
1708 E-244 Glu Gly Glu Gly Gly
1769 E-264 Gin Gin Gin His Gin
1813 E-279 Lys Lys Lys Met Met
1921 E-315 Ala Val Ala Val Val
1977 E-334 Pro Pro Ser Pro Pro
2293 E-439 Lys Arg Lys Arg Arg
3351 NSl-292 Ser Ser Gly Ser Ser
3493 NSl-339 Arg Met Arg Met Met
3528 NSl-351 Asp Asp Asp His Asp
3539 NSl-354 Asn Lys Asn Lys Lys
3652 NSl-392 Ala Val Ala Val Val
3849 NS2A-46 Val H e Val Val Val
4402-3 NS2B-63 Glu Glu Glu Asp Asp
4408 NS2B-65 Asp Asp Asp Gly Gly
4519 NS2B-102 Thr Met Met Met Met
4782 NS3-59 Met Met Met Val Val
4825 NS3-73 Arg Arg Arg Lys Lys
4921-2 NS3-105 Ala Ala Ala Gly Gly
5243 NS3-215 Ala Ala Val Val Ala
5634 NS3-343 Arg Arg Arg Trp Arg
6634 NS4A-27 H e H e H e Trp H e
6700 NS4A-49 Arg Lys Lys Lys Lys
7227 NS4B-106 H e H e H e Val Val
8658 NS5-328 Lys Glu Lys Lys Lys
8832 NS5-386 His His His Tyr Tyr
9607 NS5-644 Asn Thr Asn Asn Thr
9688 NS5-671 Val Val Val Ala Val
9898 NS5-731 Gly Gly Asp Gly Gly
10428 3'NC U U U C C
10784 3'NC C C C U C
been sequenced. The sequences of SA14/JAP and SA14-14-2/PHK viruses are taken 
from Aihara et al. (1991); SA14/CDC and SA14-14-2/PDK viruses are taken from 
Nitayaphan et al. (1990); SA14/USA are from Trent (personal communication).
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Japanese group, Aihara et a l, 1991) and SA14/CDC (SA14 sequence determined by 
the American Centres for Disease Control group, Nitayaphan et a l , 1990) and its 
attenuated SA14-14-2/PHK (Aihara et a l, 1991) and SA14-14-2/PDK (Nitayaphan 
et a l ,  1990) viruses. Over the genome of 10,969 nucleotides, there were four 
nucleotide differences in 5’ and 3’ non-coding regions, and 32 amino acid differences 
among these viruses.
Finally, the nucleotide sequence of SA 14/USA (Trent, personal 
communication)^different to that of SA14/CDC (Nitayaphan et a l ,  1990) by 20 
nucleotides, which resulted in eleven amino acids differences. Of the amino acid 
differences three were in E protein at positions E-244 (ie, E protein amino acid 244) 
(Glu ->Gly), E-315 (Val ->  Ala) and E-439 (Arg ->  Lys) (Table 1.5).
SA14-14-2/PHK and SA14-14-2/PDK vaccine viruses have seven identical 
amino acid substitutions in the structural protein genes when compared with the 
sequence of their parent; one is in the C protein (C-65) and the other six are in the 
E protein (E-107, E-138, E-176, E-279, E-315 and E-439).
Three parental SA14 viruses nonstructural protein genes differed by 67 
nucleotides and 11 amino acids, of which four were in NSl protein at positions NSl- 
292 (Ser < ->  Gly), NSl-339 (Arg < ->  Met), NSl-354 (Asn < ->  Lys) and NSl- 
392 (Ala < ->  Val); the remainder were at positions NS2A-46 (Val < ->  lie), 
NS2B-102 (Thr < ->  Met), NS3-215 (Ala < ->  Val), NS4A-49 (Arg < - >  Lys), 
NS5-328 (Lys < ->  Glu), NS5-644 (Asn < ->  Thr) and NS5-731 (Gly < ->  Asp)
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(Table 3.2). Compared to vaccine and other wild-type JE viruses, the amino acid 
changes at NS2B-102 and NS4A-49 of SA14/USA were unique changes, and 
SA14/CDC and SA14/JAP had six and three unique amino acid changes respectively 
(Table 1.5).
1.6.3 Molecular studies on JE virus varints
In addition to the JE virus full genome analyses above, the E protein genes of 
two JE Sarawak escape mutants (r27 and r30) selected by monoclonal antibodies 
(MAbs) have been sequenced (Cecilia and Gould, 1991). Both mutants showed 
reduced neurovirulence in 3-week-old sucking mice compared with their parents when 
inoculated intra-peritoneally. However, mutant r30, but not r27 induced protective 
immunity in adult mice against intracranially challenge with parent virus. Nucleotide 
sequencing of the E protein gene for the mutants revealed single base changes in 
both r30 and r27 resulting in a predicted amino acid changes from isoleucine to serine 
at position 270 in r30 and from glycine to aspatic acid at position 333 in r27.
Hasegawa et al. (1992) produced one cell passage mutant and six MAb 
neutralization-resistant mutants from wild-type JE strain Kamiyama. The MAbs 
mutants were selected with JE type specific neutralizing MAb NARMA 3. The E 
protein genes of the passage mutant (Kamiyama 2), which had two more passages on 
Vero cells proved to differ from that of the parent strain (Kamiyama 1) at E-364 (Ser 
->  Phe) and E-367 (Asn ->  lie). Of all six MAb neutralization-resistant variants,
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the two of them derived from the Kamiyama 1 virus and four from the Kamiyama 2 
virus, had a single amino acid substitution at position E-52. The two variants derived 
from the Kamiyama 2 virus showed reduced virulence in 3-week-old mice after 
peripheral inoculation but were as virulent as the parent virus when inoculated 
intracranially. They suggested that mutations at residues 52, 364 and 367 of the E 
protein affect early virus-cell interaction in Vero cells and virulence in mice.
Both mutants derived from strain Sarawak, and that from Kamiyama were 
selected on Vero cells. It is conceivable that Vero cell passage could result in 
selection^mutations in another part of the genome. Since only E protein genes of these 
strains were examined (i.e, only one-eighth of the IE virus genome) the possibility 
can not be excluded that other parts of the genome may be responsible for loss or 
reduction of the neuroinvasiveness.
1.7 Aims of the thesis
Despite the detenùination of the nucleotide sequences of the entire genomes 
of the wild-type strain SA14 and derived vaccine strains SA14-14-2/PHK and SA14- 
14-2/PDK, the molecular basis of attenuation of JE virus neurovirulence has not been 
determined yet. The three sequences of the wild-type strain SA14 differed from each 
other and the two SA14-14-2 vaccine viruses differed from their parent by many 
nucleotide and amino acid substitutions throughout the genome.
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The aim of this thesis is to analyze the molecular basis of attenuation of JE 
virus neurovirulence and the strain variation by using RT-PCR methods to amplify 
regions of the genome of strains of JE virus, specifically those coding for the 
structural proteins, and to then clone and sequence their genomes. Such information 
will undoubtedly benefit flavivirus vaccine development strategy.
A number of JE viruses were available which had previously been examined 
both biologically and antigenically with MAbs, and presented interesting properties 
often associated with the E protein. These included a vaccine virus SA14-2-8 derived 
from strain SA 14 and SA 14 virus without plaque purification. The availability of 
these viruses should provide the necessary tools to obtain important information on 
the molecular basis of JE virus attenuation. Determination of the nucleotide sequence 
of the structural protein genes of wild-type strains of JE virus and the entire genome 
of selected strains should reveal important information on the molecular biology of 
JE virus.
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Chapter 2
Materials and Methods
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2.1 Sterilisation
All media for tissue or bacterial culture, buffers for cell culture and reagents 
for molecular experiments were sterilised by autoclaving at 12 FC (15 pounds/square 
inch (PSI)) for 30 minutes (mins) or by filtration through a 0.2 juM Flowpore D-filter 
(Mill f pore). Except where indicated, Milli Q grade water was used in the preparation 
of all the media, buffer and reagents solutions. The word ’water’ used in this thesis 
indicates sterilized mili Q grade water.
2.2 Dimethyl pyrocarhonate (DEPC) treatment.
For inhibition of RNAase activity all the solutions used for isolation, 
extraction or treatment of RNA, or used for cDNA reverse transcription were treated 
with DEPC, which is a strong, but not absolute RNase inhibitor (Fedorcsak and 
Ehrenberg, 1966). The solutions were made with the mil Q grade water, which 
contained 0.1% (v/v) DEPC and was autoclaved before use. All the Glassware and 
plasticware utilised for vRNA extractions or any RNA experiments were new and 
only used for RNA work.
2.3 Cell cultures
2.3.1 Bacterial cells used
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2.3.1.1 ESCHERICHIA COL/strain INVaF: endAl, recAl, F2’, gyrA96 
thi-1, /z5</R17(rk‘mj,' )^, supE44, relAl. Obtained from Invitrogen, and contains 
4s^cllacZoM15 mutation and offers blue/white screening of plasmids by alpha 
complementation of the beta-galactosidase gene.
2.3.1.2 ESCHERICHIA COL/strain 0/I5a: endAl, recA], V , gyrA96,
hsdRl 1 (rk'mk^ ),XywpE 
âldùZAjAE
thi-l, hs l{v^ ^ ysupEA4, relAl. Obtained from BRL Inc. (Paisley, Scotland).
2.3.2 Plasmid Vectors
2.3.2.1 pUC18
s
At early stag^of this project, the TA cloning system was not available. Instead 
plasmid pUC18 and E. coli strain DH5a ™ were used. Plasmid pUC18 is a 2686 
base pair (bp) derivative of the 4362 bp pBR322 plasmid (Bolivar et al., 1977; 
Sutcliffe, 1978). This plasmid contains the ampicillin resistance gene and pBR322 
origin replication (Norrander et al., 1983); a portion of the E. coli lac operon (Vieira 
and Messing, 1982; Messing and Vieira, 1982; Messing et al., 1977); a polylinker 
containing a multiple cloning site region at the amino terminus of the lac Z gene 
encoding beta-galactosidase. This multiple cloning site permits linearization of the 
plasmid with 13 restriction enzymes (pUC18), thus allowing insertion of a variety of 
restriction fragments of foreign DNA into the plasmid. The beta-galactosidase gene 
in the pUC18 plasmid is defective by itself, as is the gene in certain bacterial hosts 
(for example E. coli INVaF’, Invitrogen). However, these inactivating mutations
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occur at different loci in the beta-galactosidase gene. Thus, although the E. coli host 
alone produces a defective enzyme, the host derived and pUClS-derived 
beta-galactosidase enzymes together complement each other (alpha complementation) 
to produce an active beta-galactosidase enzyme. This can be induced by 
isopropyl-beta-thio-galactopyranoside (IPTG) to hydrolyse the galactosidase analogue 
5-bromo-4-chloro-3-indoxyl-beta- galacto-pyranoside (X-gal) to produce the blue 
pigment, bromo-chloro-indole, in cells that have been successfully transformed. Thus, 
bacterial colonies resulting from transformation with wild-type pUC18 are ampicillin 
resistant and are blue in colour due to the hydrolysis of X-gal. However, insertion of 
foreign DNA into the multiple cloning site within the beta-galactosidase gene of
pUC18 results in a defective enzyme that is not complemented by bacterial enzyme.
A
Therefore no hydrolysis of X-gal occurs and white ’colourless’ colonies are produced. 
Thus, a combination of ampicillin resistance and histochemistry (X-gal hydrolysis) 
permits rapid one-step identification of bacterial colonies containing recombinant 
plasmid DNA. The vector, treated with Smal and calf intestinal phosphatase was 
obtained from Pharmacia.
2.3.2.1 pCR II™ (obtained from Invitrogen Inc.)
The pCR IF ^  is a 3932 bp plasmid, which is key component of the TA 
cloning kit, designed for cloning PCR products directly from a PCR reaction without 
the need for modification or restriction digestion. This plasmid takes advantage of the 
non-template dependent activity of the thermostable polymerases used in PCR that add 
single deoxyadenosines to the 3’-end of all duplex molecules provided by PCR. 
Plasmid pCR IF ^  has a lacZ gene for blue/white colour selection, ampicillin and
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kanamycin resistance gene, and a versatile polylinker. In addition, the plasmid 
contains FI for rescue of ssDNA, and T7 and Sp6 RNA promoters for production of 
sense and antisense RNA transcripts.
2.3.3 Tissue Culture Cell lines used
All cell lines utilized in this study were obtained from the stock stored in 
liquid nitrogen in the Flavivirus Research Laboratory (FRL) and were grown and 
mdmialat>4 for propagation virus. The designation and use of the cell lines are 
included in Table 2.1.
2.3.4 Media
2.3.4.1 Cell culture media.
All tissue culture reagents were obtained from Sigma and ICN Flow (U.K. and 
U.S.A.).
A. medium 199
Medium 199 was obtained containing Eagle’s salts, 2 mM glutamine and 
0.15% sodium bicarbonate. It was supplemented with 10% (for growth of cell lines) 
or 2% (for maintenance of cell lines) foetal calf serum, 1 % non-essential amino acids, 
penicillin G (100 units/ml) or Neomycin (0.05 mg/ml) and streptomycin (0.1 mg/ml)
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Table 2.1. Designation of cell cultures used in the present project.
Cell culture Abbreviations Source
African green monkey 
undifferentiated kidney 
cell line
Vero Flow Laboratories
Rhesus monkey 
undifferentiated kidney 
cell line
LLC-MK2 Flow Laboratories
Human adenocarcinoma 
cell line SW13 CDC, Fort collins
Human cervical 
carcinoma cell line HeLa Flow Laboratories
Ades albopictus 
Larvae cell line C6-36
CDC, Fort collins
Chicken embryo 
fibroblast primary 
cell culture
CEF Department stock
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sulphate.
B. Eagle’s Modified Minimal Essential Medium
Eagle’s modified minimal essential medium (EMEM) was obtained containing 
Eagle’s salts and 0.22% sodium bicarbonate but without glutamine. It was 
supplemented with 2 mM glutamine, 0.15% sodium bicarbonate, 10% (for growth of 
cell lines) or 2% (for maintenance of cell lines) foetal calf serum, 1% non-essential 
amino acids, penicillin G (100 units/ml) or Neomycin 0.05 mg/ml and streptomycin 
sulphate (0.1 mg/ml).
2.3.4.2 Microbial growth media.
A. Luria-Bertani (LB) medium (broth)
Bacto tryptone lOg
Bacto yeast extract 5g
NaCl 5g
Made up to 1000 ml with water and adjusted to pH 7.5 with 5M NaOH.
Autoclaved.
B. Luria-Bertani medium (agar)
Made as for broth with the addition of 15 g/L Bactoagar.
Autoclaved.
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c. so c
Bacto tryptone 2% (w/v)
Bacto y east extract 0.5% (w/v)
NaCl 10 mM
KCl 2.5 mM
MgClg 20 Mm
MgS0 4  20 mM
Glucose 20 mM
SOC was prepared without the magnesium salts and glucose, to a Ph of 7.0. 
After autoclaving, filter sterilized magnesium salts and glucose were added prior to 
use.
D. Antibiotics
Stock ampicillin (100 mg/ml) was made and added to LB or LB agar to a final 
concentration of 100 /xg/ml.
2.3.5 Maintenance of tissue cell lines
All the cell lines were grown and maintained in Eagles minimal essential 
medium (EMEM, SIGMA, UK and USA), supplemented with 2 mM L-glutamine 
{Sigma, UK and USA) and 1 mM non-essential amino acids {Sigma, UK and USA). 
Media was also supplemented with 20 mM sodium bicarbonate {Sigma, UK and USA) 
and penicillin G (100 units/ml) {Sigma, USA) or Neomycin 0.05 mg/ml and
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streptomycin sulphate (0.1 mg/ml) {Sigma, UK and USA). The media contained either 
2% (v/v) or 10% (v/v) heat inactivated foetal calf serum (PCS, SIGMA, UK and 
USA) for maintenance medium or growth medium respectively. Cells (except 
mosquito cells C6-36, which was grown at 28°C)were incubated at 37°C in the 
presence or absence of 5% carbon dioxide (CO2 ).
Cells were sub-cultured by trypsinization of a confluent monolayer (trypsin
2.5 % w/v in Hanks salts {Sigma, UK and USA)), triturating the cells in fresh medium 
and then seeding fresh tissue culture flasks (Falcon Laboratories, UK and USA) as 
described by Lenette and Schmidt (1969). Cells were normally split at a 1:4 ratio. 
The mosquito cells C6-36 were subculture and amplified by only to remove
the cells from the surface of a tissue culture flask prior to seeding of new tissue 
culture flasks.
2.3.6 Storage and preservation of tissue cell cultures
Subconfluent (80-90%) cell monolayer was detached from tissue culture flasks 
by trypsinization or trituration only, then cells were pelleted at 3000 rpm for 3 mins 
and resuspended in the cell frozen media (SIGMA, UK and USA). The cells were 
aliquoted into liquid nitrogen ampoules (Nunc) and left in -70°C for two hours then 
stored in liquid nitrogen (-196®C).
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2.3 .7  Resuscitation of preserved tissue cells culture
When required, o-n. ampoule of the desired cells was taken out from liquid 
nitrogen and thawed in a 37°C water bath. The cells were pelleted by centrifugation 
at 10,000 g for 3 mins to remove the containing DMSO and resuspended in 
fresh growth Then the cell suspension was transferred into tissue culture flasks 
and incubated at 37°C and grown to confluence before further subculture .
2.4 Buffers and solutions
2.4.1 Solutions used for bacterial plasmid DNA extractions
A. Solution I.
Glucose 50 mM
EDTA pH 8.0 10 mM
Tris.HCl pH 8.0 25 mM
B. Solution II.
NaOH 200 M
SDS 1.0% (w/v)
C. Solution III.
Potassium acetate (3 M potassium 5 M acetate) 
Prepared as follows:
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60ml 5 M potassium acetate
11.5 ml glacial acetic acid
28.5 ml water
D. Sucrose solution.
Sucrose 25 % (w/v)
Tris.HCl pH 8.0 50 mM
E. Brij-Doc solution.
Brij 58 1% (w/v)
Sodium deoxycholate 0.4% (w/v)
Made in 1 x TE pH 8.0
F. Isopropanol saturated with Caesium chloride (CsCl)
CsCl (10 g) was dissolved in STE (10 ml). Isopropanol (100 ml) was added 
and the mixture allowed to settle overnight.
G. Bovine pancreatic RNAase A
10 mg/ml in 10 mM Tris-HCl, pH 7.5, 15 mM sodium chloride, boiled for 
15 mins, cooled slowly to room temperature and then stored in aliquots at 
-20°C.
2.4.2 Phenol/chloroform solution
Phenol/chloroform was prepared as a 1:1 (v:v) mixture, saturated with IM 
Tris-HCl (pH 8.0) and stored in the presence of the antioxidant 8-hydroxyquiniline 
(0.1% w/v). The mixture of phenol/chloroform was equilibriumed overnight and then
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stored at 4® C in the dark. This solution was aliquoted into two bottles for extraction 
of bacterial plasmid and viral RNA.
2.4.3 Solutions used for DNA agarose-gel electrophoresis
A. Ix TAE (Tris-acetate)
Tris-acetate 40 mM
EDTA 1 mM
pH to 8.0 with glacial acetic acid.
B. DNA loading buffer, (6x).
Bromophenol blue 0.25% (w/v)
Xylene cyanol 0.25% (w/v)
Sucrose 40% (w/v)
2.4.4 Enzyme Buffers
A. lOx Kinase buffer
Tris-HCl (pH 7.6) 500 mM
MgCl2  100 mM
DTT 50 mM
Spermidine 50 mM
EDTA 1 mM
B. lOx Calf intestinal alkaline phosphatase buffer
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or restriction enzyme buffer 3 (BRL)
Tris.HCl (pH 8.0) 50 mM
MgCl2  10 mM
NaCl 1 mM
C. Restriction enzyme buffers were obtained from the manufacturers with the 
enzymes.
D. lOX Reverse transcription buffer
500 mM Tris 
500 mM KCl 
100 mM MgCl2  
30 mM DTT
E. All the buffers used for sequencing were obtained from USB with the 
sequencing kit.
2.5 Viruses
The origins and derivations of the JE virus strains employed in this study are 
shown in Table 2.2.
Viruses were grown by infecting a desired cell monolayer that was 80% 
confluent. The cell sheet was washed with phosphate buffered saline (PBS, Sigma, 
UK and USA) following by inoculation of virus at a multiplicity of infection of 
0.1-1.0 pfu was then performed. When virus was obtained as freeze-dried
77
Table 2.2. Designation of viruses used in this study.
virus
Name
Isolation
Place
Host Country Year Source
DH20 Dharan Human Nepal 1985 LSHTM*
KPP034-35CT Kampanghet Mosquito Thailand 1982 LSHTM
P3 Beijing Mosquito China 1949 YARV+
SA14 Xian Mosquito China 1954 CDC, Fort Collins^
HK8526 Taiwan Mosquito China 1982 CDC, Fort Collins
826309 Goa human India 1982 CDC, Fort Collins
Saigon Saigon NK Vietnam 1962 Institute Parsteur
Indonesia NK Mosquito Indonesia NK* CDC, Fort Collins
Beijing-1 Beijing human China 1949 LSHTM
Nakayama Tokyo Human Japan 1935 CDC, Fort Collins
Sarawak Sarawak Mosquito Malasia 1965 LSHTM
JaOArS892 Osaka Mosquito Japan 1982 CDC, Fort Collins
SA14-2-8 Beijing Vaccine China 1963 CDC, Fort Collins
Research unit, University of Yale. Division of Vector-Borne Infectious Diseases, 
National Center for Infectious Diseases, Centers for Disease Control and Prevention, 
Public Health Service, Fort Collins. NK:Not known
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preparation it was reconstituted in sterile deionized distilled water and used to prepare 
seed stocks for infection of cells. Virus was allowed to absorb to the cell sheet by 
incubation at room temperature for 30 minutes prior to the addition of cell 
maintenance medium containing only 1% FCS. Cultures were incubated at 37°C, in 
a 5% carbon dioxide atmosphere or no carbon dioxide conditions, until clear 
cytopathic effect was evident in 90-100% of the cells. The supernatant was then 
harvested, clarified by low-speed centrifugation (10,000 g for 5 minutes) to remove 
cell debris, aliquoted, and stored at -70°C in cryotubes (Nunc) until used.
2.6 Extraction of viral RNA
Viral protein was digested with 0.1 mg of autodigested (37°C for 15 mins) 
proteinase K for 30 mins at 37°C. 10% (w/v) sodium dodecyl sulphate (SDS) was 
added to final concentration 1%, and the sample incubated for a further 15 mins at 
37°C. For extraction of viral RNA directly from tissue culture fluid 20 fig of tRNA 
was added to 1 ml fluid at this point.
Protein was removed by extraction with an equal volume of phenol/ 
chloroform/8-hydroxy quinoline mixture. For each extraction, an equal volume of 
phenol/chloroform was added to the nucleic acid sample. It was thoroughly vortexed 
to form an emulsion, and was then centrifuged in an Beckman benchtop centrifuge 
(microfuge) at 10,000g for 3 mins at room temperature to separate the 
phenol/chloroform and the aqueous nucleic acid-containing phase. The aqueous phase 
was transferred to a fresh microcentrifuge tube taking care to avoid the interface.
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RNA precipitation achievecPaddition of 2.5 volumes of chilled ethanol
A
(-20°C) and one tenth volume of 3M sodium acetate pH 5.2 to the RNA suspension, 
mixing by inversion, and precipitation effected at -70°C for at least 30 mins. The 
RNA was then pelleted by centrifugation at 12,000 g for 20 mins at 4°C in a 
microfuge. The pellet was washed with 200 /xl of 70% chilled ethanol, a ftirther 
centrifugation of 12,000 g for 5 mins at 4°C was performed and the pellet was dried 
at 40°C.
RNA resuspension was effected in high performance liquid chromatography 
(HPLC) purified water (Aldrich). For direct extraction from tissue culture fluid, 6 fû 
of HPLC water for each ml extracted was used to resuspend the pellet, as this equated 
to the volume required for the initial RT reaction. RNA extracted using the other 
methods were resuspended in a total of 20-30 /xl. Crude large-scale tissue culture fluid 
and gradient-purified vRNA was quantitated by the spectrophotometric method 
(section 2.5). The vRNA was aliquoted and stored at -70°C, in the presence of 
RNAsin (Boehringer-Mannheim (5 U/lO/xl)).
2.7 Synthesis and purification of oligonucleotides
Oligonucleotide primers used in the studies (Table 2.3.) were designed with 
the help of OLIGO computer program and based on the nucleotide sequence of JE 
virus SA14 strain (Nitayaphan et al. 1990).
Some of these oligonucleotide primers were synthesised on an Applied 
Biosystems 381A synthesizer using phosphoramidite chemistry (Beaucage and 
Caruthers, 1981). Ammonia was brought from store and freshly diluted into a 35%
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Table 2.3. Oligonucleotide primers used in reverse transcription and PCR 
amplification of JE virus RNA.
Name o f  
p r im e r
S e q u e n c e  5 '  ->  3 ' P o s i t i o n O r i e n t a t i o
n
JE ! AGAAGTTTATCTGTGTGAACT 1 - 2 1 s e n s e
K a t e l TATCTGTGTGAACTTCTTGGC 8 - 2 8 s e n s e
J E 8 9 5 GTCTGGGAATGGGCAATCGTGA 8 7 4 - 8 9 5 s e n s e
S b r y GGTGGGGCAACGGATGTGGACTTTTCGGG 1 2 7 6 - 1 3 0 3 s e n s e
JE 7 TGTCAGCATGCACATTGGTC 1 2 9 8 - 1 3 1 7 a n t i s e n s e
J E 1 8 6 2 TCTGAAAGGCACAACCTATGGC 1 8 6 2 - 1 8 8 3 s e n s e
J E 1 9 3 4 GAGTTCAATGACAACTGTTCCG 1 9 1 4 - 1 9 3 4 a n t i s e n s e
J E 2 4 6 3 TGTCAGCATGCACATTGGTC 2 4 6 3 - 2 4 8 3 a n t i s e n s e
N SIE TTGGTTCGTCCATCTCGTGC 2 4 3 7 - 2 4 5 6 s e n s e
HNIA AAGACTTCGGCTTTGGCATC 2 9 4 4 - 2 9 6 3 s e n s e
HNIB GCCACACACGGGTTGATGTG 2 9 6 3 - 2 9 8 2 a n t i s e n s e
HNIC ACTGACTGGTGCTGTCGCAG 3 4 0 2 - 3 4 2 1 s e n s e
HNID TTCTGTCCGGAATCGTAGGG 3 4 4 6 - 3 4 5 5 a n t i s e n s e
H N Sl ACTGATTTGGCGAGGTATGTG 3 6 8 7 - 3 6 0 7 s e n s e
NIASE CAGGAGGTGTGCTCGTGTTC 3 8 2 0 - 3 8 3 9 a n t i s e n s e
SNS2A CTGCAAATAGGAGTCCACGG 3 8 9 4 - 3 8 1 3 s e n s e
NS2A ATGCTATAGCGGCGGCATTC 3 9 2 0 - 3 9 3 9 a n t i s e n s e
NS2B AGATATGTGGCTTGAACGGGC 4 3 6 4 - 4 3 8 4 s e n s e
NS2B2 TTGCAGCATCCATCTCCCAGC 4 4 1 6 - 4 3 9 6 a n t i s e n s e
XH2B TACCCTCTAGCCATAATTCGG 4 6 7 6 - 4 6 9 6 a n t i s e n s e
N S31 CCCGAAGGGAGTCCGAAACAC 4 9 7 0 - 4 9 5 0 a n t i s e n s e
NSNS31 GTGTTTCGGACTCCCTTCGGG 4 9 5 0 - 4 9 7 0 s e n s e
SN S32 AGGGCATGGAGCAGTGGATAC 5 6 3 4 - 5 6 5 4 s e n s e
ANS32 CACGGTTTTACCCGCATATTC 5 6 6 7 - 5 6 8 7 a n t i s e n s e
XH4A ACGAATGGCATACTGGAGGAC 6 3 1 5 - 6 3 3 5 s e n s e
AXH4A ATTTCCTCTCACCCATCCGG 6 3 5 9 - 6 3 7 9 a n t i s e n s e
AXH4A2 ATCCCAGAACCGGAAAAACAG 6 8 1 9 - 6 8 3 9 s e n s e
XH4A2 CGCCAGTTGGTTATCTGTCTG 6 8 4 6 - 6 8 6 6 a n t i s e n s e
XH4B ATTGGAGCCAGTGCCGTTTGG 7 5 4 5 - 7 5 6 5 s e n s e
AXH4B AGAGTCCCGTGGCTGTGGTGG 7 5 9 0 - 7 5 7 0 a n t i s e n s e
SN S51 AAGAACGACGCACACTACGCG 8 1 6 4 - 8 1 8 4 a n t i s e n s e
A SN S51 GTCCTCGGTGCAACCAGTCAG 8 1 8 2 - 8 2 0 2 a n t i s e n s e
ANS52 CGGGTCATCCACAGCACTACG 8 9 4 9 - 8 9 6 9 a n t i s e n s e
SNS53 GAATCAATGGAGCACGGCGCG 8 9 1 0 - 8 9 3 0 s e n s e
ASNS53 GTGGACAGGTGGTCACCTATG 9 4 8 7 - 9 5 0 7 s e n s e
SNS52 ACGAGCTGGACAGCGATGTTC 9 5 2 4 - 9 5 4 4 a n t i s e n s e
NS5END TGGACAGACGTTCCGTATGTG 1 0 1 8 8 - 1 0 2 0 8 s e n s e
ANS5 END GATCGCGTTCCGATGAGGCTG 1 0 2 3 5 - 1 0 2 5 5 a n t i s e n s e
NLAST GTGTTCTTCCTCACCACCAGC 1 0 9 4 9 - 1 0 9 6 9 a n t i s e n s e
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(v/v) solution and aliquoted into gas sealing glass bottles stored at 4°C. Each bottle 
was only used for four weeks after opened. Primers were washed out from their 
supports in the snap column by pushing 200 /xl 35 % (v/v) ammonia through with 2 
ml syringe containing 1 ml ammonia in a fiimehood, and left at room temperature for 
20 mins. The above step was repeated three times, and the ammonia was then pushed 
forwards and backwards several times. The primer suspension was placed in a screw 
capped tube and incubated at 55 °C overnight to deprotect the primers. The suspension 
was then cooled to room temperature in the fiimehood and the primers precipitated 
overnight at -20 °C by the addition of three volumes of ice cold ethanol and one/tenth 
volume of 3M sodium acetate, pH 5.2. The primers were pelleted by centrifugation 
for 20 mins at 4°C, then washed twice with 70% ethanol and dried in a vacuum. Jke 
primer was resuspended in 100 /xl of HPLC water and the primers quantitated by 
absorbance at 260 nm assuming that one A260 unit corresponds to 40 /xg/ml of single 
stranded oligonucleotide primer. An aliquot of each primer was resuspended to 
produce a working stock of 500 ng//xl stored at -20°C.
Some oligonucleotide primers used in this study were purchased from 
Biosynthesis Company. The primer obtained was column purified, and 5 OD units in 
total (equal to 165 ug) was dissolved in the HPLC water to the
appropriate concentration for use.
2.8 Quantization of nucleic acid by spectropbotometric analysis
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The concentration and purity of nucleic acid in aqueous solutions was 
estimated by measuring the u.v. absorbance of the solution over the wavelength range 
of 250-300nm. Pure solutions of DNA and RNA have an absorbance peak at 260nm 
and a 260nm/280nm ratio of 2.0 and 1.8 respectively (Maniatis et al., 1989). The 
concentration of nucleic acid was calculated using an absorbance value of one at 
260nm to be equivalent to 50 ug/ml for double stranded DNA and 40 ug/ml for single 
stranded nucleic acid.
The principle of this method (Maniatis et al., 1989) is based on the absorption 
of ultra-violet (UV) light by the bases of nucleic acid. This method was routinely 
employed for nucleic acid samples greater than 500 ng, including vRNA and 
oligonucleotides designed as primers following deprotection. The principle 
disadvantage of this method is its failure to distinguish degraded and undegraded 
nucleic acid.
The DNA suspension was diluted 1000 folds in sterile HPLC water in a quartz 
cuvette. The absorbance readings at 260 (A260) and 280 (A280) nm wavelength were 
measured using a Pye Unicon model PU8820 UV/VIS spectrophotometer.
2.9 Cloning complementary DNA (cDNA) of JE virus RNA
2.9.1. Reverse transcription of vRNA
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The RNA was suspended in a volume of 6.5 /xl (RNA extracted from tissue 
culture was not subjected to spectrophotometric analysis due to addition of tRNA, and 
so the concentration of RNA was unknown) of HPLC water. 500 ng of the 
appropriate antisense primer was added, and the tube then was boiled for 3 minutes 
(Lewis et a l ,  1992), and placed immediately into ice for three mins. Addition of 1 
/xl lOx RT buffer, 1 /xl 10 mM dNTPs, 0.5 /xl p laced  RNAses inhibitor (40 units/ul) 
and 1 /xl RAV-2 reverse transcriptase (18 units) (Amersham International) a
final volume of 10 /xl.^ample was mixed by brief spining. Reverse transcription was
pyL A.
effected /^ 55^C water bath for at least 60 mins.
2.9.2 Amplification of cDNA by Using tbe polymerase cbain reaction
Following reverse transcription, 500 ng sense primer was added into the tube. 
The cDNA and pair of primers was boiled for three mins, and quenched into ice for 
three mins.
Each reverse transcription primer mixture was transferred into a special PCR 
tube. The reaction was performed in a volume of 50 /xl, comprising 10 /xl of the first 
strand synthesis, 5 /xl of the lOx PCR reaction buffer supplied with the Taq DNA 
polymerase enzyme (Boehringer or Promega, UK and USA), 500 ng of antisense 
primer and 500 ng of sense primer. HPLC scale water was used to make the final 
volume up to 50 /xl. In the first stage of the study, amplification of cDNA was 
performed in a Hybaid Thermal Reactor (3-15 A) so that the reaction mix was overlaid
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with 50 fil of mineral oil (Sigma) to prevent evaporation. In the later studies 
amplification was performed in a Perkin-EWr PCR system 9600 with ultra-thin wall 
250 jLtl tube, which do not need to be overlaid with oil.
The reaction mix was heated to 95 °C for 4 minutes to denature the 
vRNA/cDNA hybrid, and 2.5 units of Taq DNA polymerase (Boehringer) added as 
the reaction mix cooled to the annealing temperature of 53 - 60°C, which was held 
for 1 min. An extension step was then effected at 72°C for 6 mins. Following the 
initial cycle, the following cycle of incubations was then repeated 30 times: 
dénaturation at 94°C for 40 secs, primer annealing at 53 - 60°C for 40 secs, 
extension at 72°C for 6 mins. The final cycle was as above, except that the extension 
time was 15 mins. After the final cycle the thermocycler was programmed to hold the 
reactions at 12°C if the reactions were set up overnight; otherwise, they were 
subjected to analysis by agarose gel electrophoresis immediately following 
completion.
2.9.3 Gel electrophoresis of ampliOed PCR products
The mineral oil was removed, if it was used, by the addition of 100 /xl of 
chloroform, vortexing and removal of the organic solvent lower phase. 5 /xl lOX gel 
loading buffer (50% (v/v) glycerol, 0.05% (w/v) bromophenol blue) was added to the 
amplified product mix which was then separated by electrophoresis at 100 - 150 volts 
for 30 mins to 1 hour in a 1.2% agarose gel in TAE buffer in a horizontal
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electrophoresis apparatus. The gel was stained in a solution of ethidium bromide (0.5 
/xg/ml in TAE buffer), photographed on a UV transilluminator and the cDNA bands 
of correct size located by comparison with molecular weight markers.
2.9.4 Recovery of cDNA from agarose gels
The Geneclean 11^  kit (Stratech) was used to recover DNA from agarose gels. 
This system exploits the affinity of DNA molecules to silica matrices. The kit 
contains a specially formulated suspension of silica matrix called ’Glassmilk’ which 
binds both single and double stranded DNA, without binding contaminating material. 
The system claims routinely recoveries of 80-90% of DNA. Gel slices containing the 
appropriate amplified cDNA fragments were excised into small piece and put into a 
microfuge tube, then weighed and 3 volumes (w/v) of 6 M sodium iodide stock 
solution were added. The mixture was incubated at 55°C for 2-4 mins until the cDNA 
containing agarose was melted. After vortex mixing, 6 /xl (per 5 /xg DNA) of 
Glassmilk suspension was added, the liquid was mixed by inverting the tube several 
times and incubated on ice for 4 mins. The sample was mixed by inverting after each 
minute. The silica matrix, plus adhered DNA, was then pelleted by a 10 second 
spinning at 12,000g at room temperature in the microfuge. The supernatant was 
removed and the pellet was resuspended with 500 /xl ice-cold New buffer (sodium 
chloride, ethanol and water). This last step was repeated three times. Finally the 
supernatant was removed as thoroughly as possible with a fine top tip. The pellet 
was resuspended in 12 /xl HPLC water and incubated at 55°C for 3 mins. The silica 
matrix was then pelleted by spinning at 12,000g in the microfuge for 20 secs and the
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DNA containing supernatant transferred to a fresh tube and the DNA suspension was 
stored at -20°C until use.
2.9.5 Ligation of the cDNA into the plasmid vectors
Two techniques were used for cloning of the PCR products obtained. One 
employed the plasmid pUC18 and the use of competent Escherichia coli (E. coli) 
strain DH5a ™; and another one employed TA vector and competent Escherichia
coli strain INVaF’.
\
2.9.5.1 Cloning PCR products into pUClS. ^
The vector was cleaved with the restriction enzyme Smal which produces a 
complementary blunt-end to which the blunt ended amplified cDNA fragment may be 
ligated. 5 /xg pUC18 was linearised by digestion with 20 units Smal in a final volume 
of 50 /xl, containing 33 mM Tris-acetate pH 7.9, 66 mM potassium acetate, 10 mM 
magnesium acetate, 0.5 mM DTT (incubation buffer A). Incubation was performed 
at 25 °C for 1 hour.
Restriction enzyme digestion results in the exposure of 5’ phosphate groups. 
These groups were removed to prevent self-religation (Seeburg et al., 1977; Ullrich 
et al., 1977) and to maximise the subsequent formation of recombinant molecules. 
One /xl containing one unit of calf intestinal phosphatase (Boehringer) was added to
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the digested plasmid and incubation was performed at 50°C for 30 mins. A further 
unit of calf intestinal phosphatase was added and incubation continued for a further 
30 mins. The reaction was terminated by the addition of 10 fig autodigested 
proteinase K (20 /tg//xl), and a further incubation at 37°C for 30 mins. The final 
volume was made to 100 /xl with HPLC water, a phenol/chloroform extraction and 
a back extraction were performed, and the pUC18 was precipitated by the addition 
of 2.5 volumes of ethanol with 300 mM sodium acetate pH 5.2. The mixture was 
then cooled in a dry-ice/ethanol bath for 5 mins. The pUC18 was pelleted by 
centrifugation at 12,000 g for 20 mins at 4°C, washed with 70% ethanol and dried 
in a 45°C oven. The pellet was resuspended in 20 /xl TE buffer pH 8 and the DNA 
was quantitated by spectrophotometric means and stored in aliquots at -20°C.
The plasmid pUC18 and the recovered cDNA of PCR products were mixed 
in a ratio of 2:1. Then, 1.5 /xl ligation buffer and 1 /xl T4 ligase (J units//xl 
Amersham International) were added into the tube, and water to added a final volume 
15 /xl. The ligation mixture was incubated at 15 °C overnight.
2.9.5.1 Cloning PCR products into TA vector pCR™II.
Two hundred /xg of the TA vector pCR™ II (Invetrogen) was dissolved in 8 
/xl water. 12 /xl of the PCR cDNA product and 1 /xl pCR™ II vector were mixed 
together. Then 1.5 /xl ligation buffer and 1 /xl T4 ligase (Invetrogen) were added into 
the tube and vortexed. After a brief spinning at 12,000g for 2 secs, the sample was 
incubated in 12°C overnight.
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2.9.6 Transformation of competent cells
2.9.6.1 Transformation plasmid into E. coli cells
Throughout the major part of this study the cells used for transformation were
E. coli strain INVaF’ competent cells, some DHSol ™ (BRL) or SURE™ (Phamacia) 
supercompetent cells were also used when the cDNA was cloned into pUC18 plasmid.
When E. coli strain INVaF’ was used for transformation, an aliquot of the 
cells was thawed on ice. Then 2.5 /xl 0.5 M B-mercaptoethanol was added to the cells 
and gently mixed by hand. 2 /xl ligated mixture was added into the cells, and kept on 
ice for 30 mins after mixed gently. When E. coli DH5ol ™ or SURE™ super- 
competent cells was used for transformation, an aliquot of one ml cells was thawed 
in the ice. Then a 100 /xl aliquot was removed into a pre-chilled Falcon 2059 
polypropylene tube for each transformation that was to be performed. A fresh 1:10 
dilution of B-mercaptoethanol was added to a final concentration of 25 mM. The 
cells were gently swirled to mix and then placed on ice for 10 mins, swirling 
carefully at two min intervals. A volume of 2 /xl of the diluted ligation mixture, 
calculated to contain 20 ng of total DNA, was added to the cells, careful mixing was 
effected and the cells were replaced on ice for 30 mins.
The cells were then heat shocked at 42°C for 45 seconds by placing the tube 
in a water bath. The cells were then returned to ice for a further 2 mins. nine 
hundred /xl of pre-heated (42°C) SOC medium (2% (w/v) bacto-tryptone, 0.5% (w/v) 
yeast extract, 10 mM sodium chloride, 10 mM magnesium chloride, 10 mM
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magnesium sulphate, 20 mM glucose) was added and the cells were then shaken at 
225 rpm at 37°C for 1 hour in a controlled environment shaker (G24 environmental 
incubator shaker. New Brunswick Scientific Company Incorporated) to allow the 
transformed cells time to synthesise ampicillinase. The gene for ampicillin resistance 
is carried by the pUC18 plasmid and only those cells that have been transformed by 
this plasmid or by a recombinant cDNA-pUC18 plasmid can replicate in the presence 
of ampicillin. Aliquots of 50 /xl, 100 /xl, and 200 /xl of the transformation mix were 
then spread, in duplicate, onto LB plates containing 100/xg/ml ampicillin, to which 
stock IPTG (2% (w/v) in water) and X-gal (2% (w/v) in dimethyl formamide) were 
added to achieve a final concentration of 0.01 mg and 0.02 mg of each chemical, 
respectively, per ml of agar. The plates were allowed to dry and were then inverted 
and incubated overnight at 37°C .
2.10 Screening of recombinant cDNA clones
2.10.1 Small scale extraction of plasmid DNA.
This protocol was adapted from the method of Birnboim and Doly (1979) and 
Ish-Horowicz and Burke (1981). It produces 3-5 /xg of plasmid suitable for restriction 
enzyme digestion or sequencing.
Briefly, a colony was removed from the master plate (or cells from frozen 
culture) by toothpick into 5 mis of L-broth plus ampicillin (50 ug/ml) and grown
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overnight with shaking at 250 rpm at 37°C. The cells were pelleted by centrifugation 
in a tube for 3 mins at 12,000 g at room temperature and the supernatant removed. 
The cells were resuspended by vortexing in 200 /xl solution I (section 2.4.1). 200 /xl 
of freshly made solution II (alkaline lysis buffer) was added, mixing by inversion of 
the tube. One hundred and eighty /xl of ice-cold 5 M potassium acetate pH 4.8 was 
then added, the mixture was thoroughly vortexed, then centrifuged at 12,000 rpm for 
3 mins. A 500 /xl aliquot of the supernatant was carefully removed to a fresh tube and 
2 volumes of ethanol (-20°C) and 1/lOth volume 3M sodium acetate were added. The 
plasmid DNA was precipitated at room temperature for 5 mins and then pelleted by 
centrifugation at 12,000 g for 5 mins at room temperature. The pellet was 
resuspended in 50 /xl of resuspension solution (50 mM Tris, pH 8, 100 mM sodium 
acetate) and 1 /xl of bovine pancreatic RNAase A (10 mg/ml) was added. Bacterial 
RNA was digested for 30 mins at 37°C. The DNA was extracted by equal volume 
phenol/chloroform. The plasmid DNA in supernatant was then precipitated and 
pelleted by the addition of 2 volumes of ethanol and 1/lOth 3M sodium acetate (pH 
4.3), incubation at -20°C for 20 mins and then centrifiigation at 12,000 g for 5 mins 
at room temperature. The pellet was washed with 70% ethanol, dried in a 45®C 
oven, resuspended in 50 /xl HPLC water and stored at -20°C.
Later, the commercially available "Magic Miniprep" system (Promega) was 
used for small-scale plasmid DNA extraction. Details of this system are available in 
the Promega catalogue and Technical Information sheets and briefly listed below:
First steps of the Magic miniprep are the same as above. After centrifugation,
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a 500 /xl aliquot of the supernatant was carefully removed to a fresh tube, and 1 ml 
of Magic miniprep DNA purification resin was added. The mixture was transferred 
into a 3 ml syringe barrel attached to a mini-colunm, and pushed through the column. 
The mini-colunm was then washed with 2 volumes of column wash solution (100 mM 
NaCl, 10 mM Tris-HCl, pH 7.5, 2.5 mM EDTA, 50% ethanol), spin for 20 secs, 
and transferred to a new tube. 50 /xl of water was added into the mini-column. 
Plasmid was obtained by spining the tube containing mini-colunm for 20 secs at
1 2 ,0 0 0 g.
2.10.2 Restriction digest analysis of plasmids
When pUC18 was used as vector the Smal restriction site has been described 
during the process of cloning, removal of the cDNA fragment from pUC18 was 
effected with a pair of restriction enzymes located at either side of the Smal site in 
the pUC18. Routinely, the restriction enzymes EcoEl and Hindlll (Boehringer) were 
used, with the supplied xlO reaction buffer (lOmM Tris, lOOmM NaCl, 5mM MgCl2 , 
ImM B-mercaptoethanol, pH 8.0). For inserts cloned into the TA vector, a single 
enzyme, EcoRI was used, as this site was duplicated on either side of the insert 
sequence. When EcoRI alone was used, the lOx reaction buffer differed (50mM Tris, 
lOOmM NaCl, lOmM MgCl2 , ImM dithioerythritol, pH 7.5)
Restriction digests were performed on 10 /xl aliquots of the plasmid 
preparation (section 2.12.4) using 10-12 units of each of the appropriate enzyme(s)
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in a final volume of 30 /xl. Incubation was performed at 37°C for over 1 hour. The 
products of the digestion were separated, alongside molecular weight markers, by 
electrophoresis in a 1 % agarose gel in TAE buffer for 1 hour at 100 volts, stained in 
a solution of ethidium bromide (0.5 /xg/ml in TAE buffer) for 30 mins, and then 
photographed on a UV transilluminator.
2.10.3 Preparation of bacterial stocks
The plasmid contained E. coli strains were maintained on LB-agar plates, with 
antibiotics if appropriate, and subculture every 6  to 8  weeks. For the long term 
storage of bacteria they were frozen at -70*^ 0 in LB-broth containing 15% glycerol. 
Subsequently, the aliquot was used as an inoculum for amplifying the cells.
2.11 Nucleotide sequencing of the recombinant plasmid
Recombinant plasmid (pUC18 or pCR™ll plus cDNA inserts) were then 
subjected to confirmatory sequencing. The sequence data produced was compared 
with relevant sequences of JE SA 14 virus (Nitayaphan et al. 1990), and with the 
sequence of pUC18. Confirmed cDNA inserts were then sequenced in their entirety, 
in duplicate, but where anomalies existed, in triplicate or more. These were subjected 
to more thorough computer comparisons and analyses. Finally, colonies containing 
the required recombinant pUC18 were then prepared for long term storage (Section
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2.10.3).
2.11.1 Dideoxynucleotide sequencing.
DNA sequencing was performed on recombinant plasmid clones using the 
dideoxy chain termination methodology (Sanger et a l ,  1977). This methodology 
consists of three different stages:
1. Annealing of the primer to the template DNA.
2. DNA polymerisation occurs using limiting concentrations of dNTPs 
(including radiolabelled ^^S-dATP) to extend the primer by a few, or by several 
hundred nucleotides.
3. The final stage consists of a set of four chain-extension termination 
reactions in which the radiolabelled chains are extended until terminated by the 
incorporation of a dideoxynucleoside (ddNTP). During this step, the chains are 
extended on average by 20 - 50 nucleotides.
The reactions are stopped by the addition of EDTA and formamide, denatured 
by heating and run on polyacrylamide electrophoresis gels.
All DNA sequencing reactions were performed using a Sequenase Version 2.0 
kit (United States Biochemicals). This kit contains the enzyme Sequenase Version 2.0 
(Tabor and Richardson, 1987) which is a genetic variant of the bacteriophage T7 
DNA polymerase. This enzyme is a superior enzyme for sequencing, having amongst 
its properties high processivity, high speed, the ability to use popular nucleotide
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analogues and no 3’ to 5’ exonuclease activity.
2.11.2 Preparation of the sequencing gel.
DNA sequencing was performed in 25-cm-wide, 40-cm-long, 0.4 mm thick, 
5% (w/v) acrylamide-bisacrylamide (19:1) gels.
Both front (larger) and back (smaller) plates were thoroughly cleaned with 
detergent and tap water, rinsed with distilled water and then cleaned with ethanol and 
placed in a fume hood to dry. The larger front plate was coated with a 10 mis silane 
solution (0.3% (v/v) gamma-methacryloxypropyltrimethoxysilane (BDH) and 0.15% 
acetic acid in ethanol); the excess was removed with a lint free tissue (Kimwipe) and 
the surface washed with ethanol and polished with a clean tissue. The smaller back 
plate was siliconised by the application of 7 mis of dimethyl dichlorosilane (BDH, 
UK) or Sigmacote {Sigma USA) and similarly the excess was removed, followed by 
an ethanol wash and polishing. The two treated surfaces of the plate were clamped 
together, with a 0.4 mm spacer laid down each side. The plates were then taped 
together on both sides and the base, using 3M yellow electrical tape (BRL).
2.11.3 Preparation of the sequencing gel plates.
For each plate, 75 ml of sequencing gel was used which contained 7 M urea 
(Sigma) and 5% (v/v) PAGE 1 Sequencing gel mix (acrylamide : bis-acrylamide, 38:2
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(Northumbria Biologicals Limited or Bio-Rad Laboratories)) in TBE buffer (89 mM 
Tris-borate, pH 8.3, 2 mM disodium EDTA). The solution was heated to 37°C to 
dissolve the urea and immediately before casting the gel, 0.1% (v/v) N,N,N’,N’- 
tetramethylethylene-diamine (Temed (Bio-Rad Laboratories)) and 0.06% (w/v) 
ammonium persulphate (freshly made) were added. The solution was mixed (avoiding 
bubbles) and then injected into the pre-prepared plate assembly, taking care to avoid 
trapping bubbles. Bottom of sharkstooth combs were correctly inserted into the two 
glass plates about 0.5 cm and the gel was allowed to set for at least 1 hour. Prior to 
electrophoresis of the sequencing reactions, the electrical tape along the base of the 
gel and sharktooth combs were removed, the plate was placed in a Sequencing gel 
electrophoresis system, model 82 (Gibco-BRL). The top of the gel was washed 
carefully with electrophoresis buffer and the sharktooth combs put into the two plates 
(sharktooth insert into gel about 2-3 mm. The gel was pre-electrophoresed at 65 W 
for 30 mins in TBE buffer.
2.11.4 DNA sequencing reactions.
2.11.4.1 Alkaline dénaturation of the recombinant plasmid.
In order for the primer to be able to bind to the priming site in the 
recombinant plasmid, the two DNA strands must first be separated. An alkaline 
dénaturation method based on that of Chen and Seeburg, (1985), and Zhang et al. , 
(1988), was employed.
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3-5 /xg plasmid DNA (section 2.10.1) in 20 /xl was denatured by the addition 
of 2 /xl 2M sodium hydroxide and 2 /xl 2mM disodium EDTA. The preparation was 
mixed and incubated at room temperature for 30 mins. Neutralisation and 
precipitation were effected by the addition of 2 /xl 3M sodium acetate pH 4.8 and 3 
volumes of chilled ethanol following by precipitation at a -IÇPC freezer for half hour 
or in a dry-ice/ethanol bath for 5 mins. The DNA was pelleted by centrifugation at
12,000 g for 20 mins at 4°C, washed with 70% ethanol and dried. The pellet was 
resuspended in 7 /xl HPLC water and immediately taken onto the next stage of 
sequencing.
2.11.4.2 Annealing template and primer.
A single annealing reaction was set up. The following were added to the 7 /xl 
of denatured plasmid suspension: 1 /xl primers (0.5 pmol), and 2 /xl of 5 x reaction 
buffer (200 mM Tris-HCl pH 7.5, 100 mM magnesium chloride, 250 mM sodium 
chloride) to give a final volume of 10 /xl. The reaction mix was heated to 70°C for 
4  mins, cooled slowly in the IQPC water to room temperature over a period about 30 
mins and then placed on ice.
2.11.4.3 Labelling reaction.
The following were added to the annealed template-primer suspension: 1 /xl 
100 mM DTT, 0.5 /xl dATP 5’-(o'-p*S] thio) triphosphate (specific activity > 1000 
Ci/mmol) (5 /xCi), and 2 /xl of a 1:5 dilution of the 5x labelling mix in HPLC water
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(7.5 fjM dGTP, 7.5 /xM dCTP, 7.5 /xM dTTP). Finally 2 /xl of Sequenase Version
2.0 enzyme diluted 1:8 in ice-cold enzyme dilution buffer (10 mM Tris-HCl pH 7.5, 
5 mM DTT, 0.5 mg/ml bovine serum albumin) were added. The solution was 
carefully mixed and incubated at room temperature for 5 mins.
2.11.4.4 Termination reactions.
3.5 /xl of the resultant labelling reaction mix was aliquoted into each of four 
tubes which contained 2.5 /xl of one of each of the four termination mixes:
ddG Termination mix: 80 /xM dGTP, 80 /xM dATP, 80 /xM dCTP, 80 /xM 
dTTP, 8  /xM ddGTP, 50 mM sodium chloride.
ddA Termination mix: 80 /xM dGTP, 80 /xM dATP, 80 /xM dCTP, 80 /xM 
dTTP, 8  /xM ddATP, 50 mM sodium chloride.
ddT Termination mix: 80 /xM dGTP, 80 /xM dATP, 80 /xM dCTP, 80 /xM 
dTTP, 8  /xM ddTTP, 50 mM sodium chloride.
ddC Termination mix: 80 /xM dGTP, 80 /xM dATP, 80 /xM dCTP, 80 /xM 
dTTP, 8  /xM ddCTP, 50 mM sodium chloride.
The reactions were incubated at 37°C for 15 mins, and then terminated by the 
addition of 4 /xl of stop solution (95% formamide, 20 mM EDTA, 0.05%
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bromophenol blue, 0.05% xylene cyanol FF) and thorough mixing was effected. The 
samples were then stored for up to one week at -20°C.
2.11.5 Sequencing primers.
Confirmatory sequencing was usually effected using the (-40) Universal primer 
(5’-GTTTTCCCAGTCACGAC-3’) (Sequenase kit). The region in pUC18 or PCR™ 
II TA vector to which this primer anneals, is just outside the multiple cloning site.
All other sequencing used a number of additional primers. M13 reverse primer 
(5’-AACAGCTATGACCATG-3’), a primer recommended for use with the kit is just 
outside the multiple cloning site, sequenced the opposite strand from the Universal 
primer and the region to which it primes. In the TA vector, the positions of these 
primers were more distant from the site of the insert, but this still enabled their use 
as sequencing primers. Some specific primers were also used during sequencing. 
These primers enabled sequence data to be obtained from regions placed more 
centrally in the longer (500-1200bp) cDNA fragments. They were also used to prime 
to the opposite strand of regions of cDNA containing strong secondary structure, 
thereby clarifying regions of sequence that were difficult to elucidate. In all cases the 
primers used were made to a concentration of 0.5 pmol//tl.
2.11.6 Alterations of sequencing reaction conditions.
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It is possible to alter sequencing reaction conditions to provide maximum 
information about sequences close to the primer, or alternatively more distant from 
the primer. The alterations used were based on information given in the 
manufacturer’s protocol.
Reading sequences close to the primer: -
These changes to the standard protocol were used to obtain sequence data 
close to the primer (0 - 1 2 0  bases).
Double the amounts of template and primer were used.
The labelling mix, used during the annealing of the primers, was 
subjected to greater dilution: 1 :1 0 .
The reaction times of the labelling and termination reactions were both 
reduced to 3 mins.
Electrophoresis was continued until the first dye front (bromophenol 
blue) ran 80% of the length of the gel. (Bromophenol blue 
co-migrates with DNA 35 bases long in a 5% gel).
Reading sequences more distant from the primer: -
These changes were used to obtain sequence data more distant from the primer 
(350-500 bases).
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The labelling mix, used during the annealing of the primers, was 
undiluted and 1.5 /xl of [a-^^S]dATP was added.
The reaction time of the labelling reaction was extended to 5 mins.
A higher concentration of buffer (X 1.2 TBE) was used both for 
making the sequencing gel and for the running buffer. This provided 
more buffering capacity for the longer running times employed.
Electrophoresis was continued for 2 - 3 hours beyond the passing of 
the second (xylene cyanol FF) dye front. (Xylene cyanol co-migrates 
with DNA 130 bases long in a 5% gel).
2.11.7 Denaturing gel electrophoresis.
Prior to loading, the four samples were heated at 80°C for 4 mins and then
4-5 jLtl was immediately loaded into adjacent wells in a order of G, A, T and C after 
the gel had pre-electrophoresed for half hour as previously described. Electrophoresis 
was effected at constant output of 65 watts for 2 - 8  hours. After electrophoresis, the 
front plate was removed and the gel on the back plate was fixed by sooking in a 
solution of 10% methanol and 10% glacial acetic acid in water for 15 mins. The gel 
was then washed in cold running water for 10 mins and dried in a hot (80 °C) oven 
for 1 hour. The gel was then monitored with a geiger counter, and exposed to RX
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X-ray film (Fuji or Kodak) in a spring loaded metal cassette at room temperature. 
The film was developed after 1 -6  days, depending on the intensity of the monitored 
counts.
2.12 Computer analyses
Most of the computer analyses performed during the course of this study 
employed the Beckman Microgenie (Queen & Korn, 1984) and PCGFNF programs 
for analysis, contig assembly and direct one-to-one sequence comparisons. The 
secondary structural was predicted by using the Novotny method (Novotny and 
Auffray, 1984) in the PCGFNF.
However, for multiple alignments, Clustal was used (Higgins and Sharp, 
1988), and for some searches the databases and University of Wisconsin Genetics 
Computer Group suite of programs was utilized via the SFQNFT site at Daresbury, 
Warrington.
2.13 Pathogenicity studies
Pregnant mice were obtained from Harlan, Indianapolis, IN., and housed in 
a veterinarian supervised light/dark, temperature and humidity controlled animal 
room. They were housed in cages and provided free access to tap water and Purina
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Lab Chow. Female outbred white mice, 3 to 4 weeks old and weighting between 25- 
30g were used to determined virus pathogenicity. Mice were inoculated with 20 fû 
of virus diluted in PBS by the intraperipheral or intracerebral routes. The animals wws- 
observed for a period of upto 21 days and monitored regularly. The death and signs 
of disease were recorded accordingly. The logio pfu/LDgg was then calculated where 
appropriate according to the formulae.
Logio LD5 0  = Logio highest dilution + 1 / 2  Log 1 0 dilution interval - [ Number of 
survivors/total number of mice] each vims dilution
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Chapter 3
Molecular basis of attenuation of neurovirulence
of wild-type Japanese encephalitis virus strain SA14
3.1 Introduction
Effective inactivated vaccines to control JE have been developed but they are 
expensive due to high production costs and require repeated booster vaccinations. 
Several attempts have been made to develop a live attenuated JE virus vaccine 
(Rohitayodhin and Hammon, 1962; Kodama et al. , 1968; Takehara et al. , 1969; Yu 
et a l ,  1973). The most promising attenuated JE virus vaccine is the Chinese 
SA14-14-2 virus derived from the wild-type strain SA14 (Yu etal. , 1973). The safety 
and efficacy of this attenuated vaccine have been confirmed in human vaccinees (Ao 
e ta l ,  1983; Yu e ta l ,  1981, 1988).
Wild-type JE virus strain SA14 was isolated from mosquitoes collected in 
Sian, China, in 1954 (Li, 1986). The first attenuated variant, 12-1-7, was obtained 
after passage of the virulent parent virus SA14 11 times by intracerebral inoculation 
of newborn mice followed by 100 passages in primary hamster kidney (PHK) cells 
(Yu et a l ,  1962; Li, 1986). The passage histories of the SA14 attenuated vaccine 
viruses are summarized in Figure 3.1. The SA14-2-8 virus was attenuated by 
treatment of 12-1-7 virus with ultraviolet irradiation followed by plaque purification. 
SA14-5-3 virus was derived from 12-1-7 virus by additional plaque purification 
passages in PHK cells. The SA14-14-2/PHK virus was obtained by further passage 
of the SA14-5-3 virus in suckling mice and plaque purification in PHK cells (Yu et 
a l ,  1981; Li, 1986). Eckels et al. (1988) passed SA14-14-2/PHK virus nine times 
in primary dog kidney (PDK) cells to prepare the SA14-14-2/PDK vaccine. All of the 
candidate vaccine strains (SA14-2-8, SA14-5-3, SA14-14-2/PHK and SA14-14-2/PDK
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Fig. 3.1. The passage history of three SA14 strains and derived vaccine viruses.
SA14/JAP
BHK21
mouse
brain
SA1 4 1 virulent parent isolated from 
mosquitos in China.
11 X p assages in newborn mice,
100 X p assages in PHK cell culture, 
3 X plaque purification.
SA14/us A Qione 12-1 -7 ultraviolet irradiation
3 PDK  
passages
First attenuated variant
12 p assages
SA14/CDC SA14-5-3 SA14-2-8
7 p assages
SA14-14-2/PHK
9 PDK p assages
SA14-14-2/PDK
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viruses) are attenuated for humans and are not encephalitogenic in adult mice 
inoculated intracerebrally with 10^  plaque forming units of virus (Yu et al. 1981; 
Chen and Wang, 1974; Wills et al., 1992).
The molecular basis of JE virus attenuation has not been elucidated, although 
entire genomes of both virulent parent SA14 and attenuated vaccine clones, 
SA14-14-2/PHK (Aihara et al., 1991) and SA14-14-2/PDK (Nitayaphan et al., 1990) 
have been sequenced and compared. Nucleotide sequences of SA 14 published by the 
two groups are not identical, and nucleotide differences were identified throughout 
the genome between parent and attenuated viruses SA14-14-2/PHK or SA14-14- 
2/PDK. Aihara et al. (1991) identified 57 nucleotide changes coding for 24 amino 
acid substitutions between SA14 (which is termed SA14/JAP) and SA14-14-2/PHK 
whereas Nitayaphan et al. (1990) reported 45 nucleotide changes coding for 15 amino 
acid substitutions between SA14 (which is termed SA14/CDC) and SA14-14-2/PDK 
viruses. Both groups reported that most of the amino acid substitutions were present 
in the virus structural protein genes. Recently, the genomic RNA of the parental 
SA14 virus was cloned and sequenced again in CDC (which is termed SA14/USA to 
distinguish it from previous SA14 sequences) (Trent, personal communication).
To help identify the molecular determinants of neurovirulence attenuation of 
JE virus strain SA14, the nucleotide sequence of attenuated vaccine virus SA14-2-8 
was determined, compared to three sequences of SA14 virus (SA14/USA, SA14/CDC 
and SA14/JAP) and sequences of another two vaccine viruses (SA14-14-2/PHK and 
SA14-14-2/PDK), and also other wild-type JE viruses.
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3,2 Results
3.2.1 Cloning and sequencing of the viruses
The nucleotide sequence of The entire RNA genome (10976 nucleotides) of 
SA14-2-8 virus was reverse transcribed and cDNA amplified by using reverse 
transcription and polymerase chain reaction (RT-PCR). PGR products were separated 
by agarose gel electrophoresis (see Fig. 3.2) The cDNA was recovered from the gel 
followed by cloning and sequencing by the dideoxynucleotide chain termination 
method. The nucleotide sequence of SA14-2-8 virus is shown in appendix 1.
For comparison, ^entire RNA genome of wild-type strain P3 and regions of 
nucleotides 28 to 2463, 4385-4969, 7^/- and 10290-10496 of Nakayama strain 
were also transcribed and subsequently sequenced (refer to chapters 4 and 7).
3.2.2. comparison of sequences of virulent parent and vaccine viruses
The first attenuated virus variant (clone 12-1-7) of wild-type strain SA14 no 
longer exists. Thus, it was proposed to compare the sequences of three vaccine 
viruses (SA14-2-8, SA14-14-2/PHK and SA14-14-2/PDK) derived from clone 12-1-7 
as, presumably, all must share the common nucleotide(s) and/or amino acid(s) that 
are responsible for the attenuated phenotype.
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Fig. 3.2. The cDNA fragments of JE virus from reverse transcription and PCR 
amplification JE virus SA14-2-8. Lane 1, DNA molecular size marker - Hae III 
digested (()X174 (size of first band, 1353 base pairs (bp); second, 1078 bp; third, 872 
bp; fourth, 603 bp; fifth, 310 bp; sixth, 281 bp; seventh, 271 bp and eighth, 234 bp). 
Lane 2 negative control; Lane 3, the cDNA (molecular size 637 bp) amplified with 
primers ANS51 and XH4B; Lane 4, the cDNA (805 bp) amplified with primers 
ANS52 and SNS51; the cDNA (621 bp) amplified with primers JE 2463 and JE1862.
Size
1353
1078
872
603
310(281)
271
234
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A summary of the nucleotide and amino acid differences of the entire genome 
between the three vaccine viruses (SA14-2-8, SA14-14-2/PHK and SA14-14-2/PDK) 
and three sequences of SA14 virus (SA14/JAP, SA14/CDC and SA14/USA) are 
shown in the Table 3.1. SA14-2-8 virus has less nucleotide and amino acid 
differences than SA14-14-2/PHK and SA14-14-2/PDK viruses compared to the three 
sequences of strain SA14, this may due to the different passage history and fewer 
passages required to generate SA14-2-8 virus compared to SA14-14-2 viruses (Fig.
3.1).
The amino acid differences and nucleotide differences in the 5’ and 3’ non­
coding region between SA14 virus and its attenuated vaccine viruses are shown in 
Table 3.2. For brevity this Table shows in the left-hand column the nucleotide 
number in the genome where the difference was identified and the remainder of the 
columns show the amino acid found in the codon at that position.
3.2.3 Nucleotide sequences of 5’ and 3’ non-coding regions
The nucleotide at position 39 of the 5’ non-coding region of three sequences 
of parental strain SA14, was changed from C to U in SA14-14-2/PHK and SA14-14- 
2/PDK viruses but did not change in the SA14-2-8 virus. Wild-type virus Beijing-1 
was U at this position (Table 3.2). In the 3’ non-coding region, the nucleotide at 
position 10428 was U in three sequences of parental strain SA14, while vaccine 
viruses SA14-14-2/PHK and SA14-14-2/PDK had a C at this position. However,
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Table 3.1. Number of nucleotide and amino acid differences of the entire genomic 
sequences between SA14/USA, SA14/CDC, SA14/JAP and three derived vaccine
viruses.
Nucleic Acid
Strain SA14
/USA
SA14 SA14 
/JAP /CDC
SA14-14-
2/PHK
SA14-14-
2/PDK
SA14-2-8
SA14
/USA
15 20 60 56 39
SA14
/JAP
7 17 57 58 42
Amino SA14
/CDC
1 1 1 1 62 45 43
acid
SA14-14-2
/PHK
27 24 15 2 1 60
SA14-14-2
/PDK
2 2 22 15 8 56
SA14-2-8 18 19 21 29 24
al. (1991); SA14/CDC and SA14-14-2/PDK viruses are taken from Nitayaphan et al. 
(1990); SA14/USA is taken from Trent (personal communication). SA14-2-8 viruses 
is reported in this chapter.
I l l
SA14-2-8 was U at this position, two wild-type strains, S982 and Beijing-1 had U and 
another two wild-type strains (Nakayama and P3) had C at this position (Table 3.2). 
The sequence of the SA14-14-2/PHK had a unique change in the 3’ noncoding region 
at position 10784 (C ->  U), whereas wild-type Strain S982 was also U at this 
position (Table 3.2). This suggests that the changes in the 5’ and 3’ non-coding 
regions probably do not play a role in the attenuation of virulence of wild-type JE 
virus strain SA14.
3.2.4 Comparison of nucleotide and deduced amino acid sequences of 
structural protein genes
Comparison of the nucleotide sequence of SA14/USA (Trent personal 
communication) with that of SA14/CDC reported by Nitayaphan et al. (1990) 
revealed differences at positions 1052 (G ->  A), 1708 (G ->  A), 1921 (C ->  U), 
2293 (A ->  G) and 2441 (G ->  A); which resulted in three amino acid differences 
at positions of E protein amino acid 244 (E-244 (Glu ->Gly), E-315 (Ala > Val) 
and E-439 (Lys > Arg) of the E protein (Table 3.2, appendix 1). Nucleotide 
sequences of the SA14/USA and SA14/JAP (Aihara et al., 1991) viruses differ by 
four nucleotides at positions 1052, 1217, 1708 and 1977, which introduce two amino 
acid differences at positions E-244 (Glu — > Gly) and E-334 (Pro — > Ser) (Table
3.2). These sequence differences are presumably due to the passage history of SA14 
virus used in the three studies. SA14/USA was a mouse brain preparation of SA14 
virus while SA14/CDC virus was a plaque purified virus derived from the mouse
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Table 3.2. Comparison of amino acid differences in protein genes and nucleotide 
differences in 5’ and 3’ non-coding regions between JE wild-type and vaccine viruses.
P o s i t i o n  S A 1 4 / S A 1 4 /S A 1 4 /S A 1 4 - 1 4 - 2  SA14 S 9 8 2  N a k a -  P3 B e i  j  -
NT AA USA CDC JAP PHK PDK - 2 - 8 yam a i n g - 1
15 5'N C C C C C C C C - C C
3 9 5'N C U U U A A U A A A A
2 9 2 C -6 5 L eu L eu L eu S e r S e r L eu L eu L eu L eu L eu
1 2 9 6 E - 1 0 7 L eu L eu L eu P h e P h e L eu L eu L eu L eu L eu
1 3 5 4 E -1 2 6 l i e l i e H e H e H e T h r H e H e H e H e
1 3 6 0 E -1 2 8 A rg A rg A rg A rg A rg L y s A rg A rg A r g A r g
1 3 8 9 E -1 3 8 G lu G lu G lu L y s L y s L y s G lu G lu G lu G lu
1 5 0 3 E -1 7 6 l i e l i e H e V a l V a l V a l H e H e H e H e
1 5 0 6 E - 1 7 7 T h r T h r T h r A la T h r T h r T h r T h r T h r T h r
1 5 1 2 E - 1 7 9 L y s L y s L y s L y s L y s G lu L y s L y s L y s L y s
1 7 0 4 E -2 4 3 G lu G lu G lu G lu L y s G lu G lu G lu G lu G lu
1 7 0 8 E -2 4 4 G lu G ly G lu G ly G ly G ly G lu G lu G lu G ly
1 7 6 9 E -2 6 4 G in G in G in H is G in G in G in G in G in G in
1 8 1 3 E - 2 7 9 L y s L y s L y s M et M et L y s L y s L y s L y s L y s
1 9 2 1 E -3 1 5 A la V a l A la V a l V a l V a l A la A la A la A la
1 9 7 7 E -3 3 4 P ro P ro S e r P ro P r o P ro P r o P r o P r o P r o
2 2 9 3 E -4 3 9 L y s A rg L y s A rg A rg A rg L y s L y s L y s L y s
3 1 8 4 N S l - 2 3 6 V a l V a l V a l V a l V a l A la V a l V a l V a l V a l
3 3 5 1 N S l - 2 9 2 S e r S e r G ly S e r S e r G ly G ly G ly G ly G ly
3 4 9 3 N S l - 3 3 9 A rg M et A rg M et M et A rg A rg A rg A r g A rg
3 5 2 8 N S l - 3 5 1 A sp A sp A sp H is A sp A sp A sp A sp A sp G ly
3 5 3 5 N S l - 3 5 3 P he P h e P he P h e P he S e r P h e P h e P h e P h e
3 5 3 9 N S l - 3 5 4 A sn L y s A sn L y s L y s A sn A sn A sn A sn A sn
3 6 5 2 N S l - 3 9 2 A la V a l A la V a l V a l A la A la A la A la A la
3 8 4 9 N S 2 A -4 6 V a l H e V a l V a l V a l V a l V a l V a l V a l V a l
4 4 0 2 - 3 N S 2 B -6 3 G lu G lu G lu A sp A sp G ly G lu G lu G lu G lu
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4 4 0 8 N S 2 B -6 5 A sp A sp A sp G ly G ly A sp A sp A sp A sp A sp
4 5 1 9 N S 2 B -1 0 2 T h r M et M et M et M et M et M et M et M et M et
4 7 8 2 N S 3 -5 9 M et M et M et V a l V a l M et M et M et M et M et
4 8 2 5 N S 3 -7 3 A rg A rg A rg L y s L y s A rg L y s A rg L y s L y s
4 9 2 1 - 2 N S 3 -1 0 5 A la A la A la G ly G ly G ly A la A la A la A la
5 2 4 3 N S 3 -2 1 5 A la A la V a l V a l A la A la A la - A la A la
5 6 3 4 N S 3 -3 4 3 A rg A rg A rg T rp A rg A rg A rg - A rg A rg
6 6 3 4 N S 4 A -2 7 H e H e H e T rp H e H e H e - H e H e
6 7 0 0 N S 4 A -4 9 A rg L y s L y s L y s L y s L y s L y s - L y s L y s
7 7 0 6 N S4B - G lu G lu G lu G lu G lu A sp G lu - G lu G lu
7 2 2 7 N S 4 B -1 0 6 H e H e H e V a l V a l V a l H e H e H e H e
7 7 0 6 N S 5 -5 1 G lu G lu G lu G lu G lu A sp G lu - G lu G lu
8 6 5 8 N S 5 -3 2 8 L y s G lu L y s L y s L y s L y s L y s - L y s L y s
8 8 3 2 N S 5 -3 8 6 H is H is H is T y r T y r H is H is H is T y r H is
9 6 0 3 N S 5 -6 4 3 G lu G lu G lu G lu G lu L y s G lu G lu G lu G lu
9 6 0 7 N S 5 -6 4 4 A sn T h r A sn A sn T h r A sn T h r - A sn T yp
9 6 8 8 N S 5 -6 7 1 V a l V a l V a l A la V a l V a l V a l - V a l V a l
9 8 9 8 N S 5 -7 3 1 G ly G ly A sp G ly G ly G ly G ly - G ly G ly
1 0 4 2 8 3'N C U U U C C U U C C U
1 0 7 8 4 3'N C C C C U C C U - C C
* NT: N u c l e o t i d e .  # AA: a m m o  a c i d .  NC: n o n - c o d i n g  r e g i o n .  - .  N u c l e o ­
t i d e  h a s  n o t  b e e n  s e q u e n c e d .  B o ld  a m in o  a c i d s  a r e  common a m in o  a c i d  
s u b s t i t u t i o n  f o u n d  i n  v a c c i n e  v i r u s e s .  T h e s e q u e n c e s  o f  S A 1 4 /J A P  a n d  
S A 1 4 -1 4 -2 /P H K  v i r u s e s  a r e  t a k e n  fr o m  A ih a r a  e t  a l .  ( 1 9 9 1 )  ; SA 14/C D C  a n d  
S A 1 4 -1 4 -2 /P D K  v i r u s e s  a r e  t a k e n  fr o m  N it a y a p h a n  e t  a l . ( 1 9 9 0 )  ; S A 14 /U S A  
fr o m  T r e n t  ( p e r s o n a l  c o m m u n ic a t io n ) . P a r t  o f  N akayam a v i r u s  s e q u e n c e  
( 2 4 6 3 - 3 7 2 0 )  i s  t a k e n  fr o m  McAda e t  a l .  (1 9 8 7 )  . T h e s e q u e n c e s  o f  
J aO A rS 982  v i r u s ,  fr o m  S u m iy o s h i  e t  a l .  ( 1 9 8 7 ) /  B e i j i n g - 1  fr o m  H a s h im o to  
e t  a l .  ( 1 9 8 8 ) ,  a n d  t h e  n u c l e o t i d e  a n d  a m in o  a c i d  l i s t e d  i n  t h e  t a b l e  
a r e  a t  e q u i v a l e n t  p o s i t i o n s .  O th e r  s e q u e n c e s  a r e  r e p o r t e d  i n  t h i s  
t h e s i s .
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brain preparation containing SA14/USA virus following three passages in primary dog 
kidney (PDK) cell culture (Eckels et a l , 1988; Nitayaphan et a l ,  1990). SA14/JAP 
virus was derived by plaque purification of SA14 virus in BHK-21 cells (Aihara et 
a l , 1991). Since these three preparations of SA14 virus are virulent for mice it would 
appear that the amino acid changes at E-244, E-315, E-334 and E-439 are not 
involved in attenuation of SA14 virus.
Comparison of the E protein amino acid sequence of SA14/USA, SA14/CDC 
and SA14/JAP viruses with those of published wild-type JE virus strains, Nakayama 
(McAda et a l , 1987), JaAOrS982 (Sumiyoshi et a l ,  1987), Beijing-1 (Hashimoto et 
a l ,  1988), Sarawak (Cecilia and Gould, 1991) and Kamiyama (Hasegawa et al., 
1992), revealed that the amino acid at position E-244 is variable, some strains have 
glutamic acid while others have glycine. However, amino acids at positions E-315 and 
E-439 of SA14/CDC virus were shared with the three vaccine strains and not 
SA14/USA or SA14/JAP viruses. The amino acid at position E-334 is proline in all 
wild-type strains except SA14/JAP virus. These results suggest that the SA14/USA 
virus sequence represents the dominant RNA genome of wild-type parent SA14 virus.
In the structural proteins, SA14-2-8 virus differed from its parent (SA14/USA) 
virus by 13 nucleotide and 8 amino acid differences. Amino acid substitutions 
occurred at positions E-126, E-128, E-138, E-176, E-179, E-244, E-315 and E-439. 
Of the nucleotide differences present in SA14-2-8 virus, substitutions at positions 
1052 (E-25), 1061 (E-28), 1389 (E-138), 1503 (E-176), 1708 (E-244), 1921 (E-315) 
and 2293 (E-439) were present at the same positions in the other attenuated JE virus
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vaccine strains (Table 3.2, appendix 1). Nucleotide changes at positions 1052 and 
1061 did not result in amino acid substitutions.
SA14-14-2/PHK and SA14-14-2/PDK vaccine viruses have seven identical 
amino acid substitutions in comparison to the sequence of the SA14/USA and 
SA14/JAP viruses. These included one in the C protein (C-65), and six in the E 
protein (E-107, E-138, E-176, E-279, E-315 and E-439) (Table 3.2). When the amino 
acid sequence of the SA14-2-8 virus was included in the comparison, four common 
amino acid substitutions were found at the following positions: E-138 (Glu - > Lys), 
E-176 (lie ->  Val), E-315 (Ala-> Val) and E-439 (Lys-> Arg) (Table 3.2). These 
attenuated JE vaccine viruses share two common amino acids with the virulent 
SA14/CDC virus at positions E-315 and E-439. This suggests that these two amino 
acids are not involved in the attenuated phenotype. Comparison of structural protein 
genes of three vaccine strains and wild-type JE virus strains revealed only two 
common amino acid substitutions in the vaccine strains: namely E-138 and E-176. 
Nucleotide variation at positions 1354, 1360, 1512, 1661, and 2051 of SA14-2-8 
virus resulted in three unique amino acid substitutions in the SA14-2-8 virus at 
positions E-126, E-128, and E-179. The thirteen nucleotide and nine amino acid 
differences between SA14-2-8 and SA14-14-2/PHK viruses presumably resulted from 
ultraviolet irradiation treatment of SA14-2-8 virus and the subsequent 13 animal 
passages and six plaque purifications.
3.2.5 Comparison of the nonstructural protein genes of SA14 virus and
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wild-type strains
Three parental SA14 viruses nonstructural protein genes differed by 67 
nucleotides encoding 11 amino acid changes, of which four amino acids were in NSl 
protein at positions NSl-292 (Ser < ->  Gly), NSl-339 (Arg < ->  Met), NSl-354 
(Asn < ->  Lys) and NSl-392 (Ala < ->  Val); the remainder were at positions 
NS2A-46 (Val < ->  He), NS2B-102 (Thr < ->  Met), NS3-215 (Ala < ->  Val), 
NS4A-49 (Arg < ->  Lys), NS5-328 (Lys < ->  Glu), NS5-644 (Asn < ->  Thr) and 
NS5-731 (Gly < ->  Asp) (Table 3.2). Compared to vaccine and other wild-type JE 
viruses, the amino acid changes at NS2B-102 and NS4A-49 of SA14/USA virus were 
unique changes, and SA14/CDC and SA 14/JAP viruses had six and three unique 
amino acid changes respectively (Table 3.2).
3.2.6 Comparison of nonstructural protein genes of SA14 and its vaccine 
virus derivatives
Overall, in comparison to the structural protein genes, there were few 
nucleotide and amino acid differences in the nonstructural protein region between 
parent and vaccine viruses. In the NSl protein, SA14-2-8 virus has three unique 
amino acid substitutions at positions NSl-236, NSl-292 and NSl-353 compared to 
SA14 and the other vaccine viruses. SA14-14-2/PHK virus has a unique amino acid 
substitution at NSl-351 (Table 3.2).
Amino acid NS2B-63 was substituted in all vaccine viruses. In SA14-14-
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2/PHK and SA14-14-2/PDK viruses, the glutamic acid found at this position in SA14 
virus was substituted by asparagine while in SA14-2-8 virus it was replaced by 
glycine. At NS2B-65, the asparagine of SA14 virus was changed to glycine in SA14- 
14-2/PHK and SA14-14-2/PDK viruses, but was not substituted in SA14-2-8 virus 
(Table 3.2).
In the NS3 protein, three common amino acid substitutions were found at 
positions NS3-59, NS3-73 and NS3-105 of the SA14-14-2/PHK and SA14-14-2/PDK 
vaccine viruses compared to the parental SA14 virus. When SA14-2-8 virus was 
included in the comparison only NS3-105 was substituted in all vaccine viruses, 
where an alanine in the parent SA14 virus was substituted for a glycine in the three 
vaccine viruses. The substitution at NS3-105 resulted from two nucleotide changes 
at 4921 and 4922 in all three vaccine viruses.
At NS4B-106, the isoleucine of the SA14 virus was substituted by a valine 
in all three vaccine viruses. SA14-2-8 had a unique amino acid substitution at NS4B- 
99 (Glu > Asp) compared with the other viruses. NS5-386 was a variable amino 
acid, the histidine of SA14 virus was replaced by tyrosine in SA14-14-2/PHK and 
SA14-14-2/PDK vaccine viruses. It was a histidine in SA14-2-8 virus and a tyrosine 
in the wilditype IE virus P3 (Table 3.2). SA14-2-8 virus had a unique amino acid 
change at position NS5-643 from glutamic acid to lysine (Table 3.2). Therefore, there 
were a total of three common amino acids substituted in the nonstructural protein 
genes of the three vaccine viruses compared to the parent SA14 virus, namely at 
positions NS2B-63, NS3-105 and NS4B-106 (Table 3.2).
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There were also fifteen silent nucleotide substitutions in the nonstructural
protein genes of SA14-2-8 virus at positions 2843 (C ->  U), 3085 (A ->G ), 3284
(U > C), 3290 (U ->  C), 3584 (U ->  C), 3599 (G ->  A), 3776 (C > U), 3801
(C ->  U), 5243 (C ->  U), 7337 (G > A), 7751 (U ->  C), 8276 (C ->  U), 8394
(C > U), 8882 (A ->  U) and 8891 (C ->  U) compared with its parental 
SA14/USA virus (appendix 1).
3.2.7 Comparison of common amino acid substitutions in the vaccine 
viruses with equivalent regions in wild-type JE viruses
The two amino acids at E-138 and E-176, which were substituted in all three 
vaccine viruses derived from SA14, were conserved in the sequences of all published 
wild-type JE viruses (of which the sequences of five strains are showed in Table 3.4 
Two wild-type JE viruses (Nakayama and P3) were sequenced in the regions of the 
nonstructural protein genes containing the vaccine substitutions (NS2B, NS3 and 
NS4B). In conjunction with the published sequences of Beijing-1 (Hashimoto et a l ,  
1988), SA14 (Nitayaphan et al., 1990; Aihara et al., 1991; Trent, personal 
communication) and JaOArS982 (Sumiyoshi et al., 1989) viruses a total of five wild- 
type strains were compared with the three vaccine strains (Table 3.1). Amino acid 
positions NS2B-63, NS3-105 and NS4B-106 in all three vaccine strains were 
consistently different from all five wild-type viruses examined.
3.2.8 FlavivirUS-Specific serine proteinase
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A forty amino acid "central region " of NS2B found in all mosquito 
transmitted flaviviruses is proposed to be included in the flavivirus-specific serine 
proteinase (Chambers et al. , 1993; Falgout et al. , 1993) and was investigated in detail 
(Fig. 3.3). NS2B-63 was a glutamic acid for all wild-type mosquito transmitted 
flaviviruses that have been sequenced, except DEN-4 virus. In comparison, two JE 
vaccine viruses (SA14-14-2/PHK and SA14-14-2/PDK) had an aspartic acid, the same 
amino acid seen in DEN-4 virus, SA14-2-8 was glycine at this position. Since only 
one DEN-4 virus has been sequenced (Mackow et a l ,  1987), the central region of 
another strain of DEN-4 virus (703-4) was sequenced by the author of this thesis and 
it was found that the nucleotide sequence of the two strains of DEN-4 virus were 
identical in this region. This indicates that NS2B-63 of DEN-4 virus is different to 
all the flaviviruses that have been sequenced.
The proteinase domain in the N terminal region of NS3 protein (Chambers et 
al., 1990a,b) of different flaviviruses have many conserved amino acids (Fig. 3.4). 
The amino acid equivalent to JE NS3-105 is semi-conserved. Wild-type JE and tick- 
borne encephalitis complex viruses have alanine at this position while other mosquito- 
borne flaviviruses are asparagine; the JE vaccine viruses were glycine at this position.
3.2.9 Amino acid substitution analysis
The twenty amino acids in the NS4B surrounding the common amino acid 
substitution at NS4B-106 in the JE vaccine viruses were aligned for different
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Fig. 3.3. Alignment of essential 40 amino acids in central region of NS2B domain 
from several mosquito transmitted flaviviruses. *: conserved amino acids. !: Amino 
acid substituted in JE vaccine viruses derived from SA14 virus. The sequences of 
DEN-1 and DEN-3 viruses are taken from Fu et al. (1992) and Osatomi and 
Sumiyoshi (1990), the remainder are taken from Falgout et al. (1993).
NS2B-63
N S2B -> !
DEN-1 (56AA) LEKAAEVSWEEEAEHSGASHNILVEVQDDGTMKIKDEERD
DEN-2 (56AA) . .K . , D. K . . . Q . . I . . S . P I L S I T I S E . . S . S . . N . . N N
DEN-3 (56AA) V. . . . D . T . . . E . . Q T . V . H . L M I T . D . . . T . R . . . . .  TE
DEN-4 (56AA) . . . . • N. Q . D . M . D I T . S . P I . E . K Q D E . . S F S . R . V . E T
JE (54AA) . . R . . D I . . . MD. AI T. S . RRLD. KLD. . .DFHLI.DPGV
WN (54AA) I . RT . DIT . . S D . . I T . S . ERVD. RLD. . . NFQLMNDPGA
KUN (54AA) I . RT . D I . . . GD. . I T . . . ERVD. RLD. . . NFQLMNDPGA
MVE (54AA) R , .D. . , . AG. AI T. T . ERLD. QLD. . . DFHLLVDPGV
SLE (54AA) , DIT . . QN. . I T . T . PRLD. DLDSH .NF.LLNDPGA
YF (53AA) . K . L G E . . .............. I .  .S.ARYD.ALSEQ . E F . L L S . . KV
* * * * *
121
Fig. 3.4. Alignment of amino acid sequences surrounding the catalytic triad of the 
serine proteinase and NS3-105 of several important flaviviruses. Catalytic triad. 
*: Conserved amino acid in the flaviviruses. !: Amino acid substituted in JE vaccine 
viruses derived from SA14 virus. The viral sequences of DEN-1 (dengue), DEN-2, 
DEN-3 and DEN-4 are taken from Fu et al. (1992), Blok et al. (1992), Osatomi and 
Sumiyoshi (1990) and Falgout et al. (1993); JE taken from Sumiyoshi et al. (1987); 
KUN (kunjin) taken from Coia et al. , 1988; MVE (Murray Valley encephalitis) 
taken from Dalgamo et al., (1986); WN (West Nile) from Castle et al. (1986), YF 
(yellow fever) from Hahn et al. (1987); TBE (Russia spring summer encephalitis) 
from Pletnev et al. (1990), CEE (Central European encephalitis, neudoerfl strain) 
from Mandl et al. (1989) and LGT (langat) from lacono-Connors and Schmaljohn 
(1992).
N S 3 - > JE NS3 - 5 1 NS3 - 7 5
@ @
D E N - l (43AA) DGVFHTMWHVTRG (13AA) WASVKKDLISYGGGWRFQGSWNTGEEVQ
DEN-2 
DEN-3  
DEN-4
(43AA)
(43AA)
(43AA)
E . T .  . (13AA)
(13AA)
(13AA)
. , D ....................... . . . KLE. E . K G ............
E . . . . . . . .LSAQ.QK............
E ____ . . D . R N . M . . . . . . . KL E .E .K G ............
JE (43AA) EN. . . Ti . T .  . . (13AA) . G . . R E . R . A . . . P . . F D R K . . G T D D . .
KUN (43AA) E . . . . .L . T . K . (13AA) . G . . . E . R L C . . . P . K L . H K . . G Q D . . .
MVE (43AA) E.  . . . T. . T .  . . (13AA) . G N . . E . R V T . . . P . K L D O K . . G V D D . .
WN (43AA) E . . . . .L . T . K . (13AA) . G . . . E . R L C . . . P . K L . H K . . G H D . . .
YE (45AA) E.  . . . Tt (13AA) ............E . . V A . . . S . KLE. R . DGE. . . .
TBE (45AA) K. . . . T. (13AA) . . D . R E . W C .  . .A.SLEEK.KG . T . .
CEE (45AA) K . . L . (13AA) . . D . R E . W C .  . . A .  SLEEK.KG . T . .
LGT (45AA) K. . L . (13AA) . . D . R E . W C .  . .A .SL ES R.RG  . T . .
**  ** * * * * * * * *  * * **
JE N S 3 - 1 0 5 N S 3 - 1 3 5
@
DEN-1 VIAVEPGKNPKNVQTAPGTFKTPEG-EVGAIALDFKPGTSGSPIVN
DEN-2 L.  .AV. . . . W ____ K . S L .  . V R N . - . I . .VS . . S ____ . . . .D
DEN-3 .............. F . . M .  . L . Q . T T . - . I .
DEN-4 . L . L D . . . . . R A . . . K . . L . . . N A . - T I . .VT. . . . . . . . . . .  ID
JE . .V .  . . . . A A V . I . . K . . V . R . . F . - . . . .VS . . . . . . . . . . .  ID
KUN M.V.  . . . . .  . . . . .  . . . . . .  . . .VS . . . P T . . . . . . . D
MVE M.V.  . . . . . A l . . . . K . . I . . . AH.—. I . . VS . . Y P I . . .
WN M.V.  . . .VT. . Y P T . . . . . . .D
YF L . . A V . . . . W ____ K . S L .  . V R N . G . I . .V .  . Y P S . . .
TBE . H . F P . . RAHEVH. CQ. . ELLLDT. R R I . .VP I LVK. . . . . . L .
CEE . H . F P . . RAHEVH.CQ..ELILDT. R R I . . . P I . L V K . . . . . . L .
LGT . H . F P . . RAHEVH.CQ..ELILEN. RRM. . . P I . L A K . . . . . .MA*******
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flaviviruses (Fig. 3.5). The amino acid positions for all mosquito transmitted 
flaviviruses, that have been sequenced is valine except yellow fever and wild-type JE 
viruses, which are isoleucine. Since JE vaccine viruses have a valine at this position 
in a region that is strongly conserved amongst JE serocomplex viruses, the 
significance of this amino acid substitution in the attenuated phenotype is very 
questionable.
3.2.10 Secondary structure prediction of the amino acid substitutions
Deduced amino acid sequences of the parent SA14 virus and the attenuated 
derivative viruses were analyzed by the Novotny method (Novotny and Auffray, 
1984), which calculates hydrophobicity and predicts protein conformation and 
changes. The amino acid substitution at position E-138 (Glu ->  Lys) was predicted 
to cause a change in the secondary structure (charged residues profile and alpha helix 
propensity) of the E proteins of the attenuated viruses when compared with parental 
SA14 virus (Fig. 3.6). Amino acid substitution at C-65 of SA14-14-2/PHK and SA14- 
14-2/PDK vaccine viruses would change the hydrophobicity profile and beta-sheet 
propensity of the C protein (data not shown).
Of the substitutions in the non-structural proteins, it was predicted that 
substitution at NS3-105 would alter alpha helix propensity significantly and change 
reverse turn propensity. No clear secondary structure change was predicted when 
glutamic acid at NS2B-63 was substituted by either asparagine or glycine (Fig. 3.7).
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Fig. 3.5. Alignment of amino acid sequences of NS4B of several flaviviruses 
surrounding the common amino acid substitution in the JE vaccine viruses derived 
from wild-type SA14 strain. The sources of the sequences are the same as those in 
Fig. 3.4.
N S4B -> JE N S 4B -106  
1
DEN-1 (94AA)
I
LLALGCYSQVNPLTLTAAVL
DEN-2 (93AA) . . . 1 ................... I .............L.
DEN-3 (93AA) .......................................I . . . .
DEN-4 (90AA) . . .M................... T. .A .SL V
JE (97AA) . V F . . . WG. ITLT. FLT. MV
WN (98AA) . . . A . . W G . . TLTVTVTAAA
KUN (97AA) . . . A. . WG. . TLTVTVTSAT
MVE (97AA) . V F . . . WG . . T L T . . IM. TI
YF (95AA) M. LVSGWNSITVMP. LCGIG
TBE (96AA) A . GWSLVGAT. TS . W G . G
CEE (96AA) T . GWSLIGAT . TS . MVG. G
LGT (96AA) A . GVASLVGAT. TTSLILGV
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Fig. 3.6. The secondary structure curves of the sequences surrounding the common 
amino acid substitutions at E-138 and E-176 of the E protein of JE virus SA14 before 
and after the two amino acids were changed. The top half is the result before the 
change and bottom half is that after the changes. Turn: reverse turn propensity. Beta: 
beta sheet propensity. Alpha:alpha helix propensity. +-: charged residues profile. 
Hydro: hydrophobicity profile.
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Fig. 3.7. The secondary structure curves of the sequences surrounding the common 
amino acid substitutions at NS2B-63 and NS3-105 JE virus SA14 before and after the 
amino acid was changed. The top half is the result before the change and bottom half 
is that after the changes. Turn: reverse turn propensity. Beta: beta sheet propensity. 
Alpha: alpha helix propensity. +-: charged residues profile. Hydro: hydrophobicity 
profile.
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The substitution at NS4B-106 would have a little effect on hydrophobicity profile 
(data not shown).
3.3 Discussion
In recent years, the structural and nonstructural proteins of flaviviruses have 
been studied with the aim of understanding the replication cycle of flaviviruses. Of 
particular importance to this chapter is the demonstration that NS2B and NS3 are the 
components of a trypsin-like serine proteinase that mediates a number of cleavages 
in the processing of the polyprotein translated from the single open reading frame of 
flaviviruses (Chambers et al. 1993, also see Fig. 1.1).
The complete genomes of three flavivirus wild-type parent-live attenuated 
vaccine pairs have been determined and compared. They are YF: 17D-204 and Asibi 
(RicegraA, 1985; Hahngra/., 1987), JF: SA14 and SA14-14-2 (Aihara a/., 1991; 
Nitayaphan et al., 1990) and DFN-2: 16681 and 16681/PDK53 (Blok et ai., 1992). 
However, these studies found a large number of mutations between these parents and 
their attenuated vaccine viruses and cannot identify genetic mutations responsible for 
the attenuation phenotype. In the case of JF virus, the 123 passages of the wild-type 
strain SA14 in primary hamster kidney cell culture to generate vaccine virus 
SA14-14-2/PHK resulted in 57 nucleotide changes coding for 24 amino acid 
substitutions while passage of SA14 to generate clone SA14-14-2/PDK resulted in 45 
nucleotide changes coding for 15 amino acid substitutions. Unfortunately, the
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interpretation of attenuation of JE virus is complicated by the fact that the two 
groups do not have identical sequences for the parent SA14 genome (Aihara et al. , 
1991; Nitayaphan et al., 1990).
As described above, there were some differences among the three sequences 
of the JE wild-type virus SA14; most were in the E and NSl protein genes (Table. 
3.2). Two of the three parent viruses sequenced were plaque purified and their 
virulence confirmed prior to cDNA cloning (Aihara et al., 1991; Nitayaphan et al., 
1990). However, the SA14/CDC virus was passaged three times in primary dog 
kidney cells, which may be responsible for the nucleotide differences compared with 
SA14/JAP and SA14/USA viruses. Therefore, it is necessary to compare all three 
sequences of the SA14 virus with the sequences of other wild-type JE virus strains 
and the three attenuated vaccine strains to elucidate the correct parent virus sequence. 
Conversely, the vaccine virus strains received different passages following the 
isolation of the first attenuated clone 12-1-7 virus (Chen and Wang, 1974; Yu et al., 
1981; Li, 1986; Eckels et al. 1988), which would generate nucleotide and amino acid 
variations unrelated to attenuation. Therefore, comparison of common nucleotide 
and/or amino acid difference(s) between SA14 virus and three vaccine derivatives 
enables common substitutions that may be responsible for the virus attenuation to be 
identified.
Comparison of SA14/USA and SA14/JAP viruses with the vaccine viruses 
revealed that only seven amino acids were substituted in all attenuated viruses. 
However, when SA14/CDC was included only five amino acids were substituted in
128
all three attenuated vaccine viruses, two located in the E protein gene at positions E- 
138 and E-176, one at position NS2B-63, another at position NS3-105; and finally at 
position NS4B-106 (Table 3.2).
When monoclonal antibody (MAb) reactivities of the wild-type parent SA14 
and those of its attenuated vaccine derivatives have been compared identical E protein 
antigenic changes have been found in the vaccine viruses (Sil et al., 1992). 
Specifically, in indirect immunofluorescence and haemagglutination inhibition tests, 
two MAbs (T60 and V23) prepared against SA14-5-3 virus only recognized vaccine 
strains derived from SA14: SA14-14-2/PHK, SA14-14-2/PDK, SA14-2-8 and SA14- 
5-3 viruses. Five MAbs (KIO, K13, K24, K43 and J44) prepared against wild-type 
JE viruses do not react with the vaccine virus strains (Sil et al., 1992). This indicates 
that common E protein epitope(s) are present in all of the vaccine strains derived 
from SA14 virus, possibly due to a common amino acid change(s).
This hypothesis was supported by sequence comparisons reported here. All of 
the attenuated vaccine strains derived from SA 14 virus have two identical amino acid 
substitutions in the E protein at positions E-138 and E-176 (Table 3.1). The two 
amino acids in the E protein of SA14 are conserved in all JE virus wild-type strains 
examined (Table 3.2). Therefore, one or both amino acid substitution(s) in the 
attenuated viruses could be responsible for three-dimensional structure changes in the 
E protein that alter wild-type specific epitopes and generate new vaccine-specific 
epitopes. The predicted secondary structural change in E protein at position E-138 
(Glu ->  Lys) (Fig. 3.6) supports this proposal.
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The E protein is known to play an important role in viral entry (Chambers et 
al., 1990a). Hence, these two common amino acid substitutions in E protein might 
also contribute to attenuation of the vaccine strains through decreasing the ability of 
virus binding to cells. This hypothesis is supported by the observation that the vaccine 
strains did not bind to dopamine D2 and/or 5HTj subtype receptor recognized by the 
antagonist ligand spiperone whereas the wild-type virulent parent strain SA14 did 
(Barrett g/ a /., 1991).
The flavivirus genome encodes one long open reading frame that generates a 
polyprotein in which the structural and non-structural proteins are co-translationally 
and post-translationally processed by host and viral proteinases (Chambers et al. 
1990a). The latter consists of a virus-specific serine proteinase containing NS2B and 
the N terminal approximate 180 amino acids of the NS3 protein (Chambers et al. 
1990b) and has been demonstrated to mediate several cleavages in the viral 
polyprotein. NS2B was required for site-specific cleavage activity, i.e., the functional 
proteinase requires a complex of NS2B with NS3. Examination of the three common 
changes of the vaccine viruses in the non-structural protein genes reveals that the 
change at position NS3-105 is in the serine proteinase domain of this protein. Amino 
acids in JE virus equivalent to NS3-51, NS3-75 and NS3-135 are the active site resi­
dues of the NS3 proteinase (Fig. 3.4). NS3-105 is semi-conserved in the flaviviruses 
(Fig. 3.4). Thus, the functioning of the NS3 serine proteinase would not be predicted 
to be eliminated by the change at NS3-105, however, activity of the enzyme could be 
affected through alteration of the structure of NS3. The proposal of that NS3-105 is 
involved in attenuation is supported by the observation that the amino acid substituted
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resulted from the double nucleotide changes. This would argue against that this amino 
change being a random mutation, rather than selection during the attenuation process.
NS2B-63 is found in the 40 amino acid "central region" of NS2B that is 
conserved between flaviviruses (Fig. 3.3). This amino acid may be important as the 
glutamic acid seen at position NS2B-63 in wild-type strains of JE virus is also seen 
in the analogous position of nine other mosquito-bome flaviviruses that have been 
sequenced, except DEN-4 virus (Fig. 3.3). Furthermore, Chambers et al. (1993) 
working with YF virus, and Falgout et al. (1993) working with DEN-4 virus, found 
that mutations made in this region of NS2B reduced or eliminated cleavage efficiency 
of the proteinase which would suggest that the conserved "central region" has a 
critical role in the function of the proteinase. Thus, it is hypothesized that the activity 
or otherwise of the proteinase is due to changes in conformation and/or structure of 
the NS2B/NS3 complex that may contribute to attenuation of JE virus.
Hase et al. (1993) reported that following intracerebral inoculation of adult 
mice the SA14 parent virus replicated to high titre and spread rapidly to the majority 
of neurons in the brain whereas SA14-14-2/PDK virus replicated poorly and infected 
only a small number of neurons in scattered small foci before disappearing (Hase et 
a l ,  1993). These phenomena indicate the absence of wide-spread infection among 
neurons of the brain inoculated with the SA14-14-2/PDK virus might result from 
inefficient entry of virions into neurons. These changes in the biology of virus may 
have resulted from substitutions at E-138 and E-176 in the E protein of vaccine 
viruses. The low level of infection of vaccine virus in the mouse brain could also
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result from impairment of replication and maturation of the vaccine virus within 
neurons compared to the parent virus, which may be due to serine proteinase activity 
alterations resulting from amino acid substitutions at NS2B-63 and NS3-105.
In conclusion, five amino acid substitutions have been identified in vaccine 
viruses, which may contribute to attenuation of neurovirulence of wild-type JE virus 
strain SA14. Whether these common amino acid substitutions in the E protein and 
serine proteinase complex are directly involved in attenuation of the vaccine virus will 
require an analysis of pathogenesis using recombinant viruses.
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Chapter 4
Genetic relationships of Japanese encephalitis virus from
different geographic locations and year of isolation
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4.1. Introduction
Antigenic, biochemical and genetic differences between wild-type JE virus 
strains isolated from different areas have been observed by cross-neutralization 
(Banerjee, 1975), oligonucleotide fingerprinting (Banerjee and Ranadive, 1984; Hori,
1986), monoclonal and polyclonal antibody reactivities (Kobayashi et al. , 1984,1985; 
Wills et al. , 1992), and by limited (240 bp) genomic sequence comparison (Chen et 
al., 1990, 1992). Chen et al. (1990) suggested that JE viruses could be divided into 
four genotypes using 1 2 % nucleotide divergence as a cut-off point for virus 
relationships. To date, the nucleotide and deduced amino acid sequence of the struc­
tural protein genes of wild-type JE virus have only been published for virus strains 
isolated in Japan (Sumiyoshi et al., 1987;) and the mainland of China (Hashimoto et 
al. 1988; Nitayaphan et al., 1990). In this chapter, the nucleotide sequence of the 
structural protein genes and deduced amino acid sequences of eight wild-type JE virus 
strains isolated from several Asian countries and their genetic relationships to each 
other and five other published wild-type JE virus strains were investigated.
4.2 Results
4.2.1 Nucleotide sequence of the prototype strain of JE virus
The prototype strain of JE virus, Nakayama, was the first nucleotide sequence 
published for JE virus (McAda et al., 1987). The complete nucleotide sequence of
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the prM, M and E protein regions was reported but lacked 5’ non-coding region and 
75 amino acids of C protein.
Comparison of the nucleotide (Appendix 2) and deduced amino acid sequence 
(Fig 4.1) of Nakayama-original (i.e. the original isolate from 1935) determined in this 
laboratory and that published by McAda et al. (1987) revealed that there was one 
amino acid insertion at position prM-27 of that reported by McAda et al. (1987) plus 
another two amino acid differences in prM protein region. Also there was one amino 
acid insertion at position M-60 reported by McAda et al. (1987) plus four amino acid 
differences in M protein region (see Fig. 4.1). The insertions observed in the prM 
and M proteins of the Nakayama sequence reported by McAda et al. , (1987) were 
inconsistent with all other JE virus sequences (see below). The E protein sequence 
reported here differed from that of McAda et al. (1987) at positions E-132 (Glu- > 
Gly) and E-246 (Pro->Ser).
4.2.2 Comparison of the nucleotide and amino acid sequences of wild-type 
strains of JE virus
Prior to this study, only the entire sequence of the 5’ non-coding region and 
structural protein genes of strains Beijing-1 (Hashimoto et al. , 1987) and SA14/USA 
(Ni et al. , 1994) from China, and JaOArS982 (S982 for short) (Sumiyoshi et al. ,
1987) from Japan had been published. The nucleotide sequence of the E protein gene 
had also been published for JE virus strains Kamiyama (Hashigawa et al. , 1992) and 
Nakayama (McAda et al. , 1987) from Japan while only the amino acid sequence of
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Fig. 4.1. Alignment of the deduced amino acid sequence in the prM and M protein 
regions of JE virus Nakayama reported by McAda et al. (1987) and that determined 
in this chapter. M: Amino acid sequence deduced from the nucleotide sequences of 
JE virus Nakayama published by McAda et al. (1987). N: The deduced amino acid 
sequence from JE virus Nakayama-original determined by the author.
prM->
M MKLSNFQGKLLMTVNNTDIADVIVIPNPSKGENRCWVRAIDVGYMCEDTITYECPKL
11111111111111111111111111 I 11111 i i 111111111111 ! 11 ! I i 11
N MKLSNFQGKLLMTVNNTDIADVIVIP TSIGENRCWVRAIDVGYMCEDTITYECPKL
M- >
M TMGNDPEDVDCWCDNQEVYVQYGRCTRTRHSKRSRRSVSVQTHGESSLVNKKEAWLD
N TMGNDPEDVDCWCDNQEVYVQYGRCTRTRHSKRSRRSVSVQTHGES SLVNKKEAWLD
M STKATRYLMKTENWIVRNPGYAFLAAILGWMLGSNNGQRRWYFTIALLLLVAPAYS
N STKATRYLMKTENWIVRNPGYAFLAAVLGWMLGSNNGQ RWFTIALLLLVAPAYG
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Sarawak strain had been published (Cecilia & Gould, 1991). The nucleotide 
sequences of the 5’ non-coding region and structural protein genes were determined 
of seven wild-type JE virus strains isolated from China (strain P3), Japan (Nakayama- 
original), Nepal (DH20), Vietnam (Saigon), India (826309), Indonesia and Taiwan 
(HK8256). The details of these strains are shown in Table 2.2. The nucleotide 
sequence of only the E protein gene of strain KPP03Y from Thailand was also 
determined. Thus, there are a total of 10 structural protein gene regions, and 12 
nucleotide and 13 amino acid sequences of E protein available for comparison. 
Appendix 2 shows the nucleotide alignment and Fig. 4.2 the deduced amino acid 
alignment of the sequences of the viruses examined in this study and those previously 
published.
Over 2434 nucleotides the 5’ non-coding region and structural protein
gene^ the ten strains available for analysis differed from each other by between 25 
(0.9%) to 111 (4.6%) nucleotides and by between 3 (0.4%) to 31 (4.2%) amino acids 
(See Table 4,1). All nucleotide differences between the strains were base changes, no 
insertions or deletions were found; and many of these changes were distributed as a 
cluster in the genome (appendix 2). Most of the base differences in the strains were 
silent and did not alter the encoded amino acids. In the 5’ non-coding region of the 
ten strains studied only two nucleotide differences were found at position 61 (826309, 
G - > A) and 73 (Beijing-1, G - > T) (appendix 2).
The lowest amino acid homology (95.8%) of the structural proteins as a whole 
was between P3 from China and Saigon from Vietnam (Table 4.1). The amino acid
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Fig. 4.2. Alignment of deduced amino acid sequences of the structural proteins of 13 
JE virus strains.
C - - >  60
SA14 /U S A  MTKKPGGPGKNRAINMLKRGLPRVFPLVGVKRWMSLLDGRGPVRFVLALITFFKFTALA
S 9 8 2  ........................................................................................................................................................................
B e i j i n g l  .............................................................................R .............T ......................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 ......... ........................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P 3 ( C h i n a ) ...................................................................................................................................F .................................
N ak ayam a . I . . . .  A .......................................................................................................................................................
1 2 0
S A 14/U S A  PTKALLGRWKAVEKSVAMKHLTSFKRELGTLIDAVNKRGRKQNKRGGNEGSIMWLASLAV
S 9 8 2    : ............................
B e i j i n g l  ........................................................................................................................................................................
T a iw a n  ................................................................................................... T ..............................G ..............................
8 2 6 3 0 9   T .  . .A
DH20 ........................................................................................................................................................................
I n d o n e s i a  .....................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P 3 ( C h i n a ) ...................................................................................................................................................................... A
N ak ayam a ........................................................................................................................................................................
p r M - - >  1 8 0
S A 14/U S A  VIACAGAMKLSNFQGKLLMTINNTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYEC
S 9 8 2  . . . Y ..............................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
T a iw a n  .................................................................................. A  A.  . . . .
8 2 6 3 0 9 ......... ........................................................................................................................................................................
DH20  V ....................................  A .................................
I n d o n e s i a . . . Y .............................................................................................................................................................
S a ig o n  ......................................................V ........................A ................................................................ A .............
P 3 ( C h i n a ) .................... R ................................................................................................................................................
N akayam a ...................................................... V ...................................... I ....................................................................
M—  > 2 4 0
S A 14/U S A  PKLTMGNDPEDVDCWCDNQEVYVQYGRCTRTRHSKRSRRSVSVQTHGESSLVNKKEAWLD
S 9 8 2  ........................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9  .......................... ..............................................................................................................................................
DH20  N .E ...................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ...................................................................................N .................................................................................
P 3 ( C h i n a )  ....................................................................... .................................................................................................
N akayam a ..................................................................................................................................... ..................................
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E— >
S A l  4 /U SA  STKATRYLMKTENWIIRNPGYAFLAAVLGWMLGSNNGQRWFTILLLLVAPAYSFNCLGM
S 9 8 2    T .............................................................................................
B e i j i n g l  .........................................................................I ...........................................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20  D . . V ...........................I ..........................................I ...............................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  . . Q ................................V ........................................................................ I .............................................. I
P 3 ( C h i n a )  ........................................................................................................................................................................
N akayam a ........................................V ....................................................................................................... G ................
T h a i la n d ............................................................................................................................................................. ...............
K am iyam a............................................................................................................................................................. ...............
S a r a w a k ................................................................................................................................................................ ...............
3 6 0
S A 14/U S A  GNRDFIEGASGATWVDLVLEGDSCLTIMANDKPTLDVRMINIEASQLAEVRSYCYHASVT
S 9 8 2  ......................................................................................................... ..............................................................
B e i j  i n g l  ...................................................................................................... .. ..............................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20  V  '. . . .
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  .......................................................................................................................... V .........................................
P 3 ( C h i n a ) ............................................................................................................ T ........................................................
N akayam a ............................................................................................................................ V .......................................
T h a i la n d  ...................................................................................................................................................................... T
K am iyam a ........................................................................................................................................................................
S a r a w a k  ........................................................................................................................................................................
4 2 0
S A 14/U S A  DISTVARCPTTGEAHNEKRADSSYVCKQGFTDRGWGNGCGLFGKGSIDTCAKFSCTSKAI
S 9 8 2  ........................................................................................................................................................................
B e i j i n g l  ................................................................................................... ....................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20 ................. ......................................................................................................................................................
I n d o n e s i a   ................................................................................................................................................................
S a ig o n  ........................................................................................ P  R . . .
P 3 ( C h i n a ) .......................M.............................................................................................................................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
S a r a w a k  ........................................................................................................................................................................
4 8 0
S A 14/U S A  GRTIQPENIKYEVGIFVHGTTTSENHGNYSAQVGASQAAKFTVTPNAPSITLKLGDYGEV
S 9 8 2     I ................................................
B e i j i n g l   S .......................................................................................................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a ........................................ ................................................................................................................................
S a ig o n  ....................................................................... W.................................................... D . . T ...........................
P 3 ( C h i n a )  . . A ................................................................................................................................................................
N akayam a ...............K .....................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a  ...........................................  I ................................................
S a r a w a k  ...................................................................................................... E ...................K .......................................
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5 4 0
S A 1 4 /U S A  TLDCEPRSGLNTEAFYVMTVGSKSFLVHREWFHDLALPWTSPSSTAWRNRELLMEFEEAH
S 9 8 2  ........................................................................................................................................................................
B e i j i n g l  ...............................................................................................................P  G. .
T a iw a n  ............................................................R ...........................'....................................................................G. .
8 2 6 3 0 9   R ...........................G .........................................................................
DH20  R ........................................................................................................
I n d o n e s i a .............................................................R .......................................................................................................
S a ig o n  ......................................................................................................... L  G. .
P 3 ( C h i n a ) ............................................................R ...............................................P .....................................................
N akayam a ........................................................................................................................................................................
T h a i la n d    G. .
K am iyam a ..........................K ..........................................................................................................................................
S a r a w a k  . . . . K ..........................................................................................................................................................
6 0 0
S A 14/U S A  ATKQSWALGSQEGGLHQALAGAIWEYSSSVKLTSGHLKCRLKMDKLALKGTTYGMCTE
S 9 8 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P 3 ( C h i n a ) ...................................................................................................................................................................... G
N akayam a ........................................................................................................................................................................
T h a i la n d  ...........................................................................     V ..............................
K am iyam a  1 •
S a r a w a k  ........................................................................................................................................................................
6 6 0
S A 14/U S A  KFSFAKNPADTGHGTWIELSYSGSDGPCKIPIVSVASLNDMTPVGRLVTVNPFVATSSA
S 9 8 2  ........................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
T a iw a n  ...................................................................................................................................................................... V
8 2 6 3 0 9  . . . . V ................................................................................................................................................ A .  . .
DH20  V
I n d o n e s i a ..........................................   V
S a ig o n  ...................................................................................................................................................................... V
P 3 ( C h i n a ) .......................................................................................................................... A ..........................................
N ak ayam a ........................................................................................................................................................................
T h a i la n d  ...................................................... N ..............................................................................................................
K am iyam a ........................................................................................................................................................................
S a r a w a k  ...................................................... T ............................................................................................................ S
7 2 0
SA14 /U S A  NSKVLVEMEPPFGDSYIWGRGDKQINHHWHKAGSTLGKAFSTTLKGAQRLAALGDTAWD
S 9 8 2  ........................................................................................................................................................................
B e i j i n g l  ...................................................................................Y .................................................................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P 3 ( C h i n a ) .........................................................E .....................................................L ..................................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
S a r a w a k  ........................................................................................................................................................................
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7 8 0
SA14 /U S A  FGSIGGVFNSIGKAVHQVFGGAFRTLFGGMSWITQGLMGALLLWMGVNARDRS lALAFLA
S 9 8 2 ........................................................................................................................................................................................
B e i j i n g l  ................................................................................................................................ I ....................................
T a iw a n  ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20............... R ....................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ..................................... I .............................................................................................................................V
P 3 ( C h i n a )  ........................................................................................................................................................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ..................................R ..................................................................................................................................
K am iyam a ............................................................................... ........................................................................................
S a r a w a k  .......................................................................  ..............................................................................................
7 9 0
S A 14 /U S A  TGGVLVFLAT
S 9 8 2  ....................
B e i j i n g l  ..........................
T a iw a n  ..........................
8 2 6 3 0 9  ..........................
DH20 ..........................
I n d o n e s i a  ..........................
S a ig o n  ..........................
P3 (C h in a )  ..........................
N akayam a ..........................
T h a i la n d  ..........................
K am iyam a ..........................
S a r a w a k  ..........................
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homology between the other strains was 96.7% or greater. The lower homology of 
the strains P3 and Saigon may be due to the multiple passages in mouse brain of these 
two strains.
4.2.3 Nucleotide and amino acid homologies of individual structural 
protein genes
The nucleotide and amino acid sequences of C, prM and M proteins for ten 
strains, and E protein for twelve strains, were compared separately and the homology 
of these strains are shown in Tables 4.2 - 4.5. Of the structural protein genes, the C 
protein region had the least variation at both the nucleotide and amino acid level. 
SA14/USA (Ni et al., 1994) differed from the other nine strains by 54 of 378 
nucleotides and 10 of 126 amino acids. The nucleotide and amino acid homologies 
of the ten strains are between 96.3% to 99.7% and 96.9% to 100% respectively 
(Table 4.2). One important amino acid difference was noted at position C-123 where 
cysteine replaced tyrosine in strains SA14/USA, Beijing-1, HK8256, Indonesia, 
DH20, P3 and Saigon. This changed the consensus cleavage sequence of anchored C 
and prM for JE virus from lAYAGM ! MKLSNF to I AC AGM ! MKLSNF (Chambers 
e ta l ,  1990).
The nucleotide sequence of prM region was the most variable by upto 11 of
276 nucleotides (Table 4.3) but only a maximum of four of the 92 amino acids.
thb
Nucleotide homology in^prM region is between 93.5 and 99.6%, whereas the amino 
acid homology of this region is between 94.5 and 100%. One unique amino acid
143
I
£
I
1
(S
ov
OV
00
ov
8
(S
Ov
OV
Th VO VO
0 0 0 0 r--'
o v o o o
l > o
r - ’ v d 0 0
O o o o
M M 7l-
Ov OV 0 0 0 0
O o v OV o v
8
N
OV
ov
0 0
Ov
s
00
Ov
VO
&
(S
Ov
OV
(S
ov
ov
00
ov
VO
s;
S;
S:
in
ov
Ov
t-H VO VO (S Ov VO (S
0 0 ov vd 0 0
ov ov ov ov ov ov ov
CA cd
O
I
I,
4 -1 CA
II
II
s i
I
8
I
I
t
=5'pa
SO
00
<
B
s
I
00
o (S 7l- T f i n o
o ov ov 0 0 0 0 0 0 ov Ov
T—1 Ov ov Ov Ov ov ov o ov
Th VO VO 0 0 Ov 7|-
0 0 vd r-’
ov ov Ov ov Ov ov ov ov ov
VO VO cn OV VO OV
0 0 vd
ov ov ov ov OV Ov OV ov OV
(S Tf O Ov ov o
ov 0 0 r-’ OV 0 0 Ov
Ov ov ov Ov ov ov O ov ov
(S VO rH M r> vq m OV
Ov 00 ov vd
Ov ov ov ov ov ov ov Ov OV
04 o vq
00 00 00 00 OV ov 00 00
ov ov ov ov ov ov ov Ov ov
<L>
<
B
<
00
8
0  
00
1
m
1
I o01 I Î ■I00 2 Î
144
wG
I
I  I
H %
§
I
2
f
c/5
1
I
S
i
is
I
s
S
<
B
<
0 0
00
00
&
ov
oôov
VO
S
s
vo
ov
OV
00
Ov
00
s;
8
§
I
<
00
00
Si
ov
0 0
ov
vo
si
8
S
Ov
00
O
00
si
8
C4
Ov
C7V
8
0  
00
1
00
si
ov
oô
Ov
vo
si
8
vo
o
ov
oô
ov
0 0
si
vo
oô
o
VO
oô
Ov
. s '
''S
m
ï
s
0 0
Si
00
Si
lO
i
00
si
00
si
vo
oô
Ov
I
vo
ov
00
si
in
Ov
oô
Ov
vo
Si
en
s
vo
ov
vo
ov
Ov
ov
o
ss
vo
ov
vo
si
vo
Ov
vo
Ov
C4
si
en
m
ov
SI
VO
Ov
i
00
si
ov
oô
ov
vo
si
vo
Ov
C4
oô
Ov
ov
oôov
VO
si
vo
Ov
Ov
î
SI
m
s
vo
ov
vo
Ov
(S
oô
ov
in
si
Ov
S
VO
ov
I
c/5
Si
es
oô
Ov
s
ov
&
If)
si
00
ov
00
si
es
oô
ov
If)
si
m
si
vo
ov
00
si
ov
Si
voov
VO
ov
Q
I I
145
I
I
I
e
•s
a
I
g  »
H B
I
OQ
I
2
I
Î
I
s
i
I
Î
8
ON
CO
I
<
CO
CO CO CO CO CO CO CO
vo CO VO
ON ON ON ON O n ON ON ON ON
o r-; O o O CO o q c so 0 0 o o O c d o vd 0 0
t H ON T—4 T— 1 ON t- H ON ON
O r - o o O o ON (S
vd r j- vd vd vd vd vd 0 0
O n O O n ON ON ON ON ON ON
O O o o rq oo q OO
O 0 0 O o o cd 0 0
1-H ON t- H t- H t- H O n ON ON ON
CO CO CO CO CO cq OO ON
CO c d c d c d c d vd vd
ON ON ON ON ON ON ON ON ON
O l > O o 1—4 CO s o 0 0 O so 0 0 O o *d If) vd
4-H O n t- H T—4 O n ON O n ON ON
o o CO CO o OO q 0 0o 0 0 o ( o 0 0
t-H ON t- H O n '
\ T
O n ON ON
o ( S Tj- C4 oo OO OOo 0 0 0 0 vd vd 0 0
ON ON ON ON ON O n ON ON
O n 0 0 ON T f " 0 0 O c s
0 0 vd vd vd vd 0 0
ON ON ON O n ON ON ON ON ON
c s T -H CS ON t- H q VO
0 0 0 0 ON 0 0 vd ON O n 0 0
ON ON ON ON ON ON ON ON ON
<
B
<
CO
t- H
bX) P
C s?
c s •  1—4
0 0 : p ^ •  1—1
ON 4) PS
0 0 PQ H
B
4)
'oP Ü
% <
ONos
8 I Î ■ICO 2
146
i
I'o
î
W
ë
%
!
I
1
!
ê
'o
I
i
ë
0 .
I I
& w
uô 
rr1
'o
I
1
i
2
I
I
I
î
ON0
S
s
1
tI
I
s
ON
0 0
<i
t-H
I
o 00 00 es VO VO VO q 00
ON o ô o ô o ô o ô o ô o ô o ô o ô vd • P
O n ON ON ON ON ON ON ON ON (On ON
ON
• P 
1es O vq sq 00 OO OO oo es 00 VO t-H g
o6 o ô o ô If) Ph
ON ON ON ON ON O n ON O n (ON ON ON Q 2
1vq q q OO 00 sq sq sq 00 qi> M r-’ vd t> r-' M vn rr cd
ON ON ON ON ON ON ON ON (ON ON O n
1 . 1
NO
Cd00O VO 00 es es VO ON q t-H
"SON ON O n o ô ON ON ON ON vd vd
1
ON ON ON ON ON ON ON ON ON ON (ON cd
cd
es O NO es Tt- 00 q q O ) q 4h
O n ON
cd
ON 00 o ô 00 ON o ô vd vd Cd M
ON ON ON ON ON ON ON ON ON ON (ON
1
%
g
gNO 7 f o VO O 00 q t-H q VO en
ON ON O n o ô ON o ô M M »d If) Q
ON ON ON ON ON ON O n ON ON (ON ON
g
ONt-H
2
1es Pes O NO O t-H t-H es vo VO Tf" - a O
ON ON o ô o ô ON vd M v ô vd vd vn ü tP
ON ON ON ON ON O n ON ON ON ON ON o (U
'3 bX)ü cdM
T f es OO OO q q q q H^ sq q CAO p 8
ON O n o ô o ô vd o ô O n >> cd Jh
ON ON ON ON ON ON ON O n ON (On ON
i
P4
S
O 00 1-H q es es T f O S % 1
ON o ô o ô vd vd vd vd vd vd »d 4 h OON O n ON ON O n ON ON O n ON ON ON
g
ON 1
a
"S
en (U(/] cd
NO 00 00 vo T-H 00 vo en g
ON ON vd vd vd vd vd vd vd un
It-H
6?00
ON
tSON O n ON O n ON ON O n O n ON ON ON
2
00 00 q t-H q ON rH O s q \—/ Q
ON l> o ô vd o ô o ô vd vd "q B
ON O n ON ON O n ON ON ON ON ON (ON
% ’q 2■f-» cd
% Q %
00 q es en q en es q q s O 2
o ô o ô M o ô o ô vd r-’ 2 P
O n ON ON ON ON ON ON (On O n ON (On -M
1<en R cS cd 1 1
g
t- H
<
00
8
ON
00
1
i
1
. w
PQ J ON01 I II f00 enPL, i S •£<
5
1—4
GtZî
.2
- f:
Ph
f
I
147
difference was found at position prM-2 of strain P3, which changed the consensus 
cleavage sequence of anchored C and prM from IACAGA!MKLSNF to lACAGA! 
MRLSNF (Chambers et al., 1990).
The amino acid sequence of the M protein region (75 amino acids) was the 
most divergent amongst the structural proteins (Table 4.4); between 93.3% to 100% 
(i.e. none to 4 amino acids). Nucleotide homology of^M protein region is between 
95.1% and 100%.
An amino acid difference was found at position E- 6  of strain Saigon where 
isoleucine replaced methionine and at M-75 of strain Nakayama where a glycine 
substituted for serine. These amino acid differences would change the cleavage 
sequence between M and E proteins for strains Saigon and Nakayama from 
VAPAYSIFNCLGM to VAPAYSÎFNCLGI and VAPAYGÎFNCLGM respectively 
(Chambers et al. 1990).
Comparison of E protein nucleotide and amino acid sequences revealed 
homologies are 94.3% or higher and 95.8% or greater, respectively (Table 4.5).
4.2.4 Variable amino acids in the structural proteins
Examination of the amino acid alignment in Fig. 4.2 identified six positions 
that were variable depending on the JE virus strains (Table 4.6). One variable amino
148
acid was noted in the prM protein at position prM 14 (amino acid 141 in the 
polyprotein) (He < > Val) and in the M protein at position M-37 (amino acid 256 
in the polyprotein) (He < ->  Val); four variable amino acids were noted in the E 
protein at positions 51 (amino acid 345 in the polyprotein) (Ser < ->  Val), E-209 
(503 in the polyprotein) (Lys < ->  Arg), E-244 (537 in the polyprotein) (Glu < ->  
Gly) and E-366 (660 in the polyprotein) (Ala, Ser or Val). Of these variable amino 
acids, the one at position E-51 is predicted by the Novotny method to alter E protein 
secondary structure in terms of hydrophobicity, alpha helix propensity, beta sheet 
propensity and reverse turn propensity Fig. 4.3. E-244 would result in variation of 
the charged residues profile, alpha helix propensity and reverse turn propensity 
variation, and E-366 would also result in some minor changes of the charged residues 
profile, alpha helix propensity and beta sheet propensity (Fig. 4.3).
4.2.5 Clustal analysis
In order to assess the genetic relationships between the strains examined in this 
study, a dendrogram (Fig. 4.4) was constructed by neighbour joining in MEGA 
(Kumar et a l ,  1993) based on calculating the similarity score obtained by pair 
comparison of the E protein amino acid sequences of thirteen strains (twelve strains 
described above plus a strain from Sarawak (Cecilia and Gould, 1991)). The JE virus 
strains SA14/USA, S982 and Nakayama were defined in one group, those from 
DH20, Taiwan and Indonesia were in another group, while the other strains were 
distinct (Fig. 4.4) and clustered independently from each other. One strain isolated
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Table 4.6. Variable amino acids in the structural proteins of Japanese encephalitis 
viruses studied.
Strain
prM 14 M37
Variable
E51
amino
E209
acids
E244 E366
SA14/USA He He Ser Lys Glu Ala
S982 He He Ser Lys Glu Ala
Beijing 1 He He Ser Arg Gly Ala
Taiwan He He Ser Arg Gly Val
826309 He He Ser Arg Glu Ala
DH20 Val Val Val Arg Glu Val
Indonesia He He Ser Arg Glu Val
Saigon Val Val Val Arg Gly Val
P3 He He Ser Arg Glu Ala
Nakayama Val Val Val Arg Glu Ala
Thailand - - Ser Lys Gly Ala
Sarawak - - Ser Lys Glu Ser
Kamiyama - - Ser Lys Glu Ala
unknown amino acid sequence.
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Fig. 4.3. The secondary structure curves of the sequences surrounding the variable 
amino acids of E-51, E-209, E-244 and E-366 of the JE virus E protein. The amino 
acids in the top figure are Ser, Lys, Glu and Ala; in the bottom are Val, Arg, Gly 
and Val. Turn:reverse turn propensity. Beta:beta sheet propensity. Alpha:alpha helix 
propensity. + -:charged residues profile. Hydro:hydrophobicity profile.
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Fig 4.4. Dendrogram of the genetic relationships of thirteen JE virus strains based on 
their E protein sequences. The dendrogram was constructed based on amino acid 
sequences of the E proteins using the neighbour joining method in MEGA (Kumar et 
al., 1993). The UPGMA method in the MEGA program gave almost identical 
grouping.
.002 S892
SA 14/USA
Kamiyama
— Nakayama 
.009
.008
S a
.007
.006
Beijing 1 
KPP034
826309
.015 P3
—  HK8526
Indonesia
DH20
.019
Saigon
0 . 0 0 1  divergent
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in Saigon, Vietnam and another isolated from China (P3) were divergent from all 
other wild-type JE virus strains studied. From the dendrogram, no conclusion could 
be established that strain variation was related to geographic location, year or host of 
isolation (see table 2.2) among the strains studied. Rather, the strains showed a very 
high degree of homology indicating that there is little amino acid variation over the 
47 years (1935 to 1982), different countries and host (mosquito or human) of isolation 
examined.
4.4 Discussion
Strain variation among JE virus isolates has been demonstrated by many 
workers using different methods (Okuno et a l ,  1968; Kobayashi et a l ,  1984; 
Hammam and Price, 1966; Hori, 1986; Banerjee and Ranadive, 1990; Chen et al., 
1990; Wills et al., 1992). However, the molecular basis of strain variation and 
significance of the variation has not been resolved.
In the present study the genetic relationships of ten JE virus strains were 
analyzed over their 5’ non-coding region and structural protein genes and of 13 
strains over their E protein gene. The genetic homologies of these strains are 
considerably higher than indicated by antigenic analyses with monoclonal and 
polyclonal antibodies (Okuno et al., 1968; Kobayashi et al., 1984; Wills et al., 1992) 
and oligonucleotide fingerprints (Banerjee and Ranadive, 1990; Hori, 1986).
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Sequence variation of flaviviruses has been studied previously. Chu et a l 
(1989) examined five strains of dengue-1 virus and Lobigs et a l  (1989) studied 11 
strains of Murray Valley encephalitis (MVE) virus and showed that the E protein 
differed by 2% or less at the amino acid level. Lanciotti et a l (1994) analyzed prM, 
M and E protein genes of 23 dengue-3 viruses and found that the similarity of their 
deduced amino acid sequences was 95% or greater. In comparison, Lewis et a l  
(1992) compared the E protein of 33 strains of dengue-2 virus and found that they 
differed by up to 20% at the nucleotide level and 10% at the amino acid level. In 
this study we have found that the E protein of 13 strains of JE virus differed by up 
to 4.2% at the amino acid level (Table 4.5), which would indicate that JE virus shows 
similar variation in the E protein to dengue-3 viruses, more variation in the E protein 
than dengue-1 and MVE viruses but less than dengue-2 virus. However, if the mouse 
brain passaged strains P3 and Saigon are not included the maximum variation is 
1.8%, which is consistent with the results for dengue-1 and MVE viruses.
The dendrogram in Fig. 4.4 indicates that strain variation amongst the JE 
viruses studied is not related to their geographic locations, which agrees with studies 
of Okuno et a l (1968), Wills et a l (1992), Hammam and Price (1966), Banerjee 
and Ranadive (1990) and Hori (1986). However, the results presented here are not 
entirely consistent with the hypothesis made by Chen et a l (1990). They analyzed 
a 240 nucleotide portion of the prM region of 46 JE virus isolates. 45 strains differed 
from S982 by 2% to 16%. Similar results were obtained by Huong et a l  (1993) who 
compared 16 JE viruses from Vietnam and found that the homologies of these strains 
were over 95%. In agreement with Chen et a l  (1990) our results show that the
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nucleotide sequence of the prM protein region was the most variable among the 
structural protein genes (Table 3). The ten strains examined in this study differed 
from each other between 0.4% to 6.5% in the prM protein genes. Also, the amino 
acid divergences in the report of Chen et al. (1990) were between 0 and 7.5%, which 
agree with our calculations (between 0 and 5.5%, Table 3). Although the prM 
region of JE virus strain does differ at the nucleotide level compared to the structural 
protein genes as a whole, which as determined by Chen et al. (1990) is useful in the 
genetic comparison of wild-type JE virus strains, the functional significance of the 
prM gene nucleotide variation remains to be established.
The most probable explanation for strain variation of JE virus is variation in 
particular amino acids in the structural proteins. Combinations of these variable amino 
acids plus a limited number of unique amino acid changes may have resulted in the 
strain variation detected by serological tests. Of six variable JE virus amino acids 
found in the prM, M and E protein sequence (prM-14, M-37, E-51, E-209, E-244 
and E-366), E-51 is potentially important since amino acid E-52 is part of the epitope 
recognized by JE specific MAb Narma3 (Hasegawa et al., 1992). The amino acid 
change at E-51 would change the conformation of the E protein in this region. The 
ten-fold HAI activity difference by MAb Narma3 between strains Nakayama and 
Kamiyama may result from their amino acid difference at E-51 (Kobayoshi et ah, 
1985). Also, Hasegawa et al. (1992) have reported that a combination of amino acid 
changes at E-52, E-364 and E-367 affected early virus-cell interaction and virulence 
in mice for JE virus. Thus, it is significant that E-51 and E-366 are variable amino 
acids and these may play a role in determining the relative pathogenicity of wild-type
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strains of JE virus.
Previous studies have shown that the antibody response induced by JE virus 
is dependent on the mouse strain used and that C57BL/6 (H-2^) mice respond better 
than BALB/c (H-2‘*) or C3H (H-2*^ ) mice (Jan et ah, 1993; Wills et aL, 1993). 
Furthermore, cross neutralization of JE viruses is more uniform in sera prepared in 
C57BL/6 mice than BALB/c mice (Wills et aL, 1993). The region of the E protein 
defined by MVE virus peptide 239-251 is highly conserved among JE serocomplex 
viruses and contains a dominant lA^ restricted T-helper cell epitope (Mathews et al., 
1992). This may account for the enhanced antibody response to JE virus in C57BL/6 
mice. This may also be of biological importance, since T-helper cells from C57BL/6 
mice primed with a MVE virus peptide containing this important T-helper cell 
epitope were able to recognize JE virus in lymphoblastogenesis assays (J.H. 
Mathews, personal communication). Therefore, the antigenic variation among the 
various immunotypes of JE virus as seen at the level of the B-cell response may 
represent differences in T-helper cell activation due to residue changes at E-51, E-244 
and E-366. In addition, since MVE virus and the more distantly related dengue-2 
virus share T-helper cell epitopes in the E protein regions 35-55 and 365-376 
(Mathews et al., 1992; Roehrig et al., 1994), JE virus may exhibit similar activity.
Hoke et al. (1988) found that the inactivated monovalent Nakayama-NIH 
vaccine was as good as a bivalent vaccine consisting of the Nakayama-NIH and 
Beijing-1 strains (two different immunotypes of JE virus). Also, the antibodies
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induced in recipients vaccinated with Nakayama-NIH strain can neutralize JE virus 
strains from India and other Nakayama sub-strains (Poland et aL, 1990). In China, 
an inactivated vaccine based on strain P3 has been successfully used to control JE. 
The results presented here confirm the homology of these viruses at the genetic level. 
Thus, the genetic information on JE virus described in this chapter would suggest that 
a monovalent vaccine will be successful at controlling JE, and this has been observed. 
Therefore, on the basis of the strains examined, strain variation (at the level of B-cell 
epitopes) does not appear to be a very important factor in design of a whole virus 
particle inactivated vaccine. Presumably, there are multiple T-helper and B cell 
epitopes that can interact to generate neutralizing antibody and overcome genetic 
variability in the outbred human population. Conversely, genetic restriction may be 
a problem in any potential subunit vaccine.
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Chapter 5
Comparison of structural protein genes of Japanese
encephalitis virus before and after passage in HeLa cells
159
5.1 Introduction
The HeLa cell line was isolated in February 1951, from a cervical carcinoma 
of a 31 year old woman (Henrietta LacA  ^ who subsequently died of the cancer (Gey 
et aL, 1952). HeLa cells were the first human tumor cells to be established as a 
continuous cell line. The original slides, when re-examined, showed the tumor to be 
adenocarcinoma-like in nature (Jones et aL, 1971).
The alphavirus Venezuelan equine encephalitis (VEE) was the first virus to be 
attenuated by passage through HeLa cells. After 23 consecutive passages it was found 
that there was a reduction in the virulence of the virus for mice when inoculated by 
the intraperitoneal (i.p.) route. Following 65 passages the virus was found to be 
avirulent via the i.p. route (Murphy et al., 1955 a & b).
In 1963 Hardy demonstrated that mosquito-bome wild-type yellow fever (YF) 
virus strain Asibi lost the ability to cause viscerotropic disease in monkeys following 
six passages in HeLa cells. These observations have been confirmed and extended by 
Barrett et al. (1990) and Miller and Adkins (1988). Dunster et al. (1990) reported 
that three strains of the mosquito-bome pantropic West Nile vims could also be 
attenuated by six passages in HeLa cells. Cao (1991) showed that two wild-type 
Japanese encephalitis (JE) vims strains, Nakayama-original (Nakayama-0 for short) 
isolated in Japan and 826309 isolated in India were also attenuated after six passages 
in HeLa cells.
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It is necessary to review some details of the work of Cao (1991) with regard 
to the attenuation of IE virus following passage in HeLa cells. Initially, four 
wild-type JE virus strains (Nakayama-original, SA14, 826309 and Beijing-1) were 
passaged six times in HeLa cells. All four JE viruses passaged six times in HeLa cells 
lost haemagglutination activity. However, only two (Nakayama-original and 826309) 
were attenuated for mice (Table 5.1). For simplicity, the parent Nakayama-0 virus 
before HeLa cell passage will be termed as Nakayama/HpO, and Nakayama-0 virus 
after six passages in HeLa cells will be termed as Nakayama/Hp6 . The JE strain 
826309 before and after six passages in HeLa cells will be termed 826309/HpO and 
826309/Hp6 respectively.
In the case of strain Nakayama/Hp6 , the virulence for mice was markedly 
reduced (see Table 5.1) and attenuation was retained on passage in primary chicken 
embryo fibroblast, LLC-MK2 and C6-36 cells; no infectious virus could be recovered 
from mouse brain inoculated with attenuated Nakayama/Hp6  virus at 7  days post 
infection. Both of the attenuated viruses, Nakayama/Hp6  and 826309/Hp6, can be 
distinguished from the virulent non-HeLa passaged parent viruses by examination with 
envelope (E) protein reactive vaccine and wild-type specific monoclonal antibodies 
(MAbs). The vaccine specific MAb V23, which is only reactive with attenuated live 
vaccine viruses, SA14-14-2/PHK, SA14-14-2/PDK, SA14-5-3 and SA14-2-8 derived 
from SA14 virus, recognized the HeLa cell attenuated Nakayama-/Hp6  and 
826309/Hp6 viruses, whilst two wild-type specific MAbs (Mabs K13 and K39) failed 
to recognize the attenuated viruses.
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The function of the E protein of the two attenuated HeLa p6  virus was found 
to be altered. Spiperone, an antagonist for the neurotransmitters dopamine and 
5-hydroxytryptamine, blocked the binding of the wild-type Nakayama/HpO virus to 
mouse brain membrane receptor preparations but failed to prevent the binding of the 
attenuated Nakayama/Hp6  virus.
To elucidate the molecular mechanism of attenuation of the two wild-type JE 
viruses, the structural protein genes of two pairs of viruses, Nakayama-original and 
836309, before and after six HeLa cell passages, have been sequenced and compared 
with each other and to the sequences in same region of SA14 virus and its vaccine 
virus derivatives.
5.2 Results
5.2.1 Cloning and sequencing
The nucleotide sequence of the 5’ non-coding region and structural protein 
genes (from nucleotide 28 to 2463) of JE virus strains Nakayama/HpO, 
Nakayama/Hp6 , 826309/HpO and 826309/Hp6 were determined by RT-PCR using 
primers as described previously (see chapter 2 and 4). The nucleotide sequence 
between nucleotide 915-1297 of Nakayama/Hp6  virus passaged once in C6-36 cells 
was also determined.
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5.2.2 The nucleotide and deduced amino acid sequence changes of the 
5’ non-coding region and structural protein genes of JE virus Nakayama-O 
before and after six HeLa cell passages
The region of the genome analyzed for Nakayama/Hp6  virus differed from 
that of its non-HeLa passaged parent, Nakayama/HpO, by a total of 46 nucleotides 
(Table 5.2). Of these differences, five vim  in the C protein gene, three in prM 
protein gene, three in M protein gene and 34 in the E protein gene (Table 5.2. and 
Fig. 5.1.). The 5’ non-coding region of Nakayama/HpO and Nakayama/Hp6  viruses 
were identical over the sequences examined.
Only nine of the nucleotide differences (at positions 100, 125, 361, 423, 562, 
861, 1474, 1603 and 2074) resulted in 9 amino acid differences at positions of C-1 
(Thr ->  He), C- 6  (Ala ->  Gly), C- 8 8  (Gly ->  Glu), C-109 (Gly ->  Glu), prM-29 
(lie ->  Gly), M-37 (Val ->  lie), E-133 (Lys ->  Glu), E-209 (Lys ->  Arg) and E- 
365 (A&%-> UO  (Table 5.2).
5.2.3 The nucleotide and deduced amino acid sequence changes of the 5’ 
non-coding region and the structural protein genes of JE virus 826309 before and 
after six HeLa passages
The nucleotide sequences of 826309/HpO and 826309/Hp6 viruses differed by 
39 nucleotide (Table 5.2, Fig 5.1), of which one was in 5’ non-coding region, five
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in C protein gene, seven in prM protein gene, four in M protein gene and 22 in E 
protein gene (Fig. 5.1 and Table 5.2).
The nucleotide differences (at positions 441,454, 648, 695,1636, 1920, 2064 
and 2074) resulted in amino acid differences at positions C-115 (Thr ->  Ala), C-119 
(Ala ->  Val), prM-58 (Ala ->  Met), prM- 8 8  (Lys ->  Arg), E-220 (Gly ->  Asp), 
E-315 (Ala ->  Val), E-363 (Ala ->  Thr) and E-365 (Ala ->  Val) (Table 5.2).
5.2.4 Comparison of the nucleotide and deduced amino acid sequence of 
the HeLa passaged viruses with each other and with that of SA14 virus and its 
vaccine derivatives
The nucleotide homology of the 5’ non-coding region and structural protein 
genes between Nakayama/HpO and 826309/HpO viruses is 96.3%. The amino acid 
homoology of the structural protein is 98.2%. The nucleotide homology of the 
5’ non-coding region and structural protein genes between Nakayama/Hp6  and 
826309/Hp6 is 98.2%; and the amino acid homology of structural protein genes is 
98.9%. Only one common amino acid substitution was found at E-36S' where the 
alanine in the parents were replaced by valine in both HeLa passage attenuated 
viruses.
When three sequences of wild-type JE virus SA14 strain and sequences of 
vaccine viruses derived from SA14 virus were included in the comparison, one unique
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Table 5.2. The nucleotide and amino acid differences of the 5’ non-coding region and 
structural protein genes of JE viruses Nakayama and 826309 before and after six 
HeLa passages.
Nakayama
Nucleotide
826309
Amino
Nakayama
Acid
826309
5’ NC 0 1
- -
C 5 5 4 2
prM 3 7 1 2
M 3 4 1 0
E 34 2 2 3 4
Total 45 39 9 8
NC: Non-coding region.
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Fig. 5.1. Alignment of the sequences of structural protein 
genes of non-HeLa and HeLa passaged JE viruses. Ind. c : JE 
virus 826309/HpO. Ind.h: JE virus 826309/Hp6. Nak.c: JE
virus Nakayama/HpO. Nak.h: JE virus Nakayama/Hp6.
2 9  88
I n d . C TTAGTATCGTTGAGAAGAATCGAGAGATTAGTACAGTTTAAACAGTTTTTTAGAACGGAA
I n d . h  ........................................................................................ G ............................................................................
N a k . c  ........................................................................................ G ............................................................................
N a k . h  ........................................................................................ G ...........................................................................
I n d .  c  
I n d . h  
N a k . c  
N a k .h
C ->  1 4 8
GATAACCATGACTAAAAAACCAGGAGGGCCCGGTAAAAACCGGGCTATCAATATGCTGAA
2 0 8
I n d . C ACGCGGTCTACCCCGCGTATTCCCACTAGTGGGAGTGAAGAGGGTAGTAATGAGCTTGTT
I n d . h  ...............C .....................................................................................................................................................
N a k . c  ...............CT..................................................................................................................G ............................
N a k .h  ...............CT..................................................................................................................G ............................
I n d .  c  
I n d . h  
N a k . c  
N a k .h
2 6 8
GGACGGCAGAGGGCCAGTACGTTTCGTGCTGGCTCTTATCACGTTCTTCAAGTTTACAGC
I n d .  c  
I n d . h  
N a k . c  
N a k .h
3 2 8
ATTAGCCCCGACCAAGGCGCTTTTAGGCCGATGGAAAGCAGTGGAAAAGAGTGTGGCAAT
3 8 8
I n d . c  GAAACACCTTACTAGTTTCAAACGAGAACTTGGGACACTCATTGACGCCGTGAACAAGCG
I n d . h  ...............T ..........................................................................A .......................................................................
N a k .c  ...............T ................. A ....................................................... .................
N a k .h  ...............T .......................................................................AA.......................................................................
I n d .  c  
I n d . h  
N a k . c  
N a k .h
I n d .  c  
I n d . h  
N a k . c  
N a k .h
4 4 8
GGGCAGAAAGCAAAACAAAAGAGGAGGAAATGAAGGCTCAATCATGTGGCTCACGAGCTT
...............A ...................
...............A ...................
prM -> 4 8 0
GGCAGCTGTCATAGCTTGTGCAGGAGCCATGAAGCTGTCGAATTTCCAGGGGAAGCTTTT
. . . .C . .C ........................................T . . . .A ................
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5 6 8
I n d . c  GATGACCATCAACAACACGGACATTGCAGACGTTATCGTGATTCCCACCTCAAAAGGAGA
I n d . h  ........................................................................................................................................................................
N ak . c  ................. G .............................................................................................................................. T ................
N a k . h  ...............TG..................................................................................................................................................
6 2 8
I n d . C GAACAGATGCTGGGTCCGGGCAATCGACGTCGGTTACATGTGTGAGGACACCATCACGTA
I n d . h  .............................................................................................................................................. T ......................
N ak . c  ....................... T ................................................................. C ............................................... T ....................
N ak .h  .......................T ..................................................................C ............................................... T ....................
688
I n d . c  CGAATGTCCTAAGCTTACTGCGGGCAATGATCCAGAGGACGTGGATTGCTGGTGTGACAA
I n d . h  .................................................CAT..................................................T ........................................................
N a k . c  ........................................C . . CAT........................ ..........................................C . . T ..............................
N a k . h  .................................................CAT...................................................................C . . T ..............................
7 4 8
I n d . C CCAAGAGGTCTACGTCCAATATGGACGGTGCACGCGGACCAGGCATTCCAAGCGAAGCAG
I n d  . h  ...............A ........................................................................................................................ G ........................
N a k . c  ...............A .....................................................................................................................................................
N a k .h  ...............A .....................................................................................................................................................
M-> 8 0 8
I n d .  C GAGATCCGTGTCGGTCCAGACACATGGGGAGAGTTCACTAGTGAATAAAAAAGAGGCCTG
I n d . h  .................................................A ............................................................................................................T . .
N a k .c  .................................................A ............................................................................................................T . .
N a k .h  ................................................ A ............................................................................................................T . .
868
I n d . C GCTGGATTCAACGAAAGCCACACGATATCTCATGAAAACTGAGAACTGGATCATAAGGAA
I n d . h  ........................................................................................................................................................................
N a k .c  ..........................................................................C    . .   G . . ---------
N a k . h  ........................................................................................................................................................................
9 2 8
I n d . C TCCTGGCTATGCTTTCCTGGCGGCGGTACTTGGCTGGATGCTTGGCAGTAACAACGGTCA
I n d . h  ........................................................................................................................................................................
N a k . c  ........................................................................................................................................................................
N a k . h  ........................................................................................................................................................................
E ->  9 8 8
I n d . C ACGCGTAGTATTTACCATCCTCCTGCTGTTGGTCGCCCCGGCTTACAGTTTTAATTGTCT
I n d . h  ...............G .................................................................................T .................................................................
N a k .c  ...............G .................................................................................T ........................ G ------- C. .C .............
N ak .h  ...............G .............C . .............................................................T ........................ G ------- C . . C .............
1 0 4 8
I n d . h  GGGAATGGGCAATCGTGACTTCATAGAAGGAGCCAGTGGAGCCACTTGGGTGGACTTGGT
I n d . h  ..................................................................................................................................... ..................................
N a k . c  ........................................................................................................................................................................
N a k . h  ........................................................................................................................................................................
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2 0 0 8
I n d . c  GCTAGAAGGAGATAGCTGTTTGACAATCATGGCAAACGATAAACCAACATTGGATGTCCG
I n d . h  ................................C .............C ....................................................... C ........................................................
N ak . c  .................................................C ..................... T ..............................C .......................................C .............
N ak .h  ................................C .............C ..................... T ..............................C .......................................C .............
1 1 6 8
I n d . C CATGATTAACATCGAAGCTAGCCAACTTGCTGAGGTCAGAAGTTATTGCTATCATGCCTC
I n d . h  ........................................................................................................................................................................
N a k . c  ...............C .................................. GT...................................................................C ............................. T . .
N a k . h  ...............C .................................. GT...................................................................C ............................. T . .
1 2 2 8
I n d . c  AGTCACTGACATCTCGACGGTGGCTCGGTGCCCCACGACTGGAGAAGCCCACAACGAGAA
I n d . h  ........................................................................................................................................................................
N a k . c  ................................T ....................................................................................................................................
N ak . h  ................................T ..................................................................................................T ..............................
1 2 8 8
I n d . h  GCGAGCTGATAGTAGCTATGTGTGCAAACAAGGCTTCACTGATCGTGGGTGGGGCAACGG
I n d . c  ........................................................................................................................................................................
N a k . c  ........................................................................................................................................................................
N a k .h  ........................................................................................................................................................................
1 3 4 8
I n d . C ATGTGGACTTTTCGGGAAGGGAAGCATTGACACATGTGCAAAATTCTCCTGCACCAGCAA
I n d . h  ........................................................................................................................................................................
N a k . c  ............................................................................................................................................................... T . .
N a k . h  ........................................................................................................................................................................
1 4 0 8
I n d .  c  AGCGATTGGGAGAACAATCCAGCCAGAAAACATCAAATACGAAGTTGGTATTTTTGTGCA
I n d . h ......... ......................................................................................................................................... .C ...........................
N a k .c  G ................................................................. A .............................................................C ..............................
N a k .h  G ....................................................................................................................................C ..............................
1 4 6 8
I n d .  C TGGAACCACCACTTCGGAAAACCATGGGAATTATTCAGCGCAAGTTGGGGCGTCCCAGGC
I n d . h  ........................................................................................................................................................................
N a k . c  ........................................................................................................................................................................
N a k . h  ........................................................................................................................................................................
1 5 2 8
I n d .  c  GGCAAAGTTTACAGTGACACCCAATGCTCCTTCGATAACCCTCAAACTTGGTGACTACGG
I n d . h  ........................................ A   . . . .
N a k . c   ..................................... A ........................................................................T ................................................
N a k . h  ........................................A ............................................................................................................................
1 5 8 8
I n d . C AGAAGTCACACTGGACTGTGAGCCAAGGAGTGGACTGAACACTGAAGCGTTTTATGTCAT
I n d . h  .......................................................................................................................................................C .............
N a k .c  ................................................................................................... A ..............................A .............C . .T .  .
N a k . h  .......................................................................................................................................................C .............
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1 6 4 8
I n d . c  GACCGTGGGGTCAAGGTCATTTCTGGTCCATAGGGAATGGTTTCATGGCCTCGCTCTCCC
I n d . h  ...................................................................................................................................A .................................
N a k . c  ..................................... A .................. T ...................C ........................................... A T ..............................
N ak .h  ............................................................T ...................................................................A .................................
1 7 0 8
I n d .  C CTGGACGTCCCCTTCGAGCACAGCGTGGAGAAACAGAGAACTCCTCATGGAATTTGAAGA
I n d . h  .............................................................................................................................................. G ......................
N a k . c  T .....................................................................................................................................................................
N a k . h  .............................................................................................................................................. G ......................
1 7 6 8
I n d . c  GGCGCACGCCACAAAACAGTCCGTTGTTGCTCTTGGTTCACAGGAAGGAGGCCTCCATCA
I n d . h  ....................................................................................................G ................................................................
N a k . c  ................................................................................................... G ................................................................
N a k . h  ....................................................................................................G ................................................................
1 8 2 8
I n d . C GGCGTTGGCAGGAGCCATCGTGGTGGAGTACTCAAGCTCAGTGAAGTTAACATCAGGCCA
I n d . h  ........................................................................................................................................................................
N a k .c  ................................................................................................ .......................................................................
N a k . h  ........................................................................................................................................................................
1 8 8 8
I n d . C CCTGAAATGTAGGCTGAAAATGGACAAACTAGCTCTGAAAGGCACAACCTATGGCATGTG
I n d . h  ...................................................................................G .................................................................. .. ...........
N a k .c  . . . A  C .......................................................G .................................................................................
N a k . h  ...................................................................................G .................................................................................
1 9 4 8
I n d . C TACAGAAAAATTCTCGTTCGCGAAAAATCCGGTGGACACTGGTCACGGAACAGTTGTCAT
I n d . h  ...........................................................................................C ............................................................................
N a k . c  C ......................................................................................... C ..........................................................................
N a k .h  C . . G .................................................................................C ..........................................................................
2 0 0 8
I n d .  c  TGAACTCTCCTACTCTGGGAGTGATGGCCCCTGCAAAATTCCGATTGTCTCCGTCGCGAG 
I n d . h  
N a k . c  
N a k .h
2 0 6 8
I n d . C CCTCAATGACATGACTCCTGTCGGGCGGCTGGTGACAGTGAACCCCTTCGTCGCGGCTTC
I n d . h  .........................................C . . C . . T ........................................ A . . . .
N a k .c  ........................................C. .C ..................... C ............................................................................A . . . .
N a k .h  .........................................C . . C . . T .............................................................................................A . . . .
2 1 2 8
I n d . c  CAGTGCCAACTCAAAGGTGCTGGTCGAGATGGAACCCCCCTTCGGAGACTCCTATATCGT
I n d . h  ............T . . . T ............................................................................................................................. C ............
N a k . c  .......................................................................................................................................................C .............
N ak .h  ............T . . . T ............................................................................................................................. C ............
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2 1 8 8
I n d . c  GGTTGGAAGGGGAGACAAGCAGATCAACCACCATTGGCACAAAGCTGGAAGCACGCTGGG
I n d . h  A ................. C .................................................................... ................ T ........................................................
N a k .c  A ...............................................................T .............T ..................... C . . G ...............................................
N a k .h  A ................. C .....................................................................................T ........................................................
2 2 4 8
I n d .  C CAAGGCCTTTTCAACAACTTTGAAGGGAGCTCAGAGACTGGCAGCGTTAGGCGACACAGC
I n d . h  . . .A .............................................................................................................................................................
N a k . c  . . . A ............................................................................... A ...................................... G ..............................
N a k .h  . . .A .......................................................................................................................... G ..............................
2 3 0 8
I n d .  C CTGGGACTTTGGCTCTATTGGAGGGGTTTTCAACTCTATAGGAAAAGCCGTTCACCAAGT
I n d . h  ........................................................................................................................................................................
N a k . c  ................................................................................................... C .............G ...............................................
N a k .h  .......................................................................... C ..................... C ................................................................
2 3 6 8
I n d . C GTTTGGTGGTGCCTTCAGAACACTCTTTGGGGGAATGTCTTGGATCACACAAGGGCTAAT
I n d . h  ........................................................................................................................................................................
N a k . c  .......................................................................... C ..........................................................................................
N a k . h  ........................................................................................................................................................................
2 4 2 8
I n d . C GGGCGCCCTACTACTTTGGATGGGCGTCAACGCACGAGACCGATCAATCGCTTTGGCCTT
I n d . h  ........................................................................................................................................................................
N a k . c  . . . T ............................... C ..........................................................................................T ............................
Na k  . h  . . . T . . T .......................C ..........................................................................................T ............................
2 4 6 3
I n d . c  CTTAGCCACAGGAGGTGTGCTCGTGTTCTTAGCGA
I n d . h  ................................................................................................
N a k . c  .................................................................................................
N a k . h  ............................... G .............................................................
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amino acid change was found from 826306/Hp6 virus at position prM- 8 8  (Lys - > 
Arg), and unique amino acid were found from Nakayama/Hp6  virus at positions 
C-1 (Thr ->  He), C- 8 8  (Gly ->  Glu), C109 (Gly ->  Glu) and prM-29 (Lys > He) 
(Table 5.2.). The remainder of the amino acids that differentiated the HeLa passage 
attenuated viruses (Nakayama/Hp6  and 826309/Hp6) from their parents have been 
seen in other wild-type JE viruses.
The Nakayama/Hp6  virus received one additional passage in mosquito C6-36 
cells and regained HA activity but remained attenuated for mice. It was termed 
Nakayama/Hp6 -Cl virus. 406 nucleotides between position 915-1297 were sequenced. 
These 406 nucleotides sequenced differed from Nakayama/Hp6  virus at 12 nucleotides 
which coded for 5 amino acid substitutions at M-55, M-75, E-44, E- 6 8  and E-75 
(Table 5.3). These five amino acids were identical in Nakayama/HpO and 
Nakayama/Hp6  viruses. This virus was not examined further as the high mutation rate 
would not enable substitutions involved in HA activity to be identified.
5.3 Discussion
In this study, the genetic differences between two wild-type strains of JE virus 
before and after passage in HeLa cells (Nakayama-O/HpO, Nakayama-0/Hp6, 
826309/HpO and 826309/Hp6) have been investigated to analyze the molecular basis 
of attenuation following only six passages in HeLa cells. Nucleotide sequencing of 
approximately 25 % of the genomes of Nakayama/Hp6  and 826309/Hp6 viruses and
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Table 5.2. Comparison of amino acid differences among Japanese encephalitis virus 
strains SA14, its derived vaccine strains, Nakayama/PO, Nakayama/P6 , 826309/P0 
and 826309/P6.
Amino acid 826309 Nakayama SA14 SA14 SA14 14-2 14-2 SA14-
Position pO p6 pO p6 USA CDC JAP PHK PDK 2-8
C-1 Thr Thr Thr ILE Thr Thr Thr Thr Thr Thr
C- 6 Gly Gly ALA Gly Gly Gly Gly Gly Gly Gly
C-65 Leu Leu Leu Leu Leu Leu Leu SER SER Leu
C- 8 8 Gly Gly Gly GLU Gly Gly Gly Gly Gly Gly
C-109 Gly Gly Gly GLU Gly Gly Gly Gly Gly Gly
C-115 Thr ALA Ala Ala Ala Ala Ala Ala Ala Ala
C-119 Ala VAL Val Val Val Val Val Val Val Val
prM-29 Lys Lys He Lys Lys Lys Lys Lys Lys Lys
prM-58 Ala MET Met Met Arg Arg Arg Arg Arg Arg
prM - 8 8 Lys ARG Lys Lys Cys Cys Cys Cys Cys Cys
M-37 He He Val ILE He He He He He He
E-107 Leu Leu Leu Leu Leu Leu Leu PHE PHE Leu
E-126 He He He He He He He He He THR
E-128 Arg Arg Arg Arg Arg Arg Arg Arg Arg LYS
E-133 Lys Lys Lys GLU Glu Glu Glu Glu Glu Glu
E-138 Glu Glu Glu Glu Glu Glu Glu Lys Lys Lys
E-176 He He He He He He He Val Val Val
E-177 Thr Thr Thr Thr Thr Thr Thr ALA Thr Thr
E-179 Lys Lys Lys Lys Lys Lys Lys Lys Lys GLU
E-209 Arg Arg Lys ARG Lys Lys Lys Lys Lys Lys
E-220 Gly ASP Asp Asp Asp Asp Asp Asp Asp Asp
E-243 Glu Glu Glu Glu Glu Glu Glu Glu LYS Glu
E-264 Gin Gin Gin Gin Gin Gin Gin HIS Gin Gin
E-279 Lys Lys Lys Lys Lys Lys Lys MET MET Lys
E-315 Val ALA Ala Ala Ala Val Ala Val Val Val
E-363 Ala THR Thr Thr Thr Thr Thr Thr Thr Thr
E-365 Ala VAL Ala VAL Ala Ala Ala Ala Ala Ala
E-439 Lys Lys Lys Lys Lys Arg Lys Arg Arg Arg
(1991) and Nitayaphan et al. (1990). The amino acid in capital letter is the amino 
acid different to its parent; the underlined amino acid is unique change compared to 
other JE viruses; and the bolded amino acid is common amino acid substituted in the 
vaccine viruses derived from SA 14 virus.
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Table 5.3 Comparison of nucleotide and amino acid differences of Nakayama/Hp6 -C6  
with Nakayama/HpO and Nakayama/Hp6 .
Position
NT AA
Nucleic Acid Amino Acid
Hp6 -C6 Hp6 HpO Hp6 -C6 Hp6 HpO
916 M-55 A G G Asn Ser Ser
941 M-63 C C U Phe Phe Phe
975 M-75 A G G Ser Gly Gly
980 E-1 U C C Phe Phe Phe
1034 E-19 G U U Thr Thr Thr
1055 E-26 G A A Glu Glu Glu
1070 E-31 A G G Leu Leu Leu
1107 E-44 U C C Cys Arg Arg
1145 E-56 u C C Val Val Val
1180 E- 6 8 c U U Thr He He
1 2 0 1 E-75 u C c Leu Pro Pro
1259 E-94 G A A Gin Gin Gin
174
comparison with the parent viruses revealed that there were a large number 
o f nucleotide changes and amino acid substitutions. The amino acid differences were 
spread throughout the structural protein genes (Table 5.2). In contrast, the amino acid 
mutations found in the structural proteins of vaccine viruses derived from SA14 virus 
were restricted to the E protein. Therefore, passage of wild-type JE virus in HeLa 
cells selected for a virus with many mutations. Accordingly, this would suggest that 
attenuation of JE virus by passage in HeLa cells is not simply selection of a variant 
that is able to replicate in HeLa cells but an accumulation of mutations or a high error 
rate in viral transcription. This was supported by the high rate of mutation following 
one passage of Nakayama/Hp6  virus in mosquito C6-36 cells. J .
of
^akayama/Hp6  and 826309/Hp6 viruses was accompanied by antigenic 
changes in the viral E protein when they were examined with a panel of JE wild-type 
specific and vaccine specific MAbs (Sil et al., 1992a). The JE wild-type specific 
MAbs (K13 and K39) recognized the virulent non-HeLa cell passaged parent virus but 
not the attenuated HeLa p6  virus. In contrast, one (V23) of two vaccine specific 
MAbs that reacted with the live vaccine strains (SA14-2-8, SA14-5-3 and SA14-14-2) 
also recognized Nakayama/Hp6  and 826309/Hp6 viruses but not the parent non-HeLa 
passaged viruses. Thus, wild-type epitopes on the E protein have been lost and at 
least one vaccine specific epitope gained during the passaging of the Nakayama-0 and 
826309 viruses in HeLa cells (Cao, 1991). Although, the attenuated Nakayama-0 and 
826309 Hel^ passaged variants shared the same vaccine specific epitope (recognized 
by MAb V23) with the SA14 series vaccine strains, no common amino acid changes 
between HeLa attenuated viruses and SA14 derived vaccine viruses in the E protein
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were observed. Therefore, it is likely that the wild-type and vaccine epitope(s) are 
probably conformational in nature. Mutations in the E protein may have induced the 
formation of the epitope(s), although the particular amino acid alterations may not be 
part of the physical composition of the epitope.
The only common amino acid substitution in both HeLa passaged viruses was 
E-366. However, E-366 is a variable amino acid in wild-type JE virus strains (chapter 
4). Wild-type strains with differences at E-366 were still neurovirulent in adult mice 
(Wills et al., 1992) indicating that the amino acid is not directly involved in 
attenuation. However, Hasegawa et al. (1992) have reported that a combination of 
amino acid changes at E-52, E-364 and E-367 affected early virus-cell interaction and 
virulence in mice suggesting that mutations at E-363 and E-366 of 826309 HeLa p6 
virus may be involved in attenuation.
Hase et al. (1993) reported that following intracerebral inoculation of adult 
mice the SA14 parent virus replicated to high titre and spread rapidly to the majority 
of neurons in the brain whereas SA14-14-2 virus replicated poorly and infected only 
a small number of neurons in scattered small foci and disappeared from the brain 
after 10 days infection. The Nakayama/Hp6 virus has showed a similar phenotype (no 
virus could be recovered from the brain at 7 days post infection (Cao, 1991)). The 
sequence comparison of wild-type parent SA14 virus and its attenuated vaccine 
viruses has shown that the attenuation of SA14-14-2 virus may be due to an alteration 
in the viral serine proteinase function (see chapter 3). The latter is proposed from the 
amino acid substitutions in the NS2B and NS3 proteins. Unfortunately, many attempts
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to clone the NS2B-NS3 region of Nakayama-0/Hp6 were unsuccessful. Therefore, 
it could not be confirmed if the same mutation(s) also occurred in the serine 
proteinase function complex in the HeLa passage attenuated Nakayama/Hp6 and 
826309/Hp6 viruses.
In conclusion, the results presented in this chapter provide more information 
contributing to an understanding of the molecular basis of attenuation and/or 
pathogenicity of JE virus. However, the large number of nucleotide and amino acid 
changes in the region of the genome of the JE HeLa p6 viruses that was sequenced 
indicate that the HeLa cell attenuation system will not be suitable to identify the 
molecular basis of attenuation of JE virus.
1 7 7
Chapter 6
Genetic changes in the envelope protein gene of Japanese 
encephalitis virus following limited passage in cell culture
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6.1 Introduction
JE virus replicates in a variety of primary and continuous cell cultures of 
porcine, hamster, chicken, monkey, and mosquito origin. Monkey kidney Vero and 
LLC-MK2 cells are useful for plaque assays (Monath, 1990) and used for plaque 
purification of flaviviruses before sequencing the viruses (Cecilia and Gould, 1991). 
The observation that the cell line used to assess residual infectivity post neutralization 
and also the passage history of a virus can effect its susceptibility to neutralization has 
been investigated by a number of workers using different viruses, both for 
monoclonal antibody (MAb) and polyclonal antisera neutralization assays (for review 
see Dimmock, 1993).
Grady and Kinch (1985) reported that two MAbs generated to the Bunyavirus 
La Crosse could be differentiated on their ability to neutralize virus depending on the 
cell line used to assess the residual infectivity. One MAb could neutralize virus when 
BHK-21 cells were to assay residual infectivity but failed to neutralize La Crosse 
virus when mosquito cells were used to assay the residual infectivity. The other MAb 
was the converse.
Kjellen (1985) also demonstrated differential neutralization using a polyclonal 
antisera raised to enterovirus 71. It was found that the antisera neutralized over 99% 
of enterovirus 71 when Rhabdomyosacorma cells were used to assay residual 
infectivity, but the quantity of neutralization was much lower when monkey kidney 
cells were used.
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James & Millican (1986) reported a more extensive investigation into host 
adaptive variation using Bunyamwera (BUN) virus. They observed that BUN virus 
grown in Vero and mosquito C6-36 cells did not demonstrate any significant 
difference in neutralization using a MAb, however, it was demonstrated that BUN 
virus grown in C6-36 cells produced a lower infectivity titre in C6-36 cells than in 
Vero cells. BUN (C6-36) virus was passaged into C6-36 cells six times to generate 
a p6 virus. This virus was more resistant to neutralization by MAb and also 
polyclonal antisera, but the virus produced similar titres when plaqued on either Vero 
or C6-36 cells. It was hypothesised that the relative resistance of insect cell-passaged 
virus to neutralizing antibodies had resulted from host derived factors such as post- 
translational modification of viral proteins, rather than from mutation of the viral 
genome. Passage of the p6 C6-36 virus back into Vero cells did not change the 
neutralization resistant nature of the virus. Thus, the changes in phenotype following 
passage of BUN virus in mosquito cells results from the proliferation of a variant that 
has an alteration in the structure of its envelope proteins and affects the neutralization 
sites.
There has been no investigation of the host cell specific neutralization of 
flaviviruses other than a recent brief study by Lee et al. (1993) using Den-3 virus. 
They reported that the prM and envelope (E) protein genes did not alter in sequence 
between isolation in ToxorlHnchites amboinensis mosquitos and three passages in 
mosquito Aedes albopictus C6-36 cells. No growth differences between the wild-type 
DEN-3 virus were observed. However, two further passages of this isolate in monkey 
kidney Vero or mosquito C6-36 cells resulted in phenotypic variations and amino acid
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changes in the E protein genes. Also, it has been observed that three genomic 
sequences of JE virus SA14 (SA14/JAP, Aihara e ta l, 1991; SA14/CDC, Nitayaphan 
et al., 1990; and SA14/USA, see chapter 3) had several amino acid differences. The 
SA14 strains sequenced all come from the same source in China. The differences 
between these strains were that SA14/USA virus was extracted from mouse brain 
without plaque purification (see chapter 3), SA14/CDC virus sequenced by Nitayap­
han et al. (1990) was plaque purified from SA14/USA virus and passaged three times 
in primary dog kidney (PDK) cells, the SA14/JAP virus was plaque purified in BHK- 
21 cells (Aihara et al., 1991). Finally JE virus strain Nakayama was attenuated 
following few passages in HeLa cells (see chapter 5).
Wills (1991) investigated biological characteristics of neutralization (N), 
haemagglutination (HA) and haemagglutination inhibition (HAI) of a wild-type JE 
virus strain, DH20, isolated from Nepal and compared the virus after two passages 
in five different cell lines. It is necessary to review some details of Wills’ work. Low 
passage JE virus strain DH20 isolated from Nepal was passed twice in each of the 
five cell lines used in this study (LLC-MK2, Vero, SW13, CEE and C6-36) from a 
common seed stock. The resulting p2 virus stocks were plaqued on both LLC-MK2 
and Vero cells. DH20/p2 viruses produced a higher titre on Vero cells than on LLC- 
MK2 cells. After the second passage all the DH20/p2 virus stocks tested produced a 
higher titre on Vero cells than LLC-MK2 cells.
Each of the p2 viruses was examined in N assays against a ployclonal antisera 
raised against wild-type JE virus strain Nakayama. Residual infectivity was
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Table 6.1 Neutralization patterns of JE virus strain DH20 grown in different cell 
lines against a polyclonal antisera raised to JE virus strain Nakayama. This Table is 
modified from Wills (1991).
Residural Virus grown in (cells)
Infectivity C6-36 SW13 LLC-MK2 CEE Vero
Assayed in LLC-MK2 cells
Logio
reduction
2.5 3.0 - 2.1 0.8
Assayed in Vero cells
Logio
reduction
1.8 0.1 0.7 0.7
The p2 virus stocks were used as challenge virus for the neutralization assays 
-:No neutralization, 
logio Reduction=logio —
infectivity titre of virus without antibody
infectivity titre of the virus in the presence of antibodies
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assessed on both LLC-MK2 and Vero cells (Table 6.1). The DH20/p2 LLC-MK2 
virus was resistant to neutralization by the polyclonal antisera whereas the other 
DH20 p2 viruses were neutralized to varying degrees. JE virus DH20/p2 SW13 and 
CEP viruses showed similar N patterns, being highly susceptible to N when the 
residual infectivity was assessed using LLC-MK2 cells but resistant when the residual 
infectivity was assessed using Vero cells. JE virus strain DH20/p2 C6-36 virus was 
unique in that it was sensitive to neutralization regardless of the cell line used to 
measure residual infectivity (Table 6.1).
All the p2 viruses were also tested for the ability agglutinate goose red blood 
cells using standard assays. DH20/p2 viruses grown in SW13, C6-36 and CEE cells 
produced HA and their HA:pfu titres were similar. However, the viruses grown in 
LLC-MK2 and Vero cells failed to demonstrate any detectable HA activity (ie. <20 
HAU/ml) (Table 6.2). However, when DH20/p2 LLC-MK2 virus was concentrated 
by centrifugation low titred HA activity was detected in the pellet indicating that the 
LLC-MK2 passaged virus contained a small subpopulation of HA-positive virus. It 
was found that the optimum pH for HA of virus grown in CEE cells (pH 6.4) was 
significantly higher than that required for virus grown in SW13 or C6-36 cells (pH 
6.0-6.1). DH20/p2 CEE and C6-36 viruses were used in HAI assays against a large 
panel of anti-JE virus MAbs to assess the affects of cell passage on HAI reactivity 
patterns. The reactivity patterns of C6-36 and CEE passaged viruses were markedly 
different.
The flavivirus E protein encodes the viral haemagglutinin, induces protective
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Table 6.2 Comparison of infectivity, HA titres and HA:pfli ratios for the DH20/p2 
viruses grown in different cells. This Table is modified from Wills (1991).
Cells C6-36 SW13 LLC-MK2 CEF Vero
HA titre 
(Logio HAU/ml)
4.0 3.7 ^ 1 .3 3.4 j<1.3
Infectivity titre 
(Logio pfii/ml)
8.9 8.0
) :
7.4 8.0 7.7
Logio HA/pfu 
ratio
4.9 4.3 >6.1 4.6 _>6.4
Optimum pH 
for HA
6.0 6.1 NA 6.4 NA
HA:Haemagglutination. pfu: pfu-plaque forming units. NA: Not applicable. 
Infectivity titration was performed in Vero cells.
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immunity and mediates receptor-specific virus attachment to the cell surface (Brinton, 
1986). Therefore, sequence analysis of the E protein gene of the DH20/p2 viruses 
grown on five different cell lines may enable phenotypic changes to be mapped to the 
virus genotype.
6.2 Results
6.2.1. Nucleotide sequence analysis of E and partial M protein genes of 
DH20/p2 viruses
The nucleotide sequence of E protein and part of M protein genes (nucleotides 
901 to 2463) of all DH20/p2 viruses were determined, by RT-PCR followed by 
sequencing except nucleotides between 1300 - 1863 of p2 Vero virus (see Fig. 6.1). 
All the partial M protein genes of the DH20/p2 viruses studied were identical except 
for one nucleotide difference seen in the DH20/p2 LLC-MK2 virus at nucleotide 
position 931, which is G in DH20/p2 LLC-MK2 virus while the other four viruses 
were C at this position. This nucleotide change resulted in an amino acid change (see 
below). Of the 1486 nucleotides sequenced in the E protein gene 65 bases were 
variable. However, most of these nucleotide changes were silent and did not result 
in amino acid changes.
6.2.2 Analysis of the deduced amino acid sequences of the p2 viruses
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Fig. 6.1. Alignment of the nucleotide sequences of DH20/p2 viruses passaged 
in five cell lines. Nucleotide position is equivalent to that of SA14/JAP virus 
(Aihara et al., 1991).
C 6 -3 6
LLC-MK2
SW13
CEF
VERO
9 5 0
GCTGGATGCTTGGCAGTAACAACGGTCAACCCGTGGTATTCATCATCCTC 
.................................................................................. G .....................................................
C 6 -3 6
LLC-MK2
SW13
CEF
VERO
E ->  1 0 0 0
CTGCTGTTGGTCGCTCCGGCTTACAGTTTCAACTGTCTGGGAATGGGCAA
C 6 -3 6
LLC-MK2
SW13
CEF
VERO
1 0 5 0
TCGTGACTTCATAGAAGGAGCCAGTGGAGCCACTTGGGTGGACTTGGTGC
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 1 0 0
TAGAAGGAGATAGCTGCTTGACAATTATGGCAAACGACAAACCAACATTG
 ................. C .............................................................................................................
..........................C .............................................................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 1 5 0
GACGTCCGCATGATCAACATCGAAGCTGTCCAACTTGCTGAGGTCAGAAG
1 2 0 0
TTACTGCTATCATGCTTCAGTCACTGACATTTCGACGGTGGCTCGGTGCC 
................................................ G .......................................................................................
1 2 5 0
CCACGACTGGGGAAGCTCACAACGAGAAGCGAGCTGATAGTAGCTATGTG
..........................A ..............................................................................A ...........................
..........................A .............................................................................................................
..........................A .............................................................................................................
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C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 3 0 0
TGCAAACAAGGCTTCACTGATCGTGGGTGGGGTAACGGATGTGGATGTTT 
............................................................................................................................. C . . . .
......................................c ...................... c ...............................
......................................c ...................... c ...............................
......................................c .....................c .......................c ___
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 3 5 0
CGGGAAGGGAAGCATTGACACATGTGCAAAATTCTCCTGCACCAGGAAGG
............................................................................................................................. T . . A .
............................................................................................................................. T . . . .
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 4 0 0
CTATTGGGAGAACAATCCAGCCAGAAAACATCAAATATGAAGTTGGCATT 
.G .................................................................................................C .................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 4 5 0
TTTGTGCATGGAACCACCACTTCGGAAAACCATGGGAATTATTCAGCGCA
...........................................................................................T ............................................
...........................................................................................T ............................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 5 0 0
AGTTGGGGCGTCCCAGGCGGCAAAGTTTACAGTAACACCCAATGCTCCTT
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 5 5 0
CGATAACCCTCAAACTTGGTGACTACGGAGAAGTCACACTGGACTGTGAG
.................................................................................. G .T ...............................................
..........................T ..................................................... G .T ..............................................
..........................T ..................................................... G .T ..............................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 6 0 0
CCAAGGAGTGGACTGAACACTGAAGCGTTTTACGTCATGACCGTGGGGTC
..................................... A ................................T ..............................................................
..................................... A ................................T ..............................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 6 5 0
AAGGTCATTTCTGGTCCACAGGGAATGGTTTCATGACCTCGCTCTCCCCT
................................................ T .......................................................................................
. .A ...................T ......................................................................T ..............................T .
. .A ...................T ......................................................................T ..............................T .
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C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 7 0 0
GGACGTCCCCTTCGAGCACAGCGTGGAGAAACAGAGAACTCCTCATGGAG
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 7 5 0
TTTGAAGAGGCGCACGCCACAAAACAGTCCGTTGTTGCTCTTGGGTCACA
. .C ..........................................T .....................................................................................
. .C ..........................................T .....................................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 8 0 0
GGAAGGAGGCCTCCATCAGGCGTTGGCAGGAGCCATCGTGGTGGAGTACT
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 8 5 0
CAAGCTCAGTGAAGTTAACATCAGGCCACCTGAAATGTAGGCTGAAAACG
. . .A ..........................................................................A .............C .............................C.
. . .A ..........................................................................A .............C    . . C .
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 9 0 0
GACAAACTAGCTCTGAAAGGCACAACCTATGGCATGTGCACAGAAAAATT
.................... G .................................................................................T ..............................
.................... G ...................................................................................................................
.................... G ...................................................................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
1 9 5 0
CTCCTTCGCGAAAAATCCGGCGGACACTGGTCACGGAACAGTTGTCATTG
................................................................. T ......................................................................
. . .  G .................................................................................. .............................................
. . .G ................................................................................................................................
. . .G ................................................................................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 0 0 0
AACTCTCTTACTCTGGGAGTGATGGCCCCTGCAAAATTCCGATTGTCTCC
 C ...........................................................................................................................
.G ............. C ....................................................................................................................
................. C ......................................................................................................................
................. C ......................................................................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 0 5 0
GTTGCGAGCCTCAATGACATGACCCCCGTTGGGCGGCTGGTGACAGTGAA
................................................................................C ........................................................
................................................................................C ........................................................
........................................................c .......................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 1 0 0
CCCCTTCGTCGCGACTTCCAGTGTCAATTCAAAGGTGCTGGTCGAGATGG
............................................c . . . c ...........................................
............................................c . . . c ...........................................
 C. . .C ..............................A ...........................
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C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 1 5 0
AACCCCCCTTCGGAGACTCCTACATCGTAGTTGGACGGGGAGACAAGCAG
.................................................................................................A ......................................
.................................................................................................A ......................................
.................................................................................................A ......................................
.................................................................................................A ......................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 2 0 0
ATCAACCACCATTGGCATAAAGCTGGAAGCACGCTGGGCAAAGCCTTTTC
..................................................................................................................G .....................
. . T ...................................... C....G ...............................................................................
. . T ...................................... C... .G ...............................................................................
. . T ..............................................G .................................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 2 5 0
AACAACTTTGAAGGGAGCTCAGAGACTGGCAGCGTTGGGTGACACAGCCT
.........................................................A .................................................C .........................
. . .G ..............................................A ............................................... C .........................
. . .G ............................................. A ............................................... C .........................
. . .G ............................................. A ............................................... C .........................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 3 0 0
GGGACTTTGGCTCTATTGGAGGGGTCTTCAACTCCATAGGAAAAGCCGTT
...................................  G ...................
.....................................................................................................................G ...................
.................................................................... T ....................................... G  A . .
.......................................................  T ....................................... G  A . .
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 3 5 0
CACCAAGTGTTTGGTGGTGCCTTCAGAACACTCTTTGGGGGAATGTCTTG
.................................................................................................C .......................................
......................................................T ...................................... C .......................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 4 0 0
GATCGCACAAGGGCTAATGGGTGCTCTACTACTCTGGATGGGCGTCAACG
 A ..................................................... C .............G ...................................................
 A ..................................................... C .............G ...................................................
 A ............................................G.....C ....................................................................
 A ............................................G.....C ....................................................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 4 5 0
CACGAGACCGATCAATTGCTTTGGCCTTCTTAGTCACAGGAGGTGTGCTC
...........................................................................................C ............................................
...........................................................................................C ............................................
C 6 - 3 6
LLC-MK2
SW13
CEF
VERO
2 4 6 3
GTGTTCTTAGCGA
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In the twenty-five amino acids of M protein analyzed one amino difference 
was found at position M-60 in DH20/p2 LLC-MK2 virus compared with other 
DH20/p2 viruses studied (Arg in DH20/p2 LLC-MK2 virus, Pro in the other viruses) 
(Table 6.3). Examination of the E protein revealed that 15 amino acids were 
variable. Table 6.3 shows that there were two unique amino acid changes in the E 
protein gene of p2 LLC-MK2 virus compared with other DH20/p2 viruses at positions 
E-107 (Cys ->  Leu) and E-291 (Thr > Met). DH20/p2 Vero virus had a unique 
amino acid at E-460, and DH20/p2 SW13 virus also contained an unique amino acid 
at position E-88 (Ser > Asp). All the other changes listed represented common 
changes with two of the viruses sharing the same amino acid at a particular position 
and the other viruses sharing a different amino acid.
The five unique amino acids found in DH20/p2 LLC-MK2, SW13 and Vero 
viruses in the E and partial M protein sequences were compared with equivalent 
positions of other wild-type IE viruses sequenced so far (see chapter 4). The amino 
acids M-60, E-107 and E-291 in other wild-type IE viruses are arginine, leucine and 
methionine respectively, which are the same for M-60, E-107 and E-291 of DH20/p2 
LLC-MK2 virus. The E-88 (Asn in DH20/p2 SW13 virus) and E-460 (Ala in 
DH20/p2 Vero virus) are unique amino acids compared to other IE wild-type viruses. 
These unique amino acids were also subjected to the secondary structural analysis 
with Novonty method (Novonty and Auffray, 1984). The amino acid change at E-291 
(Met - > Thr) was predicted to change the hydrophobicity profile, alpha helix profile, 
reverse turn propensity and beta sheet propensity of the E protein (Fig. 6.2). Other 
unique amino acid differences among DH20/p2 viruses were not predicted to alter the
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Fig. 6.2 The secondary structure curves of the sequences surrounding amino acid at 
E-291 of the E protein of in different JE virus DH20/P2 viruses. The top half is the 
result from DH20/p2 LLC-MK2 virus and bottom half is that from DH20/p2 C6-36 
virus. Turn: reverse turn propensity. Beta: beta sheet propensity. Alpha: alpha helix 
propensity. -F-: charged residues profile. Hydro: hydrophobicity profile.
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Table 6.3. Amino acid differences between the DH20 p2 viruses grown in five cell 
lines.
Position C6-36 SW13 LLC-MK2 CEF Vero
M-60 Pro Pro ARG Pro Pro
E-88 Ser ASN Ser Ser Ser
E-107 Cys Cys LEU Cys -
E-123 Arg Ser Ser Arg -
E-153 Gly Trp Gly Trp -
E-185 Glu Gly Glu Gly -
E-186 Val Phe Val Phe -
E-209 Arg Lys Arg Lys -
E-248 Thr Ser Thr Ser -
E-276 Ser Asn Ser Asn -
E-291 Thr Thr MET Thr Thr
E-366 Ala Ala Val Ala Val
E-439 Lys Arg Arg Lys Lys
E-441 lie Val Val He Val
E-460 Thr Thr Thr Thr ALA
E-486 Val Ala Ala Val Val
unique amon the strains compared.
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secondary structure of the E protein.
6.2.3. Comparison of amino acid sequences of JE virus strains Saigon and 
Nakayama-Original passaged in Vero and C6-36 cell lines
From the studies above, it was not clear if the amino acid differences found 
in the E and M protein of JE DH20/p2 viruses grown in different cell lines was a 
common phenomenon of wild-type JE virus or unique to strain DH20. Nucleotide 
sequences of the structural protein genes of wild-type JE virus strains Nakayama- 
Original and Saigon grown in mosquito C6-36 cells have already been determined 
(see chapter 4). Therefore, the nucleotide sequences of the E protein gene of theses 
two viruses grown in monkey kidney Vero cells were determined. Comparison of the 
sequences of these two pairs of viruses grown in two cell lines showed that JE virus 
strain Nakayama-original had three amino acid differences at E-133 (Glu [Vero] - Lys 
[C6-36]), E-209 (Arg - Lys) and E-366 (Val - Ala); while strain Saigon had three 
amino acid differences at E-227 (Pro [Vero] - Ser [C6-36]), E-276 (Asn - Ser) and 
E-366 (Ala - Val).
6.3. Discussion
This chapter analyzed genotypic characteristics of five JE virus strains derived 
from JE wild-type DH20 virus isolated in Nepal. This low passage strain of JE virus
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was selected for study to avoid the influences of cell culture adaption. Consequently, 
the virus was not plaque purified prior to the biological and sequence analyses. The 
viruses had been maintained from a seed stock in five different cell lines comprising; 
human (SW13), monkey (Vero), avian (CEF) and an invertebrate mosquito larvae 
(C6-36). The biological studies have demonstrated a considerable heterogeneity of 
these DH20/p2 viruses and nucleotide sequencing revealed genetic differences in the 
E protein of these viruses.
Sequence analysis of the E protein and part of M protein genes of each of the 
five viruses demonstrated that amino acid differences were present between the 
viruses passaged in different cell lines. Thus, the biological differences observed are 
very unlikely to be due to post-translational modification of the envelope protein as 
suggested for BUN virus (James and Millican, 1986). DH20/p2 LLC-MK2 virus 
showed the most pronounced phenotypic changes (inability to be neutralized by a 
polyclonal antisera and loss of HA activity) of the cell lines investigated. This virus 
also contains three unique amino acid substitutions, of which E-291 (Thr ->  Met) is 
located in the putative neutralization and HA domain of the E protein, according to 
the model of Heinz and co-workers for tick-home encephalitis vims (Heinz et al. , 
1993). However, M-60 (Arg), E-107 (Leu) and E-291 (Met) of DH20/p2 LLC-MK2 
vims are the same as other wild-type JE vimses (chapter 4). The substitution of E- 
291 is quite dramatic going from a hydrophilic, polar amino acid to a hydrophobic 
nonpolar amino acid, which was predicted to alter the secondary stmcture of E 
protein. This amino acid change combined with other amino acid changes in the E 
protein gene may contribute to the biological phenotype differences of DH20/p2 LLC-
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MK2 virus compared to other DH20/p2 viruses.
Neutralization, HA and HAI results would suggest that the E protein and 
envelope of DH20/p2 viruses have been sufficiently altered to inhibit attachment, and 
cross linking of, antibodies, viruses and red blood cells. These results suggested that 
two factors may be influencing the observed neutralization patterns and HA activities, 
1 ) the cell line used to grow viruses and to assess residual virus infectivity, which has 
been reported for many other viruses (for a review see Dimmock, 1993); 2) changes 
in the E protein, either genetic or post-translational, due to the cell line used to 
produce the virus stock. Sequence comparison revealed that there were five unique 
amino acids in DH20/p2 LLC-MK2, Vero and SW13 viruses among the five 
DH20/p2 viruses but the three unique amino acids found in the LLC-MK2 virus are 
the same as equivalent position in other wild-type JE viruses (see chapter 4).
Two issues remain to be answered. Firstly, are the sequence differences in the 
E protein of the virus a result of mutation in the gene or selection of variants in the 
virus population that are best adapted for replication? The latter suggestion is 
supported by the observation that as many as 90% of the viruses quantifiable by 
plaque assay are not detectable when the virus is titred in LLC-MK2 cells (Wills, 
1991). Thus, the virus preparations contain at least two populations of viruses both 
of which infect Vero cells but only one could infect or replicate in the LLC-MK2 
cells. This observation is not unique to JE virus as James and Millican (1986) have 
reported similar observations with BUN virus. Finally, the minority of HA-positive 
virions in the DH20/p2 LLC-MK2 (Wills, 1991) supports the proposed heterogeneity
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of the virus population. Therefore, if DH20 virus had been plaque purified prior to 
these studies, the virus generated for the experiments would have depended on which 
cell line had been used. These results are consistent with the proposal that the virus 
population contains virions of different nucleotide sequence that are selectfi/dy 
enriched depending on cell line used to amplify the virus. This situation has been 
proposed for HeLa cell passage of JE virus (see chapter 5).
The second question to be answered is why are the virus populations different 
biologically and genetically. Sequence studies on the E protein genes of Saigon and 
Nakayama-Original strains passaged in Vero and C6-36 cells show that the variation 
observed for the DH20 virus is not unique to this strain. In comparison to most 
flaviviruses, JE virus has been reported to be isolated from, and replicate in, many 
vertebrates including humans, birds, swine and equines, as well as frogs, snakes and 
lizards. It is possible that the wide host range of JE virus is due to the ability of the 
virus to genetically and immunogenically adapt to different hosts. Since only E and 
part of M protein genes have been compared it is not known if genetic variation of 
JE virus passaged in different cell lines exist in other coding and non-coding regions. 
However, Arias et al. (1993) reported that NS3 protein of DEN-2 virus could be 
cleaved into NS3’ (50 KD) fragment at the conserved RNA helicase sequence motif 
when virus was grown in mammalian cells but not mosquito cells. This may indicate 
that genetic variation of flavivirus is not limited to the structural protein genes.
Therefore, it can be concluded that limited passage of wild-type JE viruses 
have dramatically changed the biological properties of the virus. Whether or not the
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virulence of the virus has also changed needs to be investigated. Also, it is not known 
if these amino acid changes in the passaged viruses are irreversible. The results above 
indicate that investigations of the biological and genetic properties of JE wild-type 
virus must incorporate suitable cell line(s) and keep the cell line(s) used and passage 
of the virus to a minimum. On the basis of the studies described above, LLC-MK2 
and Vero cell lines are not as advantageous as mosquito C6-36 cells for investigation 
of biological and genetic characteristics of JE virus.
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Chapter 7
Analysis of molecular basis of increased neuroinvasiveness
for mice of wild-type JE virus strain P3
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7.1 Introduction
JE virus replicates in a wide variety of primary and continuous cell cultures 
of porcine, hamster, chicken, monkey and mosquito origin. Monkey kidney Vero and 
LLC-MK2  cells are usefiil for plaque assays (Monath, 1990). It has been confirmed 
that mice provide a good model for studying pathogenicity of JE virus (Monath, 
1993).
Infant mice are highly susceptible to lethal infection by all routes of 
inoculation of JE virus (Monath, 1990). Considerable variation of neurovirulence, 
neuroinvasiveness and peripheral pathogenicity for mice among JE virus strains was 
first demonstrated many years ago (for a review see Huang, 1989). The pathogenicity 
of different strains of JE virus isolated from human cases and from mosquitoes were 
compared by intracerebral (i.e.) and subcutaneous (s.c.) routes of inoculation in 3- 
week-old mice. The results showed that there was not much variation by the i.e. route 
of inoculation. However, there were great differences in the log^ o pfu/LD^o when 
virus was inoculated subcutaneously. In particular, the Peking 3, or P3 strain, was 
reported to be a highly neurovirulent and neuroinvasive strain of JE virus for mice 
(Huang, 1989; Konishi et al., 1992a,b).
To analyze the potential molecular determinants responsible for increased 
neuroinvasiveness of JE virus, the entire genomic RNA of P3 virus was transcribed, 
then the cDNA was amplified and sequenced. The nucleotide and deduced amino
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sequence of P3 virus was then compared with published genomic sequences of other 
JE virus strains.
7.2 Results
7.2.1 Pathogenicity of wild-type JE virus strains P3, SA14 and S982 in
mice
In order to interpret the sequence data, the pathogenicity of three wild-type JE 
viruses, P3, SA14 and S982, were examined in weanling mice ( 3 - 4  weeks age) by 
inoculation of viruses either by i.e. or introperitoneal (i.p.) routes. All mice died 
within seven days following i.e. inoculation of 1,000 pfu of P3, SA14 or S982 
viruses. In comparison, mice inoculated with 10^  ^  pfu of SA14 virus by the i.p. route 
showed no clinical signs of disease and did not die. The log^ o pfu/LD^o of mice 
following inoculation of P3 virus or S*?^ 2 virus by the i.p. route is _< 3.7 and 6.2 
respectively. The average survival time of mice inoculated with S982 virus by the i.p. 
route is significantly longer than that of P3 virus (Table 7.1).
7.2.2 Cloning and sequencing of P3 virus
The entire RNA genome (10976 nucleotides) of P3 virus was reverse tran­
scribed and cDNA amplified by reverse transcription and PCR, then cloned and
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Table 7.1. Comparison of the pathogenicity of wild-type JE virus strains P3, S982 
and SA14 by inoculation of virus into weanling mice by the intraperitoneal route.
Virus
i.p. inoculation 
Logio LD5 0 AST*±SEM^
P3 0 . 7 7.4±0.26
SA14 >6.3 NA
6 . 2 9.2±0.26
AST: Average survival time. SEM: the standard error of the mean. NA: not 
le.
Lg
N
SEM
ov-i)
X: survival time of each mouse. X:Mean of survival time. N:number of mice died. 
Lg = logio-
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Table 7.2. Summary of nucleotide and amino acid differences of the entire genomic
sequences between three wild-type JE viruses.
Strain
Nucleotide
SA14/USA Sf^,2 P3
Amino SA14/USA 154 139
acid S9%2 15 246
P3 22 27
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Table 7.3. Comparison of the percentage amino acid homology of all structural 
proteins and all nonstructural proteins of three different strains of JE virus.
Virus
nonstructural proteins 
SA14/USA S982 P3
SA14/USA 99.5 99.5
structural S982 99.6 99.4
proteins P3 98.5 98.1
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sequenced. The genomic sequence of P3 virus (see appendix 1) was compared with 
sequences of SA 14 and S892 strains, assuming that the genomic sequences published 
are representative of the virus used in the mouse pathogenicity studies perfomed in
u-
this laboratory. This is likely as SA14/USA virus was obtained^^from Dr. Trent who 
sequenced it. Strain S982 was also from Dr. Trent who obtained from Dr. Sumiyoshi, 
who worked for Dr. Trent and sequenced S982 virus (Sumiyoshi et ah, 1987). A 
summary of the nucleotide and amino acid differences ofthe entire genome between; 
these viruses is shown in Tables 7.2. and 7.3.
Comparison of the three JE virus strains shows that P3 is very closely related 
to SA14/USA and S892 viruses (see Tables 7.2 and 7.3). In total, P3 virus differed 
with SA14/USA and S982 strains by 22 and 27 amino acids, and 139 and 154 
nucleotides, respectively. Among JE virus strains P3, SA14/USA and S982, 
homologies of nonstructural proteins are higher than that of structural proteins (Table 
7.3).
7.2.3 Nucleotide sequences of 5’ and 3’ non-coding regions
There are no nucleotide differences in the 5’ non-coding region between P3, 
SA14/USA and S982 viruses. There were 12 nucleotide differences in the 3’ non­
coding region, of which P3 virus had six unique nucleotide differences at positions 
10420, 10428, 10447, 10648, 10824 and 10890 compared with SA14/USA and S982 
viruses (Table 7.4). S982 virus had five unique nucleotides at positions 10405,
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Table 7.4. Comparison of nucleotide differences in and 3 ’ non-coding regions
between three wild-type JE virus strains.
Nucleotide
Position
P3 SA14/USA S982
10405 3’NC G G A
10420 3’NC C U U
10428 3’NC C U U
10447 3’NC U C C
10505 3’NC C c u
10642 3’NC u u G
10652 3’NC A A G
10784 3’NC C c U
10824 3’NC G A A
10890 3’NC A G G
10952 3’NC G G G
SA14/USA is taken from Trent (personal communication); S982 from Sumiyoshi et 
al. (1987); sequence of P3 is reported in this thesis.
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Table 7.5. Comparison of amino acid differences in the protein coding region
between three wild-type JE viruses.
Amino acid 
position
P3 SA14/
USA
S982 Amino acid 
position
P3 SA14/U S982 
SA
C-49 PHE Leu Leu NSl-292 Gly SER Gly
C-119 ALA Val Val NS2A-50 Phe Phe LEU
C-123 Cys Cys TYR NS2A-121 His His GLN
prM-2 ARC Lys Lys NS2B-56 GLN Arg Arg
M-48 Val Val THR NS2B-102 Met THR Met
E-46 THR lie He NS3-73 Lys ARG Lys
E-76 MET Thr Thr NS3-560 Lys Lys ARG
E-129 ALA Thr Thr NS4A-3 Val Val ILE
E-169 Val Val ILE NS4A-49 Lys ARG Lys
E-209 ARC Lys Lys NS4B-18 Gly Gly VAL
E-227 PRO Ser Ser NS5-121 Trp Trp ARG
E-306 GLY Glu Glu NS5-386 TYR His His
E-352 ALA Val Val NS5-452 ARG Cys Cys
E-388 GLU Gly Gly NS5-644 Asn Asn THR
E-408 LEU Ser Ser NS5-706 LEU His His
NSl-235 Gly ASP Gly
Sumiyoshi et al. (1987); sequences of P3 is reported in this thesis. The amino acid 
in capital letter is unique among the three viruses compared.
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10505, 10642, 10652 and 10784 (Table 7.4).
7.2.4 Comparison of deduced amino acid sequences of the protein coding 
regions
There were a total 22 of amino acid differences between strains P3 and 
SA14/USA. The majority of the amino acid differences (12 of 20) were in 
structuralprotein genes (Table 7.5). Eleven of these twelve amino acid differences 
were unique compared to other strains (C-49, C-119, prM-2, E-46, E-76, E-129, E- 
209, E-227, E-306, E-352, E-388 and E-408) (Table 7.5). Ten amino acids in 
nonstructural protein genes of P3 virus were different compared to that of SA14/USA 
and S982 viruses. However, only four of the ten amino acid differences in the 
nonstructural protein genes were unique at positions of NS2B-56 (Gin < ->  Arg), 
NS3-386 (Tyr < ->  His), NS5-452 (Arg < ->  Cys) and NS5-706 (Leu < ->  His) 
(Table 7.5). SA14/USA had five unique amino acids in nonstructural protein genes 
at position NSl-235, NS2B-102, NS3-73 and NS4A-49. S982 virus had three unique 
amino acids in the structural protein genes at position C-123, M-48 and E-169, and 
in the nonstructural proteins at positions NS2A-50, NS2A-121, NS3-560, NS4A-3, 
NS4B-18, NS5-121 and NS5-644.
7.2.5 Secondary structure prediction of the unique amino acid differences
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The unique amino acid differences found in P3 virus were analyzed by the 
Novotny method (Novotny and Auffray, 1984), which calculates hydrophobicity and 
predicts protein conformation and changes. In the structural proteins genes, six of 
twelve amino acids differences at positions C-119 (Ala < ->  Val)(h,a,b), E-76 (Ala 
< ->  Thr)(h,a,t), E-129 (Ala < ->  Thr)(a,b,t), E-306 (Gly < ->  Glu) (c,a,b,t), 
E-352 (Ala < ->  Val)(h,a,b), E-388 (Glu < ->  Gly)(c,a,b,t) and E-408 (Leu < ->  
Ser)(h,a,b,t) were predicted to change at least three of five secondary structures 
analyzed (hydrophobicity profile [h], charged residues profile [c], alpha helix 
propensity [a], beta sheet propensity [b] and reverse turn propensity [t]) of C and E 
proteins of P3 virus (Fig. 7.1 and 7.2). Two of four unique amino aciddifferences in 
the nonstructural protein genes at position NS5-386 (Tyr < ->  His) and NS5-706 
(Leu < - > His) were predicted to change the secondary structure of hydrophobicity 
profile, alpha helix propensity, beta sheet propensity and reverse turn propensity (Fig.
7X%.
7.2.6 Analysis of amino acid differences in the non structural protein
genes
The amino acid NS2B-56 is located in the essential 40 amino acid central 
region of NS2B, which is, Arg or Lys, conserved in the mosquito transmitted 
flaviviruses (Fig. 7.4). NS5-386 of P3 virus is the same as two vaccine viruses 
(SA14-14-2/PHK and SA14-14-2/PDK, see chapter 3). When several flaviviruses 
were compared, the amino acids in NS5 protein at positions of NS5-386 and NS5-706
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C-119 E-76 E-129
Fig. 7.1. The secondary structure curves of the sequences surrounding the unique 
amino acid of P3 virus at positions of C-119, E-76 and E-129 of the E protein. The 
top half is the result form P3 virus and bottom half is that of SA14/USA virus. Turn: 
reverse turn propensity. Beta: beta sheet propensity. Alpha:alpha helix propensity. +- 
: charged residues profile. Hydro: hydrophobicity profile.
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Fig. 7.2. The secondary structure curves of the sequences surrounding the unique 
amino acid of P3 virus at positions of E-306, E-352, E-388 and E-408 of the E 
protein. The top half is the result form P3 virus and bottom half is that of SA14/USA 
virus. Turn: reverse turn propensity. Beta: beta sheet propensity. Alpha:alpha helix 
propensity. +-: charged residues profile. Hydro: hydrophobicity profile.
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Fig. 7.3. The secondary structure curves of the sequences surrounding the unique 
amino acid of P3 virus at positions of NS5-386 and NS5-706 of the NS5 protein. The 
top half is the result form P3 virus and bottom half is that of SA 14/USA virus. Turn: 
reverse turn propensity. Beta: beta sheet propensity. Alpha:alpha helix propensity. +- 
: charged residues profile. Hydro: hydrophobicity profile.
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Fig. 7.4. Alignment of essential 40 amino acids in central region of NS2B domain 
from several mosquito transmitted flaviviruses. *: conserved amino acids. !: Amino 
acid substituted in JE vaccine viruses derived from SA14 virus. The sequences of 
DEN-1 and DEN-3 viruses are taken from Fu et al. (1992) and Osatomi and 
Sumiyoshi (1990), the remainder are taken from Falgout et al. (1993).
N S2B-56  
NS2B-> !
DEN-1 (56AA) LEKAAEVSWEEEAEHSGASHNILVEVQDDGTMKIKDEERD
DEN-2 (56AA) . .R.  . D . K.  . .Q.  . 1 .  . S . P I L S I T I S E . . S . S .  . N.  .NN
DEN-3 (56AA) V  D . T . . . E . . QT. V . H . LMIT. D . . . T . R  TE
DEN-4 (56AA) ............ N . Q. D . M. D I T . S . P I . E . KQDE. . S F S . R . V . ET
J E- SA1 4 ( 54 A A )  . . R . . D I . . . MD. A I T . S . RRLD. KLD. . .DFHLI.DPGV
JE- P3  (54AA) . . Q . . D I . . . MD. AI T. S . R RLD. KLD . . .DFHLI.DPGV
WN (54AA) I . R T . D I T . . S D . . I T . S . E R V D . R L D . . .NFQLMNDPGA
KUN (54AA) I . RT. D I . . . GD. . I T . . . ERVD. RLD. . . NFQLMNDPGA
MVE (54AA) . . R . . D  AG. AIT.  T.  ERLD. QLD. . . DFHLLVDPGV
YF (53AA) .K.LGE . . . I . . S . ARYD. ALSEQ. E F . L L S . . KV
TBE (53AA) A.WSGG. E . HP. LMNE. CEVSLR. RQDSM. NFHLTELEKE
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were variable (data not shown). However, the amino acid at position NS5-452 is 
very conserved. All flaviviruses compared are Cys, but P3 virus is Arg, at this 
position (Fig. 7.5).
7.3 Discussion
The mouse pathogenicity results confirmed previous studies that P3 virus is 
significantly more neuroinvasive than strains SA14 and S982. The pfu/LD^o of P3 
virus is _< 10^  ^ , and of S982 virus is 10^  ^ following introperitoneal inoculation of 
weanling mice, while JE virus strain SA14 did not kill mice when virus was 
inoculated in this route (i.e. ^  10^  ^pfu/Ld^o). Nevertheless, the genomic similarity 
between P3 virus and strains SA14 and S982 is over 97.8% at the nucleotide level 
and 99% at the amino acid level.
Comparison of genomic sequences of the P3 virus with the sequences of other 
JE viruses revealed that structural protein genes are more divergent than nonstructural 
protein genes (Tables 7.2 and 7.3). Eight unique amino acids were in the E protein 
gene. None of these amino acids are shared with other wild-type JE virus strains (see 
chapter 4). Six of the amino acids were predicted to change the secondary structure 
of the E protein (Figs. 7.1 and 7.2). Therefore, these amino acid differences may be 
related to the high neuroinvasiveness of P3 virus. The unique amino acid difference 
at position E-306 (Glu < ->  Gly) may be of particular importance in relation to 
increased neuroinvasive. It has been found that an amino acid mutation at amino acid
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Fig. 7.5. Alignment of 21 amino acids surrounding NS5-452 in JE virus with several 
flaviviruses. The sources of the sequences are the same as those in Fig. 7.4.
N S 5 - 4 5 2
D E N - 1 ( 4 3  9AA) 
DEN-2(439AA)  
D E N - 3 ( 4 3  9AA) 
DEN-4(438AA)
ELHKQGKCATCVYNMMGKREKK
N . . L E . . . E .................................
. . . . L . . . G S . .
A . . Q . . . . E S . .
J E- S A1 4 (4 4 2A A )  . N . L R . E . H . . I .
J E - P 3  (442AA) . N . L R . E . H . R I .
WN(442AA)  
KUN(442AA)  
MVE (442AA)  
YF(441AA)  
TBE(44 0AA)
. A . L R . E . H . . I .
. A . LR. E . H . . I . 
. C . L R . E . R . . I .
K . . Q . . R . . H . . .
. R . L A . R . . H . V .........................
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E-303 (Lys > Gin) of yellow fever vaccine revertant P-16065 increased the 
neurovimlence damatically ; and has been confirmed by
recombinant chimeric viruses (Barrett, personal communication). It was also reported 
that an epitope containing amino acid E-308 clearly has significance in determining 
the pathogenic characteristics of louping ill virus (Jiang et a l ,  1993; Gao et a l ,  
1994). The amino acids between E-300 and E-390 belong to the domain B of the E 
protein (Heinz et a l , 1993). Two studies suggest that this region may be involved in 
tissue tropism, and perhaps in virus-host cell interactions (Heinz et a l , 1990; Lobigs 
et a l , 1990). It is difficult to interpret which of these amino acid differences in the 
structural protein genes are due to mouse brain passage or an inherited property of 
P3 virus since the detailed passage history of P3 virus is unknown. However, Huang 
(1989) reported that repeated intracerebal passages of JE virus in mice lead to a 
decrease in peripheral pathogenicity. Thus, the amino acid substitutions resulting from 
mouse passage would not be predicted to be responsible for the high 
neuroinvasiveness of P3 virus.
There were no unique amino acid differences between JE virus strains P3, 
SA14 and S982 in the M, NSl, NS2A, NS3, NS4A and NS4B protein genes, which 
suggests that these proteins are probably not directly involved in increasing 
neuroinvasiveness of P3 virus. It was found that one unique amino acid at NS2B-56 
is located in the essential 40 amino acid in central region of NS2B, which was 
required for site-specific cleavage of polyprotein of flaviviruses, i.e., the functional 
proteinase requires a complex of NS2B and NS3 proteins (Chambers et a l ,  1990). 
NS2B-56 is conserved in the JE serocomplex flaviviruses that have been examined so
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far (Fig. 7.4).
Three unique amino acids at positions NS5-386, NS5-452 and NS5 706 in P3
virus are in the RNA polymerase domain of NS5 protein. However, they are not in
the highly conserved region of all flaviviruses (in JE virus, residues 531-675) which
contains the sequence motif Gly-Asp-Asp (Rice et a l ,  1985, 1986). This motif is
present in the polymerase region and is believed to play a role in RNA-dependent
RNA synthesis of several positive stranded RNA viruses (Kamer and Argos, 1984).
Nevertheless, NS5-452 is in the region conserved among JE serocomplex flaviviruses
that have been sequenced (Fig. 7.5). This amino acid difference may be significant
tàjL .
as strain P3 kills mice very rapidly following inoculation of virus into mice by^ _i.p. 
route, which may in part be due to an altered polymerase or 3’ non-coding region 
differences that either reduces the replication cycle time and/or increases the quantity 
of virus generated during replication. Whether or not these amino acid differences in 
NS2B and NS5 protein genes would increase serine proteinase and polymerase 
activity needs to be studied with recombinant vaccinia viruses or infectious clone 
technologies.
In conclusion, P3 virus is more neuroinvasive than JE virus strains SA14 and 
S982 although the genomic similarity of these three viruses are very high. The M, 
NSl, NS2A, NS3, NS4A and NS4B proteins appear to make no obvious contribution 
to the high neuroinvasiveness of P3 virus. The structural proteins, NS2B and NS5 
proteins and 3’ non-coding region may be involved in increasing neuroinvasiveness 
of P3 virus.
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Chapter 8
General Discussion
217
The aim of these studies was to employ molecular biological techniques to 
investigate the molecular basis of attenuation, neurovimlence and neuroinvasiveness 
for JE vimses. ^  #enuation was analyzed by determining the nucleotide sequence of 
the genome of the live vaccine strain SA14-2-8 and comparison with the genomic 
sequences of related SA14-14-2/PHK and SA14-14-2/PDK vaccine strains and the 
wild-type parental strain SA14. Neurovimlence and neuroinvasiveness were studied 
by determining the nucleotide sequence of the genome of highly neurovimlent and 
neuroinvasive wild-type strain P3 and comparison of the sequence obtained to that of 
other wild-type, but less vimlent, strains of JE vims, SA14 and S982. In addition, 
the stmctural protein genes of twelve wild-type strains were examined to aid the 
genomic analysis, including two strains attenuated by passaged in HeLa cells. The 
sequence data obtained was interpreted with respect to biological and antigenic studies 
performed in this and other laboratories.
The complete genomes of three flavivimses wild-type parent-live attenuated 
vaccine pairs have been determined and compared (YF: Asibi and 17D-204 (Rice et 
a l ,  1985; Hahn et al., 1987; Dupuy et al., 1989), JE: SA14 and SA14-14-2 (Aihara 
et al., 1991; Nitayaphan et al., 1990) and DEN-2: 16681 and 16681/PDK53 (Blok 
et al., 1992). However, large number of mutations between these parents and their 
attenuated vaccine vimses have been found in those studies so that the genetic 
mutations responsible for the attenuation phenotype could not be ' identified.
A number of important points arose from the work described in this thesis. 
Firstly, the data obtained suggests that the flavivims serine proteinase may be altered
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in the attenuated phenotype. The serine proteinase of flaviviruses consists of NS2B 
and the N terminal approximate 180 amino acids of the NS3 protein (Chambers et a l  
1990b) and has been demonstrated to mediate several cleavages in the viral 
polyprotein. Examination of the three common changes of the vaccine viruses in the 
non-structural protein genes reveals that the change at position NS3-105 is in the 
serine proteinase domain of this protein but not in the active site residues of the NS3 
proteinase (Fig. 3.4), and NS2B-63 is found in the 40 amino acid "central region" of 
NS2B that is conserved between flaviviruses, and may be important as the glutamic 
acid seen at position NS2B-63 in wild-type strains of JE virus is also seen in the 
analogous position of nine other mosquito-bome flaviviruses that have been 
sequenced, except DEN-4 virus.
Analysis of nucleotide and amino acid sequence data of JE virus obtained to 
date suggests that the viral proteinase may be mutated in the vaccine viruses. 
However, this has not been experimentally investigated. Clearly, experession of
nonstructural protein genes in a recombinant vaccinia vector would help to answer
tàjL
this hypothesis. Determination of precise molecular basis for attenuation of 
neurovirulence of SA14 virus, particularly the substitutions in the NS2B/NS3 serine 
proteinase complex could not only lead to generate suitable vaccine(s) to control JE 
but also a/d in developing vaccines to control other neurotropic flavivirus infections, 
for example, the DEN virus complex which have no vaccines available yet.
Secondly, the E protein is known to play an important role in viral entry 
(Chambers et al., 1990). Hence, two common amino acid substitutions in E protein
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at E-138 and E-176 found in attenuated vaccine viruses might contribute to 
attenuation through decreasing the ability of virus binding to cells (i.e. the interaction 
between JE virus E protein and cell receptor). This hypothesis is supported by the 
observation that the vaccine strains did not bind to dopamine D2 and/or 5HTi subtype 
receptor recognized by the antagonist ligand spiperone whereas the wild-type virulent 
parent strain SA14 did (Barrett et a l , 1991).
The genomic similarities between JE virus strains P3, SA 14 and S982 are very 
high, over 98% at the nucleotide level and 99% at the amino acid level. P3 virus is 
clearly more neurovirulent and neuroinvasive than JE virus strains SA14 and S982. 
No unique amino acid differences of P3 virus in M, NSl, NS2A, NS3, NS4A and 
NS4B proteins have been found compared with SA14 and S982 strains, which 
suggests that these proteins probably make no direct contribution to the high 
neurovirulence and neuroinvasiveness of P3 virus. Conversely, the structural, NS2B 
and NS5 proteins and 3’ non-coding region are probably involved in increasing 
neuroinvasiveness of P3 virus. /Precise identification of the molecular determinant of 
neuroinvasiveness will require construction of chimeric infections clone derived virus 
(see below).
One major conclusion to be drawn from the comparison of biological and 
genetic changes among wild-type DH20/p2 viruses passage in different cells (chapter 
6) and also between wild-type parents Nakayama/HPO and 826309/HP0 and their 
attenuated derivatives after six passages in the HeLa cells (chapter 5) is that limited 
passage of wild-type JE virus dramatically altered the biological properties of the
220
virus. This could be due to environmental selection pressure during cell passage or 
acquired biological characteristics from the cell membrane during cell passage as the 
wild-type JE virus adapted to cells. Thus, the studies in this thesis indicate that the 
biological and genetic properties of JE wild-type virus must be carefully examined at 
the cell line(s) used and cell passages to be kept at minimum. With this in mind it 
was noted that passage of virus in mosquito C6-36 cells retained HA/HAI and 
neutralization properties of the virus. Thus, the virus sequences in this thesis were 
propagated in C6-36 cells prior to RT-PCR reaction.
Antigenic, biochemical and genetic differences between wild-type JE virus 
strains isolated from different areas have been observed by cross-neutralization 
(Banerjee, 1975), oligonucleotide fingerprinting (Banerjee and Ranadive, 1984; Hori, 
1986), monoclonal and polyclonal antibody reactivities (Kobayashi et al. , 1984, 1985; 
Wills et al. , 1992), and by limited (240 bp) genomic sequence comparison (Chen et 
al., 1990, 1992). However, several questions still need to be answered: what are the 
molecular basis of strain variation and significance of the variation, are the antigenic 
differences among the JE viruses important in terms of control of JE with vaccines, 
and are these strain variations related to their geographic locations? Genetic analysis 
of structural protein genes combined with other vaccination studies of several wild- 
type JE viruses provided answers and important clues for these questions. A decision
was made to concentrate on the structural protein genes of these wild-type JE viruses
iÀlL.
for a number of reasons. Firstly, it is too much work to sequence^11  genomic 
RNA of many strains. Secondly, structural protein genes of JE virus are well studied 
and their functions are reasonably well understood. Furthermore, the flavivirus E
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protein encodes the viral haemagglutinin, induces protective immunity and mediates 
receptor-specific virus attachment to the cell surface (Brinton, 1986). This protein 
plays a major role in the pathogenicity of the virus by determining cellular tropism 
and/or affecting virus penetration into susceptible cells (Gollins and Porterfield, 1984; 
Heinz, 1986).
Comparison of structural protein genes of 10 wild-type JE viruses revealed 
high genetic homology of these strains studied. The viruses differed from each other 
only by between 21 (0.9%) to 111 (4.6%) nucleotides and by between 3 (0.4%) to 
31 (4.2%) amino acids over the 2434 nucleotides examined (chapter 4). The 
dendrogram in Fig. 4.4 based on the amino acid sequences of these wild-type JE 
viruses indicates that strain variation amongst the JE viruses studied is not related to 
their geographic locations, which agrees with most other studies. It is also found that 
the most probable explanation for strain variation of JE virus is variation in particular 
amino acids in the structural proteins. The different combinations of these variable 
amino acids plus a limited number of unique amino acid changes in the viruses may 
have resulted in the strain variation detected by serological tests. Of potential 
importance is that three variable amino acids identified were located in the T-helper 
epitopes revealed by studying MVE and DEN-2 viruses. Therefore, the antigenic 
variation among the various immunotypes of JE virus as seen at the level of the B-cell 
response may represent differences in T-helper cell epitopes due to residue changes 
at E-51, E-244 and E-366 defined by MVE virus (Mathews et a l ,  1992). Littlehas 
been published on T cells epitopes of JE virus. This area requires further work to 
complement the extensive literature on B cell epitopes.
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Finally, this thesis has shown that there are relatively few nucleotide changes 
outside the structural protein genes on the basis of the strains studied, among wild- 
type JE virus strains and between virulent parental virus SA14 and its attenuated 
vaccine virus derivatives. The homologies of structural protein genes among wild-type 
strains SA14, S982 and P3 are between 99.6% and 98.1%, while homologies in 
nonstructural protein genes are between 99.5% and 99.4% (see Table 7.2). The 
variation among wild-type parent and attenuated vaccine viruses in the structural 
protein genes is 1.89% (15/795) whereas in nonstructural protein genes it is only 
0.99% (26/2637) (see Table 3.3).
In total, this project has added approximately 50 kilobases of sequence data 
to that which previously existed for JE virus. Such data is vital in furthering our 
understanding of molecular biology of JE virus, as related to the disease it causes, 
and to attenuation and virulence. The nature of these studies meant that, rather than 
providing definitive answers to these questions, it enables the number of possibilities 
to be reduced, and concentrates on laying the foundations for future work. A number 
of exciting directions are available for further study. An infectious clone exists for 
JE virus (Sumiyoshi et al., 1992), which could be used to produce a series 
recombinant viruses with single or several different combinations of mutated amino 
acids in the E, NS2B and NS3 proteins found in attenuated vaccine viruses derived 
from wild-type strain SA14, or unique amino acids found in P3 strain. Subsequently 
biological and pathogenical analysis of recombinant JE viruses will provide useful 
information to elucidate some of the theories and proposals presented here. Also,
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expression of the JE virus proteins alone or in different combinations based on 
recombinant vaccinia virus technology could be employed to analyze the function of 
important amino acids.
Unfortunately, several questions are still shrouded in mystery: the molecular 
basis of mosquito competence of JE virus, nature of the "vaccine" specific epitopes 
and function of amino acid substitutions found in vaccine viruses derived from SA14 
virus. All of these questions require further studies. Infectious clone technology may 
help to find the answers.
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A p p e n d ix  1
60
S A 14/U S A  AGAAGTTTATCTGTGTGAACTTCTTGGCTTAGTATCGTTGAGAAGAATCGAGAGATTAGT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
1 2 0
SA 14 /U S A  GCAGTTTAAACAGTTTTTTAGAACGGAAGATAACCATGACTAAAAAACCAGGAGGGCCCG
S A 1 4 - 2 - 8  .................... .. ...................... .. .......................................................................................................................
P3 ........................................................................................................................................................................
1 8 0
SA14 /U S A  GTAAAAACCGGGCTATCAATATGCTGAAACGCGGCCTACCCCGCGTATTCCCACTAGTGG
S A 1 4 - 2 - 8  ................. ......................................................................................................................................................
P3  T ...................................................................
2 4 0
S A 14/U S A  GAGTGAAGAGGGTAGTAATGAGCTTGTTGGACGGCAGAGGGCCAGTACGTTTCGTGCTGG
S A 1 4 - 2 - 8  ..................................... .. ...............................................................................................................................
P3   A . . . .
3 0 0
S A 14 /U S A  CTCTTATCACGTTCTTCAAGTTTACAGCATTAGCCCCGACCAAGGCGCTTTTAGGCCGAT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . T ................................................................................................................................................................
3 6 0
SA14 /U S A  GGAAAGCAGTGGAAAAGAGTGTGGCAATGAAACATCTTACTAGTTTCAAACGAGAACTTG
S A 1 4 - 2 - 8  ............................................................................................................ ............................................................
P3  A ............................. C .............C .....................................................
4 2 0
SA14 /U S A  GAACACTCATTGACGCCGTGAACAAGCGGGGCAGAAAGCAAAACAAAAGAGGAGGAAATG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
4 8 0
S A 14/U S A  AAGGCTCAATCATGTGGCTCGCGAGCTTGGCAGTTGTCATAGCTTGTGCAGGAGCCATGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3....................  C ........................ G ............................... T . . . .
5 4 0
S A 14/U S A  AGTTGTCGAATTTCCAGGGGAAGCTTTTGATGACCATCAACAACACGGACATTGCAGACG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 G ...............A ..................................................................................................................................................
6 0 0
S A 14/U S A  TTATCGTGATTCCCACCTCAAAAGGAGAGAACAGATGCTGGGTCCGGGCAATCGACGTCG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ...................
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6 6 0
S A 14/U S A  GCTACATGTGTGAGGACACTATCACGTACGAATGTCCTAAGCTTACCATGGGCAATGATC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
7 2 0
S A 14 /U S A  CAGAGGATGTGGATTGCTGGTGTGACAACCAAGAAGTCTACGTCCAATATGGACGGTGCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C. . T .........................................................................................................................
7 8 0
S A 14 /U S A  CGCGGACCAGGCATTCCAAGCGAAGCAGGAGATCCGTGTCGGTCCAAACACATGGGGAGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 .................................................................................................................................................... ....................
8 4 0
SA14 /U S A  GTTCACTAGTGAATAAAAAAGAGGCTTGGCTGGATTCAACGAAAGCCACACGATATCTCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
9 0 0
S A 14/U S A  TGAAAACTGAGAACTGGATCATAAGGAATCCTGGCTATGCTTTCCTGGCGGCGGTACTTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
9 6 0
S A 14/U S A  GCTGGATGCTTGGCAGTAACAACGGTCAACGCGTGGTATTTACCATCCTCCTGCTGTTGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C .........................................................................................................................
1 0 2 0
S A 14 /U S A  TCGCTCCGGCTTACAGTTTTAATTGTCTGGGAATGGGCAATCGTGACTTCATAGAAGGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C . . CT.............................................................................................
1 0 8 0
S A 14/U S A  CCAGTGGAGCCACTTGGGTGGACTTGGTGCTGGAAGGAGATAGCTGCTTGACAATCATGG
S A 1 4 - 2 - 8   A .C ...............................
P3  G ............................................... A ..............................................................................
1 1 4 0
SA14 /U S A  CAAACGACAAACCAACATTGGACGTCCGCATGATTAACATCGAAGCTAGCCAACTTGCTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C .........................................................................
1 2 0 0
S A 14/U S A  AGGTCAGAAGTTACTGCTATCATGCTTCAGTCACTGACATCTCGACGGTGGCTCGGTGCC
S A 1 4 -2 8  ........................................................................................................................................................................
P3 .A ....................................................................................................................................................................
1 2 6 0
S A l4 /U S A  CCACGACTGGAGAAGCCCACAACGAGAAGCGAGCTGATAGTAGCTATGTGTGCAAACAAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . . T ...............................................................................................................................................................
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1 3 2 0
S A 14 /U S A  GCTTCACTGACCGTGGGTGGGGCAACGGATGTGGACTTTTCGGGAAGGGAAGCATTGACA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3..................... T ..................................................................................................A ............................... T .
1 3 8 0
S A l4 /U S A  CATGTGCAAAATTCTCCTGCACCAGTAAAGCGATTGGGAGAACAATCCAGCCAGAAAACA
S A 1 4 - 2 - 8   C .............A ........................................................
P3  G .........................................
1 4 4 0
S A l4 /U S A  TCAAATACGAAGTTGGCATTTTTGTGCATGGAACCACCACTTCGGAAAACCATGGGAATT
S A 1 4 - 2 - 8   A ...............................................................................................................................................
P3 ........................................................................................................................................................................
1 5 0 0
S A l4 /U S A  ATTCAGCGCAAGTTGGGGCGTCCCAGGCGGCAAAGTTTACAGTAACACCCAATGCTCCTT
S A 1 4 - 2 - 8 .... .................................................................................................................................................... ....................
P3 ........................................................................................................................................................................
1 5 6 0
S A l4 /U S A  CGATAACCCTCAAACTTGGTGACTACGGAGAAGTCACACTGGACTGTGAGCCAAGGAGTG
S A 1 4 - 2 - 8  . . G .................... G .......................................................................................................................................
P3  T ......................................................................
1 6 2 0
S A l4 /U S A  GACTGAACACTGAAGCGTTTTACGTCATGACCGTGGGGTCAAAGTCATTTCTGGTCCATA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ................................................................G ...................T .........................
1 6 8 0
S A l4 /U S A  GGGAGTGGTTTCATGACCTCGCTCTCCCCTGGACGTCCCCTTCGAGCACAGCGTGGAGAA
S A 1 4 - 2 - 8 ...   C .....................................................
P3  A .................................................................................. C . ................ ................................................
1 7 4 0
S A 14 /U S A  ACAGAGAACTCCTCATGGAATTTGAAGAGGCGCACGCCACAAAACAGTCCGTTGTTGCTC
S A 1 4 - 2 - 8 ... G ..........................................................................................
P3    T ..............................................................
1 8 0 0
S A 14 /U S A  TTGGGTCACAGGAAGGAGGCCTCCATCAGGCGTTGGCAGGAGCCATCGTGGTGGAGTACT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
1 8 6 0
SA 14 /U S A  CAAGCTCAGTGAAGTTAACATCAGGCCACCTGAAATGTAGGCTGAAAATGGACAAACTGG
S A 1 4 - 2 - 8  ....................................................................... .. ..............................................................................................
P3 ........................................................................................................................................................................
1 9 2 0
S A l4 /U S A  CTCTGAAAGGCACAACCTATGGCATGTGTACAGAAAAATTCTCGTTCGCGAAAAATCCGG
S A 1 4 - 2 - 8  ................................................................................................................. ......................................................
P3  C . . . .  G ..................... ...................................................
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1 9 8 0
S A 14 /U S A  CGGACACTGGTCACGGAACAGTTGTCATTGAACTCTCCTACTCTGGGAGTGATGGCCCCT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .
2 0 4 0
S A 14 /U S A  GCAAAATTCCGATTGTTTCCGTTGCGAGCCTCAATGACATGACCCCCGTTGGGCGGCTGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C .......................................................................................C ..............................
2 1 0 0
S A 14/U S A  TGACAGTGAACCCCTTCGTCGCGACTTCCAGTGCCAACTCAAAGGTGCTGGTCGAGATGG
S A 1 4 - 2 - 8   T ..........................................................................................................................................
P3 ........................................................................................................................................................................
2 1 6 0
S A 14/U S A  AACCCCCCTTCGGAGACTCCTACATCGTAGTTGGAAGGGGAGACAAGCAGATCAACCACC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3..................... A ........................................................
2220
SA14 /U S A  ATTGGCACAAAGCTGGAAGCACGCTGGGCAAGGCCTTTTCAACAACTTTGAAGGGAGCTC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3    A .................. T ........................................................
2 2 8 0
S A 14 /U S A  AAAGACTGGCAGCGTTGGGCGACACAGCCTGGGACTTTGGCTCTATTGGAGGGGTCTTCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C .............................................
2 3 4 0
S A l4 /U SA  ACTCCATAGGAAAAGCCGTTCACCAAGTGTTTGGTGGTGCCTTCAGAACACTCTTTGGGG
S A 1 4 - 2 - 8   G ....................................................................................................................................
P3 ........................................................................................................................................................................
2 4 0 0
S A 14/U S A  GAATGTCTTGGATCACACAAGGGCTAATGGGTGCCCTACTGCTCTGGATGGGCGTCAACG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  A ........................................T . .T .
2 4 6 0
S A l4 /U SA  CACGAGACCGATCAATTGCTTTGGCCTTCTTAGCCACAGGGGGTGTGCTCGTGTTCTTAG
S A 1 4 - 2 - 8  ................................................................................................................A ....................................................
P3  A .....................................................
2 5 2 0
S A 14/U S A  CGACCAATGTGCATGCTGACACTGGATGTGCCATTGACATCACAAGAAAAGAGATGAGAT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G.
2 5 8 0
S A l4 /U SA  GTGGAAGTGGCATCTTCGTGCACAACGACGTGGAAGCCTGGGTGGATAGGTATAAATATT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
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2 6 4 0
SA14 /U SA  TGCCAGAAACGCCCAGATCCCTAGCGAAGATCGTCCACAAAGCGCACAAGGAAGGCGTGT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ........................................................................................................
2 7 0 0
S A 14 /U S A  GCGGAGTCAGATCTGTCACTAGACTGGAGCACCAAATGTGGGAAGCCGTAAGGGACGAAT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T . . .C ........................
2 7 6 0
S A 14/U S A  TGAACGTCCTGCTCAAAGAGAATGCAGTGGACCTCAGTGTGGTTGTGAACAAGCCCGTGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ............................................
2 8 2 0
SA14 /U S A  GAAGATATCGCTCAGCCCCTAAACGCCTATCCATGACGCAAGAGAAGTTTGAAATGGGCT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . G . . .............................................................................................................................................................
2 8 8 0
S A l4 /U S A  GGAAAGCATGGGGAAAAAGCATCCTCTTTGCCCCGGAATTGGCTAACTCCACATTTGTCG
S A 1 4 - 2 - 8   T ........................................................................................................
P3 ........................................................................................................................................................................
2 9 4 0
S A 14 /U S A  TAGATGGACCTGAGACAAAGGAATGCCCTGATGAGCACAGAGCTTGGAACAGCATGCAAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
3 0 0 0
S A l4 /U S A  TCGAAGACTTCGGCTTTGGCATCACATCAACCCGTGTGTGGCTGAAAATTAGAGAGGAGA
S A 1 4 - 2 - 8  ................................................................................................................................................. ......................
P3
3 0 6 0
S A 14/U S A  GCACTGACGAGTGTGATGGAGCGATCATAGGCACGGCTGTCAAAGGACATGTGGCAGTCC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
3 1 2 0
S A 14/U S A  ATAGTGACTTGTCGTACTGGATTGAGAGTCGCTACAACGACACATGGAAACTTGAGAGGG
S A 1 4 - 2 - 8   G ..................................................................................................
P3 ........................................................................................................................................................................
3 1 8 0
S A 14/U S A  CAGTCTTTGGAGAGGTCAAATCTTGCACTTGGCCAGAGACACACACCCTTTGGGGAGATG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
3 2 4 0
S A 14/U S A  ATGTTGAGGAAAGTGAACTCATCATTCCGCACACCATAGCCGGACCAAAAAGCAAGCACA
S A 1 4 - 2 - 8  . . . C .............................................................................................................................................................
P3 G .................................................................................. T ...............................................................................
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3 3 0 0
S A 14/U S A  ATCGGAGGGAAGGGTATAAGACACAAAACCAGGGACCTTGGGATGAGAATGGCATAGTCT
S A 1 4 - 2 - 8   C .............C ...........................
P3 ........................................................................................................................................................................
3 3 6 0
S A 14/U S A  TGGACTTTGATTATTGCCCAGGGACAAAAGTCACCATTACAGAGGATTGTAGCAAGAGAG
S A 1 4 - 2 - 8  ............................................................................................................................................. G .......................
P3  G ........................
3 4 2 0
S A 14 /U S A  GCCCTTCGGTCAGAACCACTACTGACAGTGGAAAGTTGATCACTGACTGGTGCTGTCGCA
S A 1 4 - 2 - 8  ........................................................................................................... ............................................................
P3 ........................................................................................................................................................................
3 4 8 0
S A 14 /U S A  GTTGCTCCCTTCCGCCCCTACGATTCCGGACAGAAAATGGCTGCTGGTACGGAATGGAAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ..................................... .. ................................................................................................................................
3 5 4 0
S A 14/U S A  TCAGACCTGTTAGGCATGATGAAACAACACTCGTCAGATCACAGGTTGATGCTTTCAATG
S A 1 4 - 2 - 8   C .............
P3  T . . . .
3 6 0 0
S A 14/U S A  GTGAAATGGTTGACCCTTTTCAGCTGGGCCTTCTGGTGATGTTTCTGGCCACCCAGGAGG
S A 1 4 - 2 - 8   C ........................................A .
P3 ........................................................................................................................................................................
3 6 6 0
S A 14 /U S A  TCCTTCGCAAGAGGTGGACGGCCAGATTGACCATTCCTGCGGTTTTGGGGGCCCTACTTG
S A 1 4 - 2 - 8  ........................................................................................................................................... ............................
P3 ........................................................................................................................................................................
3 7 2 0
S A 14/U S A  TGCTGATGCTTGGGGGCATCACTTACACTGATTTGGCGAGGTATGTGGTGCTAGTCGCTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
3 7 8 0
S A 14/U S A  CTGCTTTCGCAGAGGCCAACAGTGGAGGAGACGTCCTGCACCTTGCTTTGATTGCCGTTT
S A 1 4 - 2 - 8   T . . . .
P3 ........................................................................................................................................................................
3 8 4 0
S A 14/U S A  TTAAGATCCAACCAGCATTTCTAGTGATGAACATGCTTAGCACGAGATGGACGAACCAAG
S A 1 4 - 2 - 8  ......................................................T ..............................................................................................................
P3 .C .....................................................................................................................................................................
3 9 0 0
S A 14/U S A  AAAACGTGGTTCTGGTCCTAGGGGCTGCCTTTTTCCAATTGGCCTCAGTAGATCTGCAAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
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3 9 6 0
S A l  4 /U S A  TAGGAGTCCACGGAATCCTGAATGCCGCCGCTATAGCATGGATGATTGTCCGAGCGATCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
4 0 2 0
S A 14/U S A  CCTTCCCCACAACCTCCTCCGTCACCATGCCAGTCTTAGCGCTTCTAACTCCGGGGATGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .................................................................. ...............................................................................
4 0 8 0
S A 14/U S A  GGGCTCTATACCTAGACACTTACAGAATCATCCTCCTCGTCATAGGGATTTGCTCCCTGC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ............................................................................. .................................... ......................................................
4 1 4 0
SA14 /U S A  TGCACGAGAGGAAAAAGACCATGGCAAAAAAGAAAGGAGCTGTACTCTTGGGCTTAGCGC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ..................... .. ......................
4 2 0 0
S A 14/U S A  TCACATCCACTGGATGGTTCTCGCCCACCACTATAGCTGCCGGACTAATGGTCTGCAACC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ................................................................. .. ...................................................................................................
4 2 6 0
S A 14 /U S A  CAAACAAGAAGAGAGGGTGGCCAGCTACTGAGTTTTTGTCGGCAGTTGGATTGATGTTTG
S A 1 4 - 2 - 8  ............................................................................................................................. .. ........................................
P3 ..............  .......................................................................................................................................................
4 3 2 0
S A 14/U S A  CCATCGTAGGTGGTTTGGCCGAGTTGGATATTGAATCCATGTCAATACCCTTCATGCTGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ...............................................
4 3 8 0
S A 14 /U S A  CAGGTCTCATGGCAGTGTCCTACGTGGTGTCAGGAAAAGCAACAGATATGTGGCTTGAAC
S A 1 4 - 2 - 8  .................................. .....................................................................................................................................
P3 ........................................................................................................................................................................
4 4 4 0
S A 14/U S A  GGGCCGCCGACATCAGCTGGGAGATGGATGCTGCAATCACAGGAAGCAGTCGGAGGCTGG
S A 1 4 - 2 - 8   G ...........................................................................................................
P3 AA...................................................................................................................................................................
4 5 0 0
S A 14/U S A  ATGTGAAACTGGATGATGACGGAGATTTTCACTTGATTGATGATCCCGGTGTTCCATGGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ........................................................................................................................ ..........................
4 5 6 0
S A 14/U S A  AGGTCTGGGTCCTGCGCACGTCTTGCATTGGCTTAGCCGCCCTCACGCCTTGGGCCATCG
S A 1 4 - 2 - 8   T ...................................................................................................................
P3  T ...............................................................................................................T .
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4 6 2 0
SA14 /U S A  TTCCCGCCGCTTTCGGTTATTGGCTCACTTTAAAAACAACAAAAAGAGGGGGCGTGTTTT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .................................................................................................................................
4 6 8 0
S A l  4 /U S A  GGGACACGCCATCCCCAAAACCTTGCTCAAAAGGAGACACCACTACAGGAGTCTACCGAA
S A 1 4 - 2 - 8  ................................................... ....................................................................................................................
P3  C .............................................
4 7 4 0
S A 14/U S A  TTATGGCTAGAGGGATTCTTGGCACTTACCAGGCCGGCGTCGGAGTCATGTACGAGAATG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .....................................................
4 8 0 0
S A l 4 /U S A  TTTTCCACACACTATGGCACACAACTAGAGGAGCAGCCATTATGAGTGGAGAAGGAAAAT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3....................  T .............................................................G ...................................... ...............................
4 8 6 0
S A 14/U S A  TGACGCCATACTGGGGTAGTGTGAGAGAAGACCGCATAGCTTACGGAGGCCCATGGAGGT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ............................................A ..................................................................................................
4 9 2 0
SA14 /U S A  TTGACCGAAAATGGAATGGAACAGATGACGTGCAAGTGATCGTGGTAGAACCGGGGAAGG
A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ...........................................................................................................................................................
4 9 8 0
S A 14/U S A  CTGCAGTAAACATCCAGACAAAACCAGGAGTGTTTCGGACTCCCTTCGGGGAGGTTGGGG
S A 1 4 - 2 - 8  TC..................................................................................................................................................................
P3 ........................................................................................................................................................................
5 0 4 0
S A 14 /U S A  CTGTTAGTCTGGATTACCCGCGAGGAACATCCGGCTCACCCATTCTGGATTCCAATGGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
5 1 0 0
S A l  4 /U SA  ACATTATAGGCCTATACGGCAATGGAGTTGAGCTTGGCGATGGCTCATACGTCAGCGCCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . . .C ..........................................................................................................................................................
5 1 6 0
S A 14/U S A  TCGTGCAGGGTGACCGTCAGGAGGAACCAGTCCCAGAAGCTTACACCCCAAACATGTTGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
5 2 2 0
SA14 /U S A  GAAAGAGACAGATGACTGTGCTAGATTTGCACCCTGGTTCAGGGAAAACCAGGAAAATTC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
270
5 2 8 0
S A 14/U S A  TGCCACAAATAATTAAGGACGCCATCCAGCAGCGCCTAAGAACAGCTGTGTTGGCACCGA
S A 1 4 - 2 - 8  ............................................................T ........................................................................................................
P3  T ...................................... G .............................................................
5 3 4 0
S A l 4 /U S A  CGCGGGTGGTAGCAGCAGAAATGGCAGAAGCTTTGAGAGGGCTCCCAGTACGATATCAAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3..................  A ..................................................................................................................................................
5 4 0 0
S A 14/U S A  CTTCAGCAGTGCAGAGAGAGCACCAAGGGAATGAAATAGTGGATGTGATGTGCCACGCCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3   A .....................T ........................................................................................................
5 4 6 0
S A 14/U S A  CTCTGACCCATAGACTGATGTCACCGAACAGAGTGCCCAACTACAACCTATTTGTCATGG
S A 1 4 - 2 - 8  ................................................ .......................................................................................... .. .........................
P3  T ............................................
5 5 2 0
S A 14/U S A  ATGAAGCTCATTTCACCGACCCAGCCAGTATAGCCGCACGAGGATACATTGCTACCAAGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
5 5 8 0
S A 14/U S A  TGGAATTAGGGGAGGCAGCAGCCATCTTTATGACAGCGACCCCGCCTGGAACCACGGATC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . .  .G . .G .................................................................................................................................................
5 6 4 0
S A l 4 /U S A  CTTTTCCTGACTCAAATGCCCCAATCCATGATTTGCAAGATGAGATACCAGACAGGGCAT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G .......................................T ...................
5 7 0 0
S A 14 /U S A  GGAGCAGTGGATACGAATGGATCACAGAATATGCGGGTAAAACCGTGTGGTTTGTGGCGA
S A 1 4 - 2 - 8  ...................................................................................................... ..................................................................
P3 ........................................................................................................................................................................
5 7 6 0
SA14 /U S A  GCGTAAAAATGGGGAATGAGATTGCAATGTGCCTCCAAAGAGCGGGGAAAAAGGTCATCC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
5 8 2 0
SA14 /U SA  AACTCAACCGCAAGTCCTATGACACAGAATACCCAAAATGTAAGAATGGAGACTGGGATT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .C ...............................
5 8 8 0
S A 14/U S A  TTGTCATTACCACCGACATCTCTGAAATGGGGGCCAACTTCGGTGCGAGCAGGGTCATCG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ...................................................................................................................................................
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5 9 4 0
S A l  4 /U SA  ACTGTAGAAAGAGCGTGAAACCCACCATCTTAGAAGAGGGAGAAGGCAGAGTCATCCTCG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ........................................................................ T ....................................
6 0 0 0
S A l  4 /U S A  GAAACCCATCTCCCATAACCAGTGCAAGCGCAGCTCAACGGAGGGGCAGAGTAGGCAGAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ...............................................
6 0 6 0
S A 14 /U S A  ACCCCAACCAAGTTGGAGATGAATACCACTATGGGGGGGCTACCAGTGAAGATGACAGTA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ...........................
6 1 2 0
S A 14 /U S A  ACCTAGCCCATTGGACAGAGGCAAAGATCATGTTAGACAACATACACATGCCCAATGGAC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
6 1 8 0
S A 14/U S A  TGGTGGCCCAGCTCTATGGACCAGAGAGGGAAAAGGCTTTCACAATGGATGGCGAATACC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ........................................................
6 2 4 0
S A l  4 /U S A  GTCTCAGAGGTGAAGAAAAGAAAAACTTCTTAGAGCTGCTTAGGACGGCTGACCTCCCGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T . . . .
6 3 0 0
S A 14/U S A  TGTGGCTGGCCTACAAGGTGGCGTCCAATGGCATTCAGTACACCGACAGAAAGTGGTGTT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
6 3 6 0
S A 14/U S A  TTGATGGGCCGCGTACGAATGCCATACTGGAGGACAACACCGAGGTAGAGATAGTCACCC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
6 4 2 0
S A 14/U S A  GGATGGGTGAGAGGAAAATCCTCAAGCCGAGATGGCTTGATGCAAGAGTTTATGCAGATC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C.
6 4 8 0
S A 14 /U S A  ACCAAGCCCTCAAGTGGTTCAAAGACTTTGCAGCAGGGAAGAGATCAGCCGTTAGCTTCA
S A 1 4 - 2 - 8  ..................................................................................................................................................................
P3  C ...................
6 5 4 0
S 14  /U SA  TAGAGGTGCTCGGTCGCATGCCTGAGCATTTCATGGGAAAGACGCGGGAAGCTTTAGACA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3   C .........................................................................................................
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6 6 0 0
S A 1 4 /U SA  CCATGTACTTGGTTGCAACGGCTGAGAAAGGTGGGAAAGCACACCGAATGGCTCTCGAAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
6 6 6 0
S A 14/U S A  AGCTGCCAGATGCACTGGAAACCATCACACTTATTGTCGCCATTACTGTGATGACAGGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
6 7 2 0
S A l  4 /U S A  GATTCTTCCTACTAATGATGCAGCGAAAGGGTATAGGGAGGATGGGTCTTGGAGCTCTAG
S A 1 4 - 2 - 8  ............................................................................................................... A ....................................................
P3  A .
6 7 8 0
S A 14 /U S A  TGCTCACGCTAGCTACCTTCTTCCTGTGGGCGGCAGAGGTTCCTGGAACCAAAATAGCAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
6 8 4 0
S A l  4 /U S A  GGACCCTGCTGATCGCCCTGCTGCTGATGGTGGTTCTCATCCCAGAACCGGAAAAACAGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .............................................................
6 9 0 0
S A l  4 /U S A  GGTCACAGACAGATAACCAACTGGCGGTGTTTCTCATCTGTGTCTTGACCGTGGTTGGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... .......................... .......................................................................................... ..  ..............................................
6 9 6 0
S A l 4 /U S A  TGGTGGCAGCAAACGAGTACGGGATGCTAGAAAAAACCAAAGCAGATCTCAAGAGCATGT
S A 1 4 - 2 - 8  ........................................................................................................................................ ...............................
P3................... ........................................................................................................................................................................
7 0 2 0
S A 14 /U S A  TTGGCGGAAAGACGCAGGCATCAGGACTGACTGGATTGCCAAGCATGGCACTGGACCTGC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
7 0 8 0
S A 14 /U S A  GTCCAGCCACAGCCTGGGCACTGTATGGGGGGAGCACAGTCGTGCTAACCCCTCTTCTGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C . . . .
7 1 4 0
S A 14 /U S A  AGCACCTGATCACGTCGGAATACGTCACCACATCGCTAGCCTCAATTAACTCACAAGCTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ......................C ....................................
7 2 0 0
S A 14/U S A  GCTCATTATTCGTCTTGCCACGAGGCGTGCCTTTTACCGACCTAGACTTGACCGTTGGCC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
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7 2 6 0
S A 14/U S A  TCGTCTTCCTTGGCTGTTGGGGTCAAATCACCCTCACAACGTTTCTGACAGCCATGGTTC
S A 1 4 - 2 - 8  ....................................................................... G .............................................................................................
P3................... ........................................................................................................................................................................
7 3 2 0
S A 14/U S A  TGGCGACACTTCACTATGGGTACATGCTCCCTGGATGGCAAGCAGAAGCACTCAGGGCTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
7 3 8 0
S A 14 /U S A  CCCAGAGAAGGACAGCGGCTGGAATAATGAAGAATGCCGTTGTTGACGGAATGGTCGCCA
S A 1 4 - 2 - 8 ................... A .........................................................................................................................
P3................... ........................................................................................................................................................................
7 4 4 0
SA14 /U S A  CTGATGTGCCTGAACTGGAAAGGACTACTCCTCTGATGCAAAAGAAAGTCGGACAGGTGC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
7 5 0 0
S A 14/U S A  TCCTCATAGGGGTAAGCGTGGCAGCGTTCCTCGTCAACCCTAATGTCACCACTGTGAGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
7 5 6 0
S A 14/U S A  AAGCAGGGGTGTTGGTGACGGCGGCTACGCTTACTTTGTGGGACAATGGAGCCAGTGCCG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
7 6 2 0
S A 14 /U S A  TTTGGAATTCCACCACAGCCACGGGACTCTGCCATGTCATGCGAGGTAGCTACCTGGCTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ..............................................................
7 6 8 0
SA14 /U S A  GAGGCTCCATTGCTTGGACTCTCATCAAGAACGCTGATAAGCCCTCCTTGAAAAGGGGAA
S A 1 4 - 2 - 8  ........................................................................................ ................................................................................
P3  C ..............................................................
7 7 4 0
SA14 /U S A  GGCCTGGGGGCAGGACGCTAGGGGAGCAGTGGAAGGAAAAACTAAATGCCATGAGCAGAG
S A 1 4 - 2 - 8   T ................................................................................................
P3  A ..................................................................................................................................................
7 8 0 0
S A 14 /U S A  AAGAGTTTTTTAAATACCGGAGAGAGGCCATAATCGAGGTGGACCGCACTGAAGCACGCA
S A 1 4 - 2 - 8 ..........................C ..........................................................................................................................................
P3  G ..................................................................................................................................
7 8 6 0
SA14 /U S A  GGGCCAGACGTGAAAATAACATAGTGGGAGGACATCCGGTTTCGCGAGGCTCAGCAAAAC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . . . T .............................................................. G ....................................................... G ............................
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7 9 2 0
S A 14/U S A  TCCGTTGGCTCGTGGAGAAAGGATTTGTCTCGCCAATAGGAAAAGTCATTGATCTAGGGT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . . .C ...................................................................................................... .. ................................................
7 9 8 0
S A 14/U S A  GTGGGCGTGGAGGATGGAGCTACTACGCAGCAACCCTGAAGAAGGTCCAGGAAGTCAGAG
S A 1 4 - 2 - 8  ......................................................... .. ............................................................................................................
P3................... .................................................................................................................................................... ....................
8 0 4 0
S A 14/U S A  GATACACGAAAGGTGGGGCGGGACATGAAGAACCGATGCTCATGCAGAGCTACGGCTGGA
S A 1 4 - 2 - 8  .................................................................................................................... .. ................................................
P3 ............................. ...........................................................................................................................................
8 1 0 0
S A 14/U S A  ACCTGGTCTCCCTGAAGAGTGGAGTGGACGTGTTTTACAAACCTTCAGAGCCCAGTGACA
S A 1 4 - 2 - 8 ....................... .. ..............................................................................................................................................
P3................... ........................................................................................................................................................................
8 1 6 0
S A 14/U S A  CCCTGTTCTGTGACATAGGGGAATCCTCCCCAAGTCCAGAAGTAGAAGAACAACGCACAC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ..........................................................................................................................................
8 2 2 0
S A 14/U S A  TACGCGTCCTAGAGATGACATCTGACTGGTTGCACCGAGGACCTAGAGAGTTCTGCATTA
S A 1 4 - 2 - 8  ............................................................................................................ ............................................................
P3    A .
8 2 8 0
SA14 /U SA  AAGTTCTCTGCCCTTACATGCCCAAGGTTATAGAAAAAATGGAAGTTCTGCAGCGCCGCT
S A 1 4 - 2 - 8   T . . . .
P3 ........................................................................................................................................................................
8 3 4 0
S A 14 /U S A  TCGGAGGTGGGCTAGTGCGTCTCCCCCTGTCCCGAAACTCCAATCACGAGATGTATTGGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
8 4 0 0
S A 14/U S A  TTAGTGGAGCCGCTGGCAATGTGGTGCACGCTGTGAACATGACCAGCCAGGTACTACTGG
S A 1 4 - 2 - 8  ....................................................................................................................................................T ................
P3................... ........................................................................................................................................................................
8 4 6 0
S A 14/U S A  GGCGAATGGATCGCACAGTGTGGAGAGGGCCAAAGTATGAGGAAGATGTCAACCTAGGGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 .................................. .. ................... .. ............................................................................................................
8 5 2 0
SA14 /U S A  GCGGAACAAGAGCCGTGGGAAAGGGAGAAGTCCATAGCAATCAGGAGAAAATCAAGAAGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ..................................................................................... ...................................................................................
275
8 5 8 0
S A l  4 /U S A  GAATCCAGAAGCTTAAAGAAGAATTCGCCACAACGTGGCACAAAGACCCTGAGCATCCAT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
8 6 4 0
S A 14 /U S A  ACCGCACTTGGACATACCACGGAAGCTATGAAGTGAAGGCTACTGGCTCAGCCAGCTCTC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 . . . . T ..........................................................................................................................................................
8 7 0 0
S A l  4 /U S A  TCGTCAACGGAGTGGTGAAGCTCATGAGCAAACCTTGGGACGCCATTGCCAACGTCACCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
8 7 6 0
S A 14 /U S A  CCATGGCCATGACTGACACCACCCCTTTTGGACAGCAAAGAGTTTTCAAGGAGAAAGTTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
8 8 2 0
S A 14 /U S A  ACACGAAGGCTCCTGAGCCACCAGCTGGAGCCAAGGAAGTGCTCAACGAGACCACCAACT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  A .........................................................................................................................
8 8 8 0
SA14 /U S A  GGCTGTGGGCCCACTTGTCACGGGAAAAAAGACCCCGCTTGTGCACCAAGGAAGAATTCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .......................................................................................................................................
8 9 4 0
SA14 /U S A  TAAAGAAAGTCAACAGCAACGCGGCTCTTGGAGCAGTGTTCGCTGAACAGAATCAATGGA
S A 1 4 - 2 - 8  . T .................... T ..........................................................................................................................................
P3  T ..................................................................................................................................
9 0 0 0
S A 14 /U S A  GCACGGCGCGTGAGGCTGTGGATGACCCGCGGTTTTGGGAGATGGTTGATGAAGAGAGGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
9 0 6 0
SA14 /U S A  AAAACCATCTGCGAGGAGAGTGTCACACATGTATCTACAACATGATGGGAAAAAGAGAGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ...........................................
9 1 2 0
S A l  4 /U S A  AGAAGCCTGGAGAGTTTGGAAAAGCTAAAGGAAGCAGGGCCATTTGGTTCATGTGGCTTT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ................................................................................................
9 1 8 0
S A 14/U S A  GAGCACGGTATCTAGAGTTTGAAGCTTTGGGGTTCCTGAATGAAGACCATTGGCTGAGCC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
276
9 2 4 0
S A 14/U S A  GAGAGAATTCAGGAGGTGGAGTGGAAGGCTCAGGCGTCCAAAAGCTGGGATACATCCTCC 
S A 1 4 - 2 - 8  ..........................................................................................................................
P3  G  ' ' .........................................
9 3 0 0
S A 14 /U S A  GTGACATAGCAGGAAAGCAAGGAGGGAAAATGTACGCTGATGATACCGCCGGGTGGGACA
S A 1 4 - 2 - 8  ...................................................................................................................................
P3 ...........................................................................................
9 3 6 0
SA14 /U S A  CTAGAATTACCAGAACTGATTTAGAAAATGAAGCTAAGGTACTGGAGCTCCTAGACGGTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C .............G .....................................................
9 4 2 0
S A 14/U S A  AACACCGCATGCTCGCCCGAGCCATAATTGAACTGACTTACAGGCACAAAGTGGTCAAGG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ...........................................................................
9 4 8 0
SA14 /U SA  TCATGAGACCTGCAGCAGAAGGAAAGACCGTGATGGACGTGATATCAAGAGAAGATCAAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ...........................................................................................
9 5 4 0
S A 14/U S A  GGGGGAGTGGACAGGTGGTCACTTATGCTCTTAACACTTTCACGAACATCGCTGTCCAGC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  !.!!!]!!]!!!!!]!!
9 6 0 0
S A 14/U S A  TCGTCAGGCTGATGGAGGCTGAGGGGGTCATTGGACCACAACACTTGGAACAGCTACCTA 
S A 1 4 - 2 - 8  .....................................................................................
...........................................................................................................
9 6 6 0
SA 14 /U S A  GGAAAAACAAGATAGCTGTCAGGACCTGGCTCTTTGAGAATGGAGAGGAGAGAGTGACCA
S A 1 4 - 2 - 8  . . G .............................................................................................................................
P3 .A ...............................................................................................................
9 7 2 0
S A 14/U S A  GGATGGCGATCAGCGGAGACGACTGTGTCGTCAAGCCGCTGGACGACAGATTCGCCACAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ..............................T .......................................................................... G.
9 7 8 0
S A 14/U S A  CCCTCCACTTCCTCAACGCAATGTCAAAGGTCAGAAAAGACATCCAGGAATGGAAGCCTT
S A 1 4 - 2 - 8  ..........................................................................................................................
P3 ................................................................................
9 8 4 0
S A 14/U S A  CGCATGGCTGGCACGATTGGCAGCAAGTTCCCTTCTGCTCTAATCATTTTCAGGAGATTG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3....................  T ....................................................................................C .............................................
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9 9 0 0
S A 14/U S A  TGATGAAAGATGGAAGGAGTATAGTTGTCCCGTGCAGAGGACAGGATGAGCTGATAGGCA
S A 1 4 - 2 - 8  .....................................................................................................................................................................
P3  C ................................................................................................
9 9 6 0
S A 14 /U S A  GGGCTCGCATCTCTCCAGGAGCTGGATGGAATGTGAAGGACACAGCTTGCCTGGCCAAAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C .................................................................................................................................
1 0 0 2 0
S A 14/U S A  CATATGCACAGATGTGGCTACTCCTATACTTCCATCGCAGGGACTTGCGTCTCATGGCAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
1 0 0 8 0
S A 14/U S A  ATGCGATTTGCTCAGCAGTGCCAGTGGATTGGGTGCCCACAGGCAGGACATCCTGGTCAA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
1 0 1 4 0
S A l4 /U S A  TACACTCGAAAGGAGAGTGGATGACCACGGAAGACATGCTGCAGGTCTGGAACAGAGTCT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ........................................................................................................................................................................
1 0 2 0 0
S A l4 /U S A  GGATTGAAGAAAATGAATGGATGATGGACAAGACTCCAATCACAAGCTGGACAGACGTTC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3 ...................................................................................................... .. ...............................................................
1 0 2 6 0
S A 14/U S A  CGTATGTGGGAAAGCGTGAGGACATCTGGTGTGGCAGCCTCATCGGAACGCGATCCAGAG
S A 1 4 - 2 - 8 .............. ................................................................................................................... .....................................
P3  T . . . .
1 0 3 2 0
S A 14/U S A  CAACCTGGGCTGAGAACATCTATGCGGCGATAAACCAGGTTAGAGCTGTCATTGGGAAAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
1 0 3 8 0
S A l4 /U S A  AAAATTATGTTGACTACATGACCTCACTCAGGAGATACGAAGACGTCTTGATCCAGGAAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T ....................................................... T .............................................
1 0 4 4 0
S A l4 /U S A  ACAGGGTCATCTAGTGTGATTTAAGGTAGAAAAGTAGACTATGTAAATAATGTAAATGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  C ........................................................
1 0 5 0 0
S A 14/U S A  AA7VATGCATGCATATGGAGTCAGGCCAGCAAAAGCTGCCACCGGATACTGGGTAGACGGT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  T .....................................................................................................................................................
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1 0 5 6 0
S A 14/U S A  GCTGCCTGCGTCTCAGTCCCAGGAGGACTGGGTTAACAAATCTGACAACAGAAAGTGAGA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3................... ........................................................................................................................................................................
1 0 6 2 0
S A 14/U S A  AAGCCCTCAGAACCGTCTCGGAAGTAGGTCCCTGCTCACTGGAAGTTGAAAGACCAACGT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3..................... ............................................................................................................ ............................................................
1 0 6 8 0
S A 14/U S A  CAGGCCACAAATTTGTGCCACTCCGCTAGGGAGTGCGGCCTGCGCAGCCCCAGGAGGACT
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G ..........................................................................................
1 0 7 4 0
S A 14/U S A  GGGTTACCAAAGCCGTTGAGCCCCCACGGCCCAAGCCTCGTCTAGGATGCAATAGACGAG
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3..................... ........................................................................................................................................................................
1 0 8 0 0
S A 14/U S A  GTGTAAGGACTAGAGGTTAGAGGAGACCCCGTGGAAACAACAACATGCGGCCCAAGCCCC
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3..................... ........................................................................................................................................................................
1 0 8 6 0
S A 14/U S A  CTCGAAGCTGTAGAGGAGGTGGAAGGACTAGAGGTTAGAGGAGACCCCGCATTTGCATCA
S A 1 4 - 2 - 8  ........................................................................................................................................................................
P3  G .....................................................................................................
1 0 9 2 0
S A 14/U S A  AACAGCATATTGACACCTGGGAATAGACTGGGAGATCTTCTGCTCTATCTCAACATCAGC
S A 1 4 - 2 - 8  .............. .........................................................................................................................................................
P3   A ...........................................
1 0 9 6 9
SA14 /U S A  TACTAGGCACAGAGCGCCGAAGTATGTAGCTGGTGGTGAGGAAGAACAC
S A 1 4 - 2 - 8  ........................................................................................................................................
P3 .........................................................................................................................................
279
A p p e n d ix  2
60
S A l4 /U S A  CTTAGTATCGTTGAGAAGAATCGAGAGATTAGTGCAGTTTAAACAGTTTTTTAGAACGGA 
S 8 9 2
B e i j i n g l  ............................................................................................................................. T .......................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   A .........................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3..................... ........................................................................................................................................................................
N akayam a ........................................................................................................................................................................
120
S A l4 /U SA  AGATAACCATGACTAAAAAACCAGGAGGGCCCGGTAAAAACCGGGCTATCAATATGCTGA
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20  C ....................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ................................................................................................................................C ....................................
P3..................... ........................................................................................................................................................................
N akayam a .......................................................................... C ..........................................................................................
18 0
S A 14/U S A  AACGCGGCCTACCCCGCGTATTCCCACTAGTGGGAGTGAAGAGGGTAGTAATGAGCTTGT
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  .................... T ................................................................A ............................................................................
H K 8526 .................... ...................................................................................................................................................
8 2 6 3 0 9 ......... T ..................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  .................... T ................................................................................................................. G ..........................
P3  T ................................................................................................................................................
N akayam a ...................... T ............................................................................................................... G ..........................
2 4 0
S A 14/U S A  TGGACGGCAGAGGGCCAGTACGTTTCGTGCTGGCTCTTATCACGTTCTTCAAGTTTACAG
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................... .............................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3  A ................T ...................................................................
N akayam a ........................................................................................................................................................................
3 0 0
SA14 /U S A  CATTAGCCCCGACCAAGGCGCTTTTAGGCCGATGGAAAGCAGTGGAAAAGAGTGTGGCAA
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  ..................................................................................... G ...............................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3  A . . . .
N akayam a ........................................................................................................................................................................
2 8 0
360
S A l4 /U S A  TGAAACATCTTACTAGTTTCAAACGAGAACTTGGAACACTCATTGACGCCGTGAACAAGC
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526  C ...................................................................................................................................C . .
8 2 6 3 0 9   C ........................................................................ G ......................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ............................................................... .......................................................................................................
P3  C .............C .................................................................................................................................
N ak ayam a ........................................................................................................................................................................
4 2 0
S A l4 /U S A  GGGGCAGAAAGCAAAACAAAAGAGGAGGAAATGAAGGCTCAATCATGTGGCTCGCGAGCT
S 8 9 2  . .   A  A . . . .
B e i j i n g l  ........................................................................................................................................................................
HK 8526......... G .........................................................................
8 2 6 3 0 9 .........  A ...............
DH20 .......................... ..............................................................................................................................................
I n d o n e s i a .........................   A . . . .
S a ig o n  ............ ..........................................................................................................................................................
P3..................... ........................................................................................................................................................................
N akayam a ........................................................................................................................................................................
4 8 0
S A l4 /U S A  TGGCAGTTGTCATAGCTTGTGCAGGAGCCATGAAGTTGTCGAATTTCCAGGGGAAGCTTT
S 8 9 2   AC..................... A .......................................................................................
B e i j  i n g l  ...........................T ............C . . C ........................................................ A ....................................................
H K 8526  A .....................................................
8 2 6 3 0 9 ......... C ..............................................................................C ...................................................................
DH20 ...........................................C. .C ..................................... A .....................................................
I n d o n e s i a ................................................. AC.................... A .......................................................................................
S a ig o n  ...........................................C . . C .........................................................A ....................................................
P3....................  C ........................ G ...............................T . . .. . G ................A .....................................................
N akayam a ...........................................C . . C .........................................................A ...................................................
54 0
S A l4 /U S A  TGATGACCATCAACAACACGGACATTGCAGACGTTATCGTGATTCCCACCTCAAAAGGAG
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
HK 8526  T ..............................................................................C ........................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH2 0  TG................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ................ T G . ..................................................................................C ........................................................
P3..................... ........................................................................................................................................................................
N akayam a .......................................................................................................................................................T .............
6 0 0
S A l4 /U SA  AGAACAGATGCTGGGTCCGGGCAATCGACGTCGGCTACATGTGTGAGGACACTATCACGT
S 8 9 2   A ................................................................................................
B e i j i n g l  ................................................... A ............ A ................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   T ............................................... C ...................
DH20  T ........................................................T ..............................................................................
I n d o n e s i a .................................................................... A ...............................................................................................
S a ig o n  ..........................T ..........................................................................................................................................
P3  T ................................................................................................
N akayam a ...........................T .........................................................................................................................................
2 8 1
6 60
S A 14/U S A  ACGAATGTCCTAAGCTTACCATGGGCAATGATCCAGAGGATGTGGATTGCTGGTGTGACA
S 8 9 2 ............... C .........................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526  G ......................................................................................................................
8 2 6 3 0 9   TGC..................................................C .....................................................
DH20 ................................................................................................................................C. . T ...........................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ..............................................G ..............................................................................C . . T ...........................
P3 ................................................................................................................................C . . T ...........................
N akayam a ...........................................C .................................................................................C . . T ...........................
720
S A l4 /U S A  ACCAAGAAGTCTACGTCCAATATGGACGGTGCACGCGGACCAGGCATTCCAAGCGAAGCA
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  .................. G ..................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   G ..................................................................................................................................................
DH20  A .......................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ............................................................................................................A ........................................................
P3 ........................................................................................................................................................................
N akayam a ........................................................................................................................................................................
780
S A l4 /U S A  GGAGATCCGTGTCGGTCCAAACACATGGGGAGAGTTCACTAGTGAATAAAAAAGAGGCTT
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  .................................. A .................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   G ............................................................................................................C.
DH20  A ....................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3..................... ........................................................................................................................................................................
N akayam a ........................................................................................................................................................................
8 4 0
S A l4 /U S A  GGCTGGATTCAACGAAAGCCACACGATATCTCATGAAAACTGAGAACTGGATCATAAGGA
S 8 9 2   G ............................................................
B e i j i n g l  ............................................................................. C .......................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20  G ......................G ................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ..................................... C ....................................C .................................................................. G ................
P3..................... ........................................................................................................................................................................
N akayam a ............................................................................. C .................................................................. G ................
90 0
S A 14/U S A  ATCCTGGCTATGCTTTCCTGGCGGCGGTACTTGGCTGGATGCTTGGCAGTAACAACGGTC
S 8 9 2 .......................................................................................AC..........................................................................................
B e i j i n g l  ........................................................................................................................................................................
HK8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ....................................................................... A .............................................................................................
I n d o n e s i a  . . .  ; .............................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3  C ............................
N akayam a ........................................................................................................................................................................
2 8 2
960
S A l 4 /U S A  AACGCGTGGTATTTACCATCCTCCTGCTGTTGGTCGCTCCGGCTTACAGTTTTAATTGTC
S 8 9 2 ........................................................................................................................................................................................
B e i j  i n g l  ....................................C ........................................................................................ T .............. C . . C . . . .
H K 8526  C ........................C ...................................................................................
8 2 6 3 0 9   A .................................................................................C .............................................................
DH20  C .T ..................................................................................
I n d o n e s i a ................................... C ..........................................C ...................................................................................
S a ig o n  ...................................C .T ..................................................................................................... C . . C . . . .
P3  C . . CT
N ak ayam a .................................................................................................................................................C . . C . . . .
T h a i l a n d  ...............
K am iyam a ...............
1 0 2 0
S A 14 /U S A  TGGGAATGGGCAATCGTGACTTCATAGAAGGAGCCAGTGGAGCCACTTGGGTGGACTTGG
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526..................................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH20........................................................................................................................................................................................
I n d o n e s i a   ..........................................................................................................................................................
S a ig o n  ................. T ................................... ...............................................................................................................
P3  G ....................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 0 8 0
SA14 /U S A  TGCTGGAAGGAGATAGCTGCTTGACAATCATGGCAAACGACAAACCAACATTGGACGTCC
S 8 9 2  . . .  .A ..........................................................................................................................................................
B e i j i n g l  . . .  .A .................... C .................................................................................................................................
HK 8526 . . . . A ...............................................................T ......................................................................................
8 2 6 3 0 9  . . .  . A ..................................... T ....................................................... T  T.  . . .
DH20 . . . . A ................................................... . . . . T ........................ ...............................................................
I n d o n e s i a  . . .  .A ................................................................T ......................................................................................
S a ig o n  . . . . A .................... C ...................................... T .......................................................................................
P3  A ...........................................................................................................................................................
N akayam a . . .  .A ...............................................................T ......................................................................................
T h a i la n d  ............ ................................................  .......................................................................................................
K am iyam a   ..................................................................................................................................................................
1 1 4 0
S A 14/U S A  GCATGATTAACATCGAAGCTAGCCAACTTGCTGAGGTCAGAAGTTACTGCTATCATGCTT
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526  C ...................................................................................................................T ...........................
8 2 6 3 0 9   T ................................C.
DH20  C ................................GT............................................................................................................
I n d o n e s i a ................. C ..............................G ................................................................................................................
S a ig o n  ................. C ................................G ...............................................................................................................
P3....................  C ...........................................................................A ......................................................................
N akayam a ................. C ................................GT............................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ..................................................................................................................................................................
2 8 3
1200
S A 14/U S A  CAGTCACTGACATCTCGACGGTGGCTCGGTGCCCCACGACTGGAGAAGCCCACAACGAGA
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 ..................................................................................................................................................................................
DH2 0  T ..................................................................................G ..............T .........................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  .................................. T ..................................................................................................T ...........................
P3  T ................................................................
N akayam a .................................. T .................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 2 6 0
S A 14/U S A  AGCGAGCTGATAGTAGCTATGTGTGCAAACAAGGCTTCACTGACCGTGGGTGGGGCAACG
S 8 9 2   T ............................................
B e i j i n g l  ....................................................................................................................... T ............................................
H K 8526  T ............................................
8 2 6 3 0 9   T ............................................
DH20  T  T . . . .
I n d o n e s i a   ............................................................................................................ T ............................................
S a ig o n  . . . .  G ......................................................................................................... T . CC. . C ...........................
P3  T ............................................
N akayam a ....................................................................................................................... T .............................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 3 2 0
S A l4 /U S A  GATGTGGACTTTTCGGGAAGGGAAGCATTGACACATGTGCAAAATTCTCCTGCACCAGTA
S 8 9 2    C.
B e i j i n g l  .................................................................... T ................................................................................................
H K 8526  C.
8 2 6 3 0 9   C.
DH20 ........................................................................................................................................................................
I n d o n e s i a ....................................................................................................................................................................C .
S a ig o n  ..........................G . . T .............................................................................................................................G.
P3   A ..............................T ................................... ...........................................
N ak ayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 3 8 0
SA14 /U S A  AAGCGATTGGGAGAACAATCCAGCCAGAAAACATCAAATACGAAGTTGGCATTTTTGTGC
S 8 9 2   A ..........................................................................................................................................
B e i j i n g l  ..........................A ................................ T .....................................................................................................
HK 8526 ........................................................................................................................................................................
8 2 6 3 0 9   T ...........................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3  G ........................ .. ...................................................................................................
N akayam a . G ................................................................. A .............................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 8 4
1 4 4 0
S A l4 /U S A  ATGGAACCACCACTTCGGAAAACCATGGGAATTATTCAGCGCAAGTTGGGGCGTCCCAGG
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a ............................... ........................................................ ................ ..............................................................
S a ig o n  .......................................................................T .............................................................................................
P3................................................................................................ .............................................................................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 5 0 0
SA14 /U SA  CGGCAAAGTTTACAGTAACACCCAATGCTCCTTCGATAACCCTCAAACTTGGTGACTACG
S 8 9 2 ............... A ..............................................................................................................................
B e i j i n g l  ............................................................T ........................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   G ............... .........................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ..........................................................................A .....................C ................T ............................................
P3 ........................................................................................................................................................................
N akayam a .................................................  T ............................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ....................  .................................................................................................................................................
1 5 6 0
S A l4 /U SA  GAGAAGTCACACTGGACTGTGAGCCAAGGAGTGGACTGAACACTGAAGCGTTTTACGTCA
S 8 9 2   G ..........................................................................................................................................
B e i j i n g l  ....................................................................................................... A ............................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   T . . . .
DH20 ........................................................................................................................................................................
I n d o n e s i a ........................................................................................................................................................................
S a ig o n  ...................................................................................................... A .............................................................
P3  T ........................................................................................................................... C ...................
N akayam a ...................................................................................................... A ..............................A .......................T .
T h a i la n d
K am iyam a
1 6 2 0
S A 14 /U S A  TGACCGTGGGGTCAAAGTCATTTCTGGTCCATAGGGAGTGGTTTCATGACCTCGCTCTCC
S 8 9 2   A .............................................................
B e i j i n g l  ...............................................................T ................................... A .............................................................
H K 8526   G ................. A .............................................................
8 2 6 3 0 9   G ..........................................................A ...........................G ..............................
DH20  G ..........................................................A .............................................................
I n d o n e s i a ......................................... G .......................................................... A ............................................................
S a ig o n  ...............................................................T ...................C ............ A ..............................................................
P3  G .................. T ................................... A .............................................................
N akayam a ........................................G .................. T ...................C ............ A . . ....................... T ...........................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 8 5
1 6 8 0
S A 14/U S A  CCTGGACGTCCCCTTCGAGCACAGCGTGGAGAAACAGAGAACTCCTCATGGAATTTGAAG
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  . T .............. C ................................................................................................................................................
H K 8526 .................................................................................................................................................G ...................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ................................................................................................................................................. G ...................
I n d o n e s i a ...................................................................................................... .......................................... G ...................
S a ig o n  . . . T ......................................................................................................................................G . . C . . . .
P3  C ................................................................................................................................................
N ak ayam a . T ..................................................................................................................................................................
T h a i l a n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 7 4 0
S A 14/U S A  AGGCGCACGCCACAAAACAGTCCGTTGTTGCTCTTGGGTCACAGGAAGGAGGCCTCCATC
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  GA..................................................................................................................................................................
H K 8526 GA..................................................................................................................................................................
8 2 6 3 0 9   T .............................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a ........................................................................................................................................................................
S a ig o n  G A .  ..........................................................................................................................................................
P3  T ..........................................................................................................................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 8 0 0
S A 14 /U S A  AGGCGTTGGCAGGAGCCATCGTGGTGGAGTACTCAAGCTCAGTGAAGTTAACATCAGGCC
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3..............................................................................................................................................................................................
N akayam a ........................................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
1 8 6 0
S A l4 /U SA  ACCTGAAATGTAGGCTGAAAATGGACAAACTGGCTCTGAAAGGCACAACCTATGGCATGT
S 8 9 2 ........................................................................................................................................................................................
B e i j i n g l  . . . . A  C ............................................................................................................................T . . . .
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   A ..............................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  .........................C ..........................................................................................................................................
P3..................... ........................................................................................................................................................................
N akayam a . . . .  A .............C .........................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 8 6
1 9 2 0
S A 1 4 /U S A  GTACAGAAAAATTCTCGTTCGCGAAAAATCCGGCGGACACTGGTCACGGAACAGTTGTCA
S 8 9 2   C ............................................
B e i j i n g l  . C ..................................................................................................................................................................
H K 8526 .C ...................................... C ........................................................................................................................
8 2 6 3 0 9   T......................
DH2 0  C .........................................................T ............................................................
I n d o n e s i a  . C ...................................... C ........................................................................................................................
S a ig o n  . C ...................................... C ........................................................................................................................
P3 . C . . . . G ....................................................................................................................................................
N akayam a . C ..................................................................................................................................................................
T h a i la n d  . .  ...............................................................................................................................................................
K am iyam a .................................................................................................................. ....................................................
1 9 8 0
S A l4 /U SA  TTGAACTCTCCTACTCTGGGAGTGATGGCCCCTGCAAAATTCCGATTGTTTCCGTTGCGA
S 8 9 2  ................. A ..........................................................................................  C ...........................
B e i j  i n g l  ................. T . . A ........................................................................ G ..............................C .......................T.
H K 8526  T .............................................................................     . .C ...........................
8 2 6 3 0 9   C .............C . . . .
DH20  T .......................................................................................................... C ...........................
I n d o n e s i a .............. ..  . . . T ...........................................................................................................C ..........................
S a ig o n  ................. T ................................................................ T .............................................. C ...........................
P3  T . C .................
N akayam a ................. T ................................................................ T ............ G ..............................C ...........................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 0 4 0
S A 14/U S A  GCCTCAATGACATGACCCCCGTTGGGCGGCTGGTGACAGTGAACCCCTTCGTCGCGACTT
S 8 9 2   T ..................... ..............
B e i j i n g l  ............................................................C ....................................... G. ..........................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9   T . .T .  .C  G. . .
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  ........................................................................................................................................................................
P3....................  C ...........................................................................................................
N akayam a ............................................................C .............C .......................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 1 0 0
S A 14/U S A  CCAGTGCCAACTCAAAGGTGCTGGTCGAGATGGAACCCCCCTTCGGAGACTCCTACATCG
S 8 9 2  ........................................................................................................................................................................
B e i j  i n g l  . . . . C ..........................................................................................................................................................
H K 8526  T . . . T .........................................................................................................................................
8 2 6 3 0 9   T . . . .
DH20  T . . . T .........................................................................................................................................
I n d o n e s i a ................T . . . T .........................................................................................................................................
S a ig o n  . . . . C . T ........................................A ........................................................................................................
P3..................... ........................................................................................................................................................................
N akayam a . . . . C ..........................................................................................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 8 7
2 1 6 0
S A 14/U S A  TAGTTGGAAGGGGAGACAAGCAGATCAACCACCATTGGCACAAAGCTGGAAGCACGCTGG
S 8 9 2  .G ............................................................................................................................................................. A .
B e i j i n g l  .................................................................... T ..................................T . T .  . G .............................. ..
H K 8526  C ...............................................................................................................................................
8 2 6 3 0 9  . G ..................................................................................................................................................................
DH20  T .....................................................
I n d o n e s i a ..................... C ...............................................................................................................................................
S a ig o n  .................... C ............................................T ...............................................................................................
P3..................... A ....................................................................................................................................
N akayam a .................................................................... T .............T ..............................G ............................................
T h a i la n d  .......................................................................  ..............................................................................................
K am iyam a ........................................................................................................................................................................
2 2 0 0
S A l4 /U S A  GCAAGGCCTTTTCAACAACTTTGAAGGGAGCTCAAAGACTGGCAGCGTTGGGCGACACAG
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  . . . . A ..........................................................................................................................................................
H K 8526 . . . . A ................................................................................G ...............................................T ...................
8 2 6 3 0 9   G ...................................... A ...........................
DH20 ........................................................................................................................................................................
I n d o n e s i a  . . .  .A ................................................................................G ......................................................................
S a ig o n  . . .  .A .............................G .........................................................................................................................
P3 . . .  .A ................. T ....................................................................................................................................
N akayam a . . . . A ..........................................................................................................................................................
T h a i la n d
K am iyam a
2 2 6 0
S A 14 /U S A  CCTGGGACTTTGGCTCTATTGGAGGGGTCTTCAACTCCATAGGAAAAGCCGTTCACCAAG
S 8 9 2   C .........................................................................................................................
B e i j i n g l  ........................................................................  T ...........................
H K 8526  C .........................................................................................................................
8 2 6 3 0 9   T ..................... T ..............................................................
DH20   G .......................................
I n d o n e s i a ............................................ C ........................................................................................................................
S a ig o n  .............................................................................T ........................................................GA........................
P3  C .........................................................................................................................
N akayam a .............................................................................T ...................................... G .............................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 3 2 0
S A 14/U S A  TGTTTGGTGGTGCCTTCAGAACACTCTTTGGGGGAATGTCTTGGATCACACAAGGGCTAA
S 8 9 2  ........................................................................................................................................................................
B e i j i n g l  ........................................................................................................................................................................
H K 8526 ........................................................................................................................................................................
8 2 6 3 0 9 .......... ........................................................................................................................................................................
DH20 ........................................................................................................................................................................
I n d o n e s i a  ........................................................................................................................................................................
S a ig o n  .................................. T ........................................C ......................................................................................
P3..............................................................................................................................................................................................
N ak ayam a ....................................C .......................................C ......................................................................................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 8 8
2 3 8 0
S A 14/U S A  TGGGTGCCCTACTGCTCTGGATGGGCGTCAACGCACGAGACCGATCAATTGCTTTGGCCT
S 8 9 2 .................................  A ...............................................................................................................
B e i j i n g l  . . . . C .....................A . . T ........................A ............................................................................................
H K 8526  T ...A ............... .................................................................................................................
8 2 6 3 0 9  . . . . C ..................... A.  . T .........................................................................................C ...........................
DH20............................................................................................................................................................................ ..
I n d o n e s i a ..................T  A ................................................................................... .. ..........................................
S a ig o n  ................. T . . . . . A .................................................................................................................................
P3  T ..............................................................................
N akayam a .................................................................  ................................................................................  ..................
T h a i la n d  ........................................................................................................................................................................
K am iyam a ........................................................................................................................................................................
2 4 1 6
S A l4 /U S A  TCTTAGCCACAGGGGGTGTGCTCGTGTTCTTAGCGA
S 8 9 2  ....................................................................................................
B e i j i n g l  ...............................................................................................T .
HK8526 ...................................................................................................
8 2 6 3 0 9  ...................................................................................................
DH20 ...................................................................................................
I n d o n e s i a  ...................................................................................................
S a ig o n   T ....... A ........................................ ...................
P3 ...................................................................................................
N akayam a ...................................................................................................
T h a i la n d  .................................................................................. ................
K am iyam a ...................................................................................................
2 8 9
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